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ABSTRACT 
DESIGN AND SYNTHESIS OF STIMULI-RESPONSIVE POLYMERIC 
NANOGELS TOWARDS THERAPEUTIC TRANSLATION 
 
FEBRUARY 2018 
 
MALLORY R. GORDON 
 
B.A., FRANKLIN & MARSHALL COLLEGE 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Sankaran Thayumanavan 
 
 
In the application of delivery of therapeutics, nanostructures of various composition 
have been employed due to their capacity to act as a host for lipophilic payloads. Advances 
in the synthetic preparation, size, morphology, and chemical or physical characteristics of 
polymers have impacted their development and versatility. A detailed understanding of 
polymeric nanoparticle host-guest properties is crucial to their practical translation to 
specific delivery applications. Further, these features must be highly tailorable to overcome 
biological barriers, stably encapsulate their therapeutic contexts, and exhibit payload 
release selectively in the target environment. In this dissertation, we aim to rationally 
design polymeric nano-scale assemblies with well-defined compositions and unique 
stimuli-responsiveness to achieve desirable host properties and interfacial characteristics. 
While each chapter is specific in focus, we expect that the fundamental findings in this 
dissertation to broadly impact principles in drug delivery, including nanoparticle 
biodistribution (chapter 2), hydrophobic delivery (chapter 3), stimuli-responsive “smart” 
materials (chapter 4), and polymeric composition development (chapter 5). 
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CHAPTER 1 
 
INTRODUCTION 
The field of nanotechnology encompasses the development of materials in the range 
of 1 to 100 nanometers, and is of considerable interest towards various applications due to 
the morphological and chemical diversity, high surface to volume ratio, and capacity to 
either adsorb or encapsulate compounds at that scale.1-4 The material’s chemical 
composition, such as polymers, inorganic materials, metals and biologics,5-11 as well as 
their morphology, such as spheres, disks, or cylinders,12-16 are specific and adaptable to the 
purpose of interest. This rich diversity has implications in fundamental science and many 
fields including biotechnology, micro and photoelectronics, and optical materials.17-21 In 
the application of delivery of therapeutics, nanostructures of various composition been 
employed including polymeric nanoparticles, 22-24
 
 liposomes, 25-27
 
gold nanoparticles, 28, 29 
carbon nanotubes,30, 31
 
iron oxide nanoparticles,32-34
 
and dendrimers35, 36 Advances in the 
synthetic preparation, size and morphological control, and chemical or physical 
characteristics of polymers have aided in their development and practical application.  Here 
will discuss polymeric nanoassemblies in the context of drug delivery of hydrophobic 
guests, with specific focus on the stimuli-responsivity of such materials and their material 
requirements for biological application in therapeutics. 
1.1 Supramolecular Self-Assembly 
Supramolecular materials of various structures, including micelles, vesicles, 
helices, and fibers, are formed through spontaneous non-covalent self-organization of 
amphiphiles that minimize its free energy to reach thermodynamic equilibrium in the 
system.37-41 In aqueous media, this self-assembly is dictated by the differential interactions 
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of the amphiphile hydrophilic functionalities with the bulk solvent and hydrophobic 
functionalities among themselves. Those that display the capacity to encapsulate contents 
in their water-excluded interior such as drug molecules or reporters have vast implications 
in therapeutics and diagnostics.42-45  The relative volume and position of hydrophobic and 
hydrophilic functional groups dictate the type of assembly that forms, and the concentration 
of amphiphile dictates the capability for assembly formation.46-48 This critical aggregation 
concentration (CAC) are often large for small molecules amphiphiles such as detergents 
and have low mechanical stabilities. Macromolecules such as amphiphilic polymers, 
however, generally have assemblies with low CAC values and higher stability, yielding 
practical application in their use to retain guest molecules.49-55 
1.2 Amphiphilic Random Copolymers 
Advances in in controlled polymerization techniques, such as reversible addition–
fragmentation chain transfer polymerization (RAFT), atom transfer radical polymerization 
(ATRP), ring-opening mediated radical polymerization (ROMP), and as nitroxide 
mediated radical polymerization (NMP), has led to significant progress in synthesis of 
diverse copolymers, both block and random.56-61 Block copolymer are arranged where each 
block in the chain contains repetition of a particular monomer, while random copolymers 
have different monomer components indiscriminately arranged throughout the chain. 
Block copolymers’ reproducible access to unique self-assembled morphologies has led to 
substantial focus towards understanding their supramolecular behaviors.62-64 Synthesis, 
however, requires consecutive controlled polymerization reactions or post modifications 
through reactions such as substitutions, grafting, or assorted “click” chemistries.65-67 
Random copolymers, alternatively are more synthetically facile, and can be prepared with 
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different monomers copolymerized in one step. Investigation of nanomaterial capabilities 
using random copolymers can potentially expand their versatility towards various fields of 
study. 
1.3 Nanoparticles for Drug Delivery and Passive Targeting 
 Many small molecule therapeutics, including chemotherapeutics, are lipophilic and 
suffer from poor aqueous solubility and are susceptible to decomposition through 
hydrolysis. This can require frequent administration to achieve therapeutic benefits due to 
short half-life, and low efficacy and tissue selectivity, and deleterious side effects.68, 69 
Nanoparticles can potentially improve the therapeutic profiles of such drugs through 
improved solubility and stability, and by minimizing toxicity from side effects. In the 
treatment of solid tumor-type cancers, nanoparticles have gained increased interest due to 
their observed increased tumor accumulation due to the enhanced permeation and retention 
(EPR) effect.70, 71 This phenomena is a result of extravasation of nano-sized 
macromolecules through fenestrated blood vessels from rapid and irregular growth in 
angiogenesis, and poor lymphatic drainage of contents.72 Biological physical barriers for 
particles include accumulation from the leaky endothelium of other organs such as the liver 
and spleen, and renal clearance through filtering of small particles (<10 nm) the kidneys.73, 
74 Also, nanoparticles face recognition and clearance through the reticuloendothelial 
system (RES), from immune cells in circulation, liver, lymph nodes and spleen.75-77 This 
clearance is often occurs through the pathway of opsonization, which occurs when plasma 
proteins, or opsonins, are adsorbed onto the particle surface.76 To achieve stealthy character 
and extended circulation half-lives for tumor accumulation through the EPR effect, a 
mechanism called “passive” targeting, nanocarriers are often coated with poly(ethylene 
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glycol) (PEG). PEG imparts a well hydrated corona to the surface of these nanoassemblies, 
generating steric stabilization and non-fouling characteristics to reduce non-specific 
interactions with proteins.77-79 The grafting, conjugation, and adsorption of PEG to 
nanoparticle surfaces have been shown to decrease protein adsorption and improve 
residence times.80-82 Even with PEG incorporation to the corona, several parameters 
including size, morphology, and chemical composition can influence non-specific 
interactions and impact biodistribution, leading to some contrasting trends depending on 
nanomaterial.  
 
Figure 1. Schematic representation of passive targeting via the enhanced permeation and 
retention (EPR) effect and active targeting through ligands and cell surface receptors. 
1.4 Active Targeting for Drug Delivery 
Passive targeting have inherent limitations including inability distinguish disease 
tissue form healthy tissue, and reduced endosomolytic activity from inhibited cellular 
interactions.83, 84 Active targeting aims to achieve cell-type selectivity though binding 
unique or over expressed surface receptors on cancer cells through receptor-mediated 
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endocytosis.70, 85 Incorporation of ligands such as cell-penetrating peptides, targeting 
peptides, monoclonal antibodies, or small molecules can vastly improve the selective 
cellular internalization of nanoparticles.86-89 This surface decoration, however, can increase 
the ability for RES recognition and in vivo clearance.90 An approach to this concern is 
development of “smart” nanoparticles that can change their physical or chemical properties 
to expose targeting ligands or achieve “active” characteristics in response to stimuli.  
1.5 Delivery Vehicle Requirements 
Considering the afore mentioned biological considerations, the design and 
development of delivery vehicles must satisfy extensive criteria. Delivery vehicles should 
be able to i) stably encapsulate hydrophobic compounds such as drugs at their core without 
non-specific release ii) possess appropriate size and surface chemistry to achieve stealthy 
character to benefit from the EPR effect, iii) have the capability for surface modification 
for active targeting strategies through ligands or “smart” strategies, iv) release contents 
according to a specific stimulus in a desired location, and v) be biocompatible and exhibit 
low toxicity. Some current advances in the engineering of “intelligent” polymeric based 
nanomaterials in stimuli responsiveness, encapsulation stability, size control, and surface 
modification chemistries aim to fulfill these requirements.   
1.6 Stimuli-Responsive Polymeric Nanomaterials 
Stimuli responsive nanoparticles are materials that contain components that can 
respond to a stimulus in the local environment in a chemical or physical manor. The 
applications of such systems have implications in many fields including drug delivery, 
sensing, catalysis, surface coating, and tissue engineering.91-97 Stimuli can be broadly 
categorized as chemical, physical, or biological.98 Chemical stimuli can include pH, redox 
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potential, and ionic strength. Physical stimuli are those such as temperature, light, 
mechanical force, ultrasound, and electric or magnetic field. Biological stimuli can 
encompass proteins, enzymes, nucleic acids, among others. Our interests reside in 
polymeric nanoparticles that are responsive to inherent biological and chemical stimuli that 
provide tools in improving site-selectivity of therapeutic delivery. Here we will introduce 
the developments of polymeric nanogels with redox-sensitivity, followed by developments 
which expand upon the amphiphilic random copolymer nanogel platform.  
1.6.1 Redox-Responsive Polymeric Nanogels 
Redox responsive nanomaterials are attractive for biological purposes to the high 
intracellular concentration of reducing agents such as glutathione (GSH) and 
thioredoxin.99-105 Serum and extracellular concentrations of GSH is low micromolar, while 
in cytosol concentrations are about 10 mM.106 Further, the cytosolic GSH concentration in 
cancer cells are much higher than those in healthy normal cells.  Therefore, nanoparticle 
systems that are responsive to reducing conditions have the capacity for selective 
intracellular release of encapsulated contents. The most heavily employed strategy for 
introducing GSH responsivity is the incorporation of disulfide functionality in the polymer. 
Disulfides can be synthetically installed in either the polymer backbone or side chains to 
achieve distinctive structural responsivity to reducing conditions. For example, one 
investigation achieved the cargo release of doxorubicin in the cytoplasm of cells through 
deshielding of poly(ethylamine) shells from disulfide incorporation in the polymer 
backbone of polymeric micelles.107 Alternatively, GSH responsivity in the core or shell of 
aggregates is can be achieved by disulfide incorporation in polymer side chains. Our group 
has developed the GSH responsivity of amphiphilic random copolymers with hydrophilic 
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tri(ethylene glycol) moieties and hydrophobic alkyl moieties containing disulfide 
functionality prepared by free radical polymerization.106  These polymers, capable of 
forming micelle-type assemblies and encapsulate lipophilic guests, displayed disassembly 
and release of guest in response to reducing agent. The disintegration is due to cleavage of 
alkyl disulfide and loss in assembly hydrophobicity. 
These findings inspired introducing strategies to improve the aggregate stability. 
Upon dilution, these micelle-type copolymer aggregate were destabilized, leading to 
release. A strategy to introduce chemical crosslinking between and within chemical chains 
was developed to maintain their structural integrity and control their stimuli-specific guest 
release.108, 109 The random copolymer prepared by RAFT polymerization in comprised of 
hydrophilic oligoethylene glycol (OEG) and hydrophobic pyridyldisulfide (PDS) moieties 
as side chain functionalities. The amphiphilic copolymer self-assembles in aqueous 
medium with the PDS units at the core. Addition of reducing agent dithiothreitol (DTT) 
results in a stoichiometric generation of free thiols from PDS units at the particle interior, 
which results in intra- and inter-polymer chain disulfide exchange reactions with adjacent 
PDS moieties, affording core crosslinked nanogels. These nanogels were capable of stably 
encapsulating hydrophobic guest molecules, and releasing them in response to reducing 
environment due to the disulfide core. Further, the polymer molecular weight and relative 
monomer composition were shown to tune the size of the aggregates. 
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Figure 2. (a) Polymer structure of precursors and nanogels: (i) DTT cleavage of deficient 
amount of PDS functional groups, and (ii) inter and intra-chain crosslinking and nanogel 
formation. (b) Schematic representation of the preparation of the GSH-responsive nanogels 
(reprinted with permission from reference108. Copyright 2010 American Chemical 
Society). 
 
The encapsulation stability of these nanogels were probed by guest exchange 
dynamics using a fluorescence resonance energy transfer (FRET) based method.110 Fret 
donor and acceptor, 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI), respectively, were 
separately encapsulated in nanogels. When the solutions of the two nanogels are mixed, no 
FRET observation indicates the distance between FRET pairs is longer than their Förster 
radius, signifying stable encapsulation in separate containers. However, unstable 
encapsulation is expected to allow guest exchange, resulting in an increased in observed 
FRET. The dynamics of exchange determined from FRET ratio over time demonstrated 
that the encapsulation stability is depended on the percentage of crosslinking.  
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Figure 3. a) Nanogels encapsulated with DiI or DiO and FRET behavior of mixed solutions 
of stable containers and leaky containers (adapted with permission from reference110. 
Copyright 2010 American Chemical Society). 
 
 The dynamics were further probed to establish whether these guests are exchanging 
by collision-based collision-exchange-separation mechanism or diffusion-based exit-re-
entry mechanism.111 the former depends on the particle collision frequency, while the later 
depends on the ability of guest molecule to exit and re-enter the particle. The dynamics 
were investigated using the FRET method, and found that exchange in guest increased with 
particle concentration, supporting exchange occurs dominantly according to the collision-
based mechanism. Investigation with pH sensitive host found that when the nanogel 
interior was hydrophobic, the collision-based mechanism, like non-pH sensitive control, 
was dominant. However, under pH conditions when the particle interior hydrophobicity 
was compromised, the dominant pathway observed to be the diffusion-based mechanism.   
 
Figure 4. Schematic representation of (top) Collision-Exchange-Separation mechanism, 
and (bottom) Exit-Re-entry Mechanism for encapsulated guest exchange (reproduced with 
permission from reference111. Copyright 2014 American Chemical Society). 
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1.6.2 pH-Responsive Polymeric Nanoparticles 
The varied environmental pH of different organs, extracellular tissues, and 
subcellular compartments is an attractive means to achieve unique nanoparticle 
responsiveness. Methods for oral delivery are often designed depending on the pH of 
intended locale in the gastrointestinal tract, for instance. A common technique to bypass 
digestion in the acidic stomach (pH 1-3) to achieve drug release in the upper tract of the 
intestines (pH 5-7.5) is the use of methacrylic acid copolymers as enteric coatings, such 
that they are collapsed as protonated carboxylic acid in low pH and swollen as deprotonated 
carboxylate at increased pH.112-115  
In application of chemotherapeutic delivery, nanomaterials with pH sensitivity 
have been well explored because tumor anaerobic hypoxia results in lactate production a 
pH decrease (6.2-6.9) in the extracellular milieu compared to normal healthy tissue (7.2-
7.4).116 Thus, extensive work on nanoscopic systems that undergo chemical or physical 
changes at reduce pH has been explored to develop cationic character to induce local drug 
release or facilitate cellular internalization. 117-126 The former is a common strategy in 
developing systems with enhanced aqueous solubility at decreased pH, such that the 
hydrophobic-hydrophobic balance is disrupted resulting in content release. An example of 
this is the protonation of hydrophobic β-amino ester-containing polymers below pH 6.5, 
converting the polymer to hydrophilic.117, 118 The latter is motivated by the affinity of 
cationic materials to the anionic phospholipid bilayer of cell membranes resulting in rapid 
internalization.127, 128 Cationic polymers including polylysine, polyamidoamine, and 
polypropylene have been used towards this aim, particularly for layer-by-layer techniques 
for anion contents such as siRNA, mRNA, and DNA.129 However, the indiscriminate 
cellular internalization and the adsorption of proteins on cationic nanomaterials limits their 
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practicality for in vivo translation.130-132 Stimuli-specific charge development thus aims 
improve specificity and avoid the RES clearance of such materials.  
Nanogels that are responsive to changes in have been developed within the 
group.119, 120 One approach that was investigated involved using electrostatic 
complementarity to coat polycationic nanogels with a polyanionic nanogel.119 The 
polycationic nanogel was achieved by incorporating quaternary ammonium and N-
isopropyl moieties into the amphiphilic polymer. The coating polymer contained pH-
sensitive and anionic tetrahydrophthalic acid units, such that when the pH is decreased the 
tetrahydrophthalic acid is cleaved, converting the coating to a polycationic material. The 
charge repulsion causes this coating to shed, and reveals the underlying cationic nanogel. 
This aim was pursued with interest that cationic materials internalize much more rapidly 
in cells, but have an inherent lack of specificity and are not applicable for direct use in vivo. 
 
Figure 5. Schematic representation of the polymer nanogel coating with charge 
complementarity electrostatic assembly, followed by pH-induced charge conversion and 
redox-induced release processes (reproduced with permission from reference119. Copyright 
2014 American Chemical Society). 
Similarly, a pH-responsive nanogel system was developed in the group, which was 
achieved by incorporation of pH-sensitive 2-diisopropyl amine moieties into the 
amphiphilic polymer.120 These groups are hydrophobic and buried under physiological pH 
(7.4), however become protonated at hydrophilic when the pH is decreased to 6.5, 
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representative of tumor extracellular milieu. This conversion was monitored by zeta 
potential change, and it was that the pH of charge conversion from negative to positive was 
dependent on the extent of 2-diisoproylamine groups present in the particle. Enhanced 
cellular uptake under mildly acidic conditions was demonstrated, supporting the potential 
of such systems to improve specificity and extent of delivery.  
 
Figure 6. Schematic illustration of nanogel and corresponding chemical structure of 
polymer for pH-induced cationic surface generation for enhanced cellular uptake (reprinted 
with permission from reference120. Copyright 2013 Royal Society of Chemistry). 
 
Further subcellular specificity can also be achieved with responsive materials due 
to the varied pH of compartments such as the endosomes and lysosomes (pH 5 or lower) 
compared to the cytosol (pH 7.4) extracellular regions.133 Polymers that contain imidazole 
and poly(amidoamine) or poly(ethyleneimine) with pH responsivity are capable of 
buffering endosomal pH and have been demonstrated to improve endosomal escape for 
cytosolic delivery.134 
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1.6.3 Enzyme-Responsive Polymeric Nanoparticles 
Nanomaterials that respond to biochemical stimuli such as enzymes can be 
advantageous for delivery of therapeutics, sensing, diagnostics, imagining, and bio-
mimicry applications. Responses such as surface modifications, supramolecular assembly 
or disassembly, and sol-gel transitions can occur in response to enzymes.135 The advantage 
of exploiting enzymes as stimuli is their specificity for biomedical function, particularly in 
disease states. Enzyme dysregulation is common in different cancers, for instance, and can 
be unique to the tumor environment.  The advantage of incorporating biochemical stimuli-
induced responses to a molecular design is that they have the potential to be specific for a 
biomedical function.136, 137 Due to their upregulation in cancer cells, several protease-
responsive systems have been investigated. Those of immense interest include matrix 
metalloproteinases (MMPs), which are zinc-dependent proteases that degrade the 
extracellular matrix. MMPs are associated with tumor invasiveness, metastasis, and 
angiogenesis, and are observed in many solid tumor types.138 MMPs have been 
demonstrated to induce nanoparticle size139 or morphological changes140 or disassembly141, 
142 to result in therapeutic release specifically in the extracellular milieu. In the interest in 
site-selective cell uptake, several reports have pursued MMP-activation through changes 
in nanoassembly surface chemistry.143-149 
1.6.4 Temperature-Responsive Polymeric Nanoparticles 
Temperature changes can also impact the solubility or confirmation of some 
polymers leading to changes in their hydrophobic-hydrophilic balance. The polymer 
poly(N-isopropyl acrylamide), for instance, is thermoresponsive and exists as hydrated 
swollen expanded coil below its lower critical solution temperature (LCST), but collapses 
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into a hydrophobic globular state when heated above its LCST (32 °C), which is close to 
biological temperature.150, 151 Poly(2-dimethyamino)ethyl methacrylate is also commonly 
employed in temperature responsive systems due to its hydrophobic transition when heated 
to its LCST (40-50 °C).152 Upper critical solution temperature (UCST), the temperature 
above which components of a mixture are miscible, is also employed in thermoresponsive 
systems using polymers such as polyoxazolines or poly(sulfobetaine)s.  
The LCST of poly(ethylene glycol) is commonly employed in such temperature 
responsive systems. The reduced solubility at elevated temperatures is attributed to the 
reduced hydrogen bonding between the polymer and water.153 In the context of OEG 
containing polymeric nanogels, temperature has been used to manipulate their aggregation 
characteristics to achieve particles of different sizes.108  The fine-tuning of nanogel size 
was further investigated by the use of Hofmeister inorganic salts.154 Salts have been 
observed to enhance or hinder the solubility of proteins, according to the Hofmeister 
series.155-157 Likewise, it has been shown that salts can affect the LCST of water soluble 
polymers according to the identity of Hofmeister salt.158-161 In investigation of salts effects 
on nanogel aggregation characteristics, it was found that Hofmeister anions could 
systematically cause aggregation of the polymer. Kosmotropic “salting out” sulfate 
systematically tuned particle size with concentration, while chaotropic “salting in” 
thiocyanate led to a loose nature of aggregates and lessened encapsulation stability of guest. 
This fine tuning was attributed to the relative hydration of OEG units, causing aggregation 
behavior when less water soluble, and leaky character when loose inter-aggregate 
crosslinking occurred.  
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Figure 7. Schematic illustration of the use of Hofmeister ions to vary size and guest 
encapsulation stability in polymeric nanogels (reprinted with permission from reference154. 
Copyright 2013 American Chemical Society).  
1.7 Post-Modification of Nanogels Through Thiol-Disulfide Exchange 
 The activated disulfide PDS moiety in the polymer can also serve as a functional 
handle with free thiol molecules by thiol-disulfide exchange, and this has been shown to 
modify the nanogel with targeting ligands.109 The random copolymer nature of the 
aggregate means that some percentage of PDS units will be surface exposed accessible for 
surface conjugation. Nanogels were post modified with ligands including folic acid, cell-
penetrating peptide tri-arginine, and cyclic arginine-glycine-aspartic acid (cRGD) peptide 
by installing cysteine as a thiol handle on the ligand. Their conjugation processes could be 
monitored and quantified by the release of PDS byproduct pyridinethione. Tri-arginine 
ligand-modified nanogels were shown to be rapidly internalized in cells regardless of cell 
type. RGD and folic acid modified nanogels were shown to selectively internalize in cells 
overexpressing integrin and folate receptor, respectively.  
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Figure 8. (a) Schematic representation of synthesis of targeting nanogels, (b) Polymer and 
targeting nanogel structures, and (c) Cysteine-modified targeting ligands (reprinted with 
permission from reference 109. Copyright 2010 American Chemical Society). 
1.8 Considerations of Polymeric Nanoparticle Biocompatibility 
 An additional caveat to therapeutic translation of polymeric nanomaterials is their 
biocompatibility. Polymers, and any byproducts that result from biological degradation or 
metabolism, should by non-toxic and non-immunogenic.162 In contrast to time-release 
systems, stimuli-release systems should evade biological degradation until the intended 
therapeutic function is achieved. Polymeric nanocarriers achieved through radical 
polymerization methods are generally not biodegradable.163 Various hydrolytically labile 
and enzymatically labile groups can be incorporated in polymers using ring opening 
polymerization and condensation polymerization methods, including esters, anhydrides, 
carbonates, amides, imines, and ureas.164 Several of such biodegradable polymers have 
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appropriate lack of toxicity in biological use, yet suffer from rapid degradation and 
clearance limit their versatility in drug delivery. However, the ability to chemically and 
structurally modify these polymers to influence their self-assembly characteristics and 
particle surface properties may alter their degradation susceptibility for use in therapeutics.  
1.9 Thesis Overview 
In this chapter, we discussed the merits and applications of polymeric nanoparticles 
to encapsulate therapeutic contents, be structurally of chemically modified according to 
application, and respond to appropriate stimuli of the local environment. Design principles 
that satisfy figures of merit as delivery vehicles were outlined by discussing specific 
examples. The amphiphilic random copolymer-based nanogels developed in our group 
have been highlighted.  In this dissertation, we expand upon this platform to address some 
unmet needs including 1) understanding the biodistribution pattern of these nanogels, 2) 
compromising the passive and active targeting features of these nanogels, and 3) 
considerations of nanomaterials’ nanotoxicity. We address these points by through specific 
structural manipulations in size and surface composition, incorporation of extracellular and 
intracellular stimuli responsivity, and biocompatible polymeric design for applications in 
delivery of therapeutics. In Chapter 2 we systematically manipulated the size and surface 
composition of nanogels to determine their impact on biodistribution in triple negative 
human mammary carcinoma bearing mice. In Chapter 3 we further expanded the polymer 
nanogel design and strategy of surface chemistry modification to investigate the safety and 
efficacy of these nanogels loaded with docetaxel in mice bearing triple negative breast 
cancer models. In Chapter 4 we describe a novel abridged strategy to achieve enhanced 
cellular uptake from activation with disease-relevant extracellular MMP-9. In Chapter 5 
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we investigated the application of amphiphilic random copolymer design to polymer 
comprised biocompatible poly(L-glutamic) acid as the backbone. Similar aggregation 
characteristics to traditional poly(methacrylate)-based amphiphiles were achieved. 
Summaries of findings and future research directions will be discussed in Chapter 6.  
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CHAPTER 2 
 
BIODISTRIBUTION ANALYSIS OF NIR-LABELED NANOGELS USING IN 
VIVO FMT IMAGING IN TRIPLE NEGATIVE HUMAN MAMMARY 
CARCINOMA MODELS 
2.1 Introduction 
In recent years, the advancements in polymeric nanoparticle synthesis, formulation, 
and modification chemistries have advanced their use for applications including 
diagnostics and therapeutics for various diseases, particularly cancer. Nanoparticles have 
the potential to improve the solubility, stability, and clearance profiles and weaken side 
effects of therapeutics which are otherwise plagued with short half-life, low efficacy, and 
poor tissue selectivity, requiring frequent administration.1,2 Parameters such as their 
morphology, polymer composition, size, and surface chemistry can all impact their extent 
of nonspecific interaction and circulation residence time to substantially influence their 
biodistribution. A more detailed understanding of these features relation to in vivo 
performance is required to improve the effectiveness of delivery to the region of interest, 
specifically solid tumors.  
Nanoparticles have been under investigation following the discovery of the 
enhanced permeability and retention (EPR) effect, which showed increased tumoral 
accumulation of macromolecules by extravasation through fenestrated blood vessels from 
100 nm to 2 µM, depending on tumor type.3, 4 The poor lymphatic drainage of tumors also 
aids extracellular retention of contents.5 There are many biological features that can impact 
biodistribution, including the propensity of nano-sized materials to accumulate in specific 
tissues with leaky endothelial walls, including the liver, spleen, and bone marrow.6 The 
kidneys are also capable of filtering particles smaller than 10 nm, while the liver is capable 
of capturing particles larger than 100 nm.7 A large obstacle facing nanocarriers is clearance 
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through the reticuloendothelial system (RES), also known mononuclear phagocyte system 
(MPS), which is the body’s natural immune response to destroy foreign material. Immune 
cells in the blood stream by monocytes, platelets, leukocytes, and dendritic cells, and in 
phagocytes present in the liver (Kupffer cells), lymph nodes (dendritic cells), and in the 
spleen (B cells) can all clear nanoparticles from circulation.8-11 A common pathway for 
uptake by these immune cells is opsonization, which is facilitated by the adsorption of 
plasma proteins, or opsonins, on the particle surface.9 Currently, it is not clear that the 
binding of specific proteins, or a combination or conformation thereof, impact the extent 
of phagocytosis.12  
Coating the nanocarrier surface with poly(ethylene glycol) (PEG), a method 
referred to as PEGylation, through grafting, conjugation, or adsorption has been shown to 
reduce their filtration and achieve extended blood circulation half-lives.13-15 The favorable 
results due to its inherent physiochemical properties of PEG to impart a hydrated corona 
which generates steric stabilization and reduces non-specific interactions with proteins and 
compliment activation. 16, 17 PEG also has low toxicity and non-immunogenicity, and is 
approved for clinical use by the Food and Drug Administration (FDA). Long PEG chains 
and high surface density have been shown as optimal conditions for protein resistance by 
mathematical modeling.18, 19 Investigations of PEG length and density effect on either 
protein absorption or biodistribution has led to some varied conclusion, likely heavily 
dependent on specific nanomaterial investigated and is also particle size. A significant 
correlation between size and protein absorption was found, with 80, 171, and 243 nm 
poly(cyanoacrylate-co-n-hexadecyl) cyanoacrylate (PHDCA) nanoparticles with PEG 
block of 5000 Mn, having 6%, 23% and 34% protein absorption, respectively.20 The in vivo 
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blood clearance was twice as slow with the small compared to larger particles, which 
allowed smaller particles to accumulate in tumors twice greater than larger particles. One 
study systematically varied the PEG length and percentage in PLA-b-PEG diblock 
copolymer-based nanoparticles and found PEG between 2000 and 5000 Mn were able to 
most reduce surface protein adsorption, with maximum reduction at 5 wt. % PEG.12 
Additional advantage weren’t obtained at higher weight percentages, and protein 
adsorption could not be completely prevented, potentially because PEG chains could not 
fully cover the surface.21 Investigation of protein absorption of PEG5K-b-PLA and 
PEG2K-b-PLA diblock copolymer nanoparticles found no detectable differences in 
albumin adsorption could be detected.22 Alternatively, investigation of PEG reduction of 
albumin and fibrinogen absorption on poly(ethylene terephthalate) found 3500 to be the 
critical Mn in reducing absorption.21 A threshold of PEG Mn 1500 was found for restriction 
of protein absorption on planar polystyrene surfaces, with no improved effect up to 20000 
Mn.23, 24 A minimum PEG length producing a protein absorption benefit is thought to be 
due to a loss in flexibility in shorter chains. It is expected that a threshold benefit of PEG 
is that at a certain length the chains fold leading to coils with loosely bound water 
molecules. A more heavily hydrated random conformation of PEG chains is expected to 
best inhibit protein absorption due to the unfavorable entropy change from compressing 
this coating.21, 24  
Currently the relationship between size and biodistribution of nanoparticles has 
some contrasting trends in results, likely due to nanomaterial differences. It is generally 
thought that the high curvature of smaller particles can reduce opsonization reactions and 
subsequent clearance by macrophages, however smaller particles have not always 
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performed better in vivo. For instance, one study investigated the tumor accumulation of 
20, 30 and 60 nm nanolatex polymeric core-crosslinked nanoparticles, comprised of 
amphiphilic block copolymer poly(PEG-methacrylate-b-methoxyethylmethacrylate, and 
found a correlation between tumor accumulation and an increase in particle size.25 The 
tissue which primarily removed the nanolatex polymers was the liver, and the size trend of 
localization was converse to tumor accumulation, with smaller particles resulting in higher 
%ID/g liver. Although they have different surface composition, liposome size-dependence 
on biodistribution was also investigated, and found that smaller particles (50 nm) more 
heavily accumulated in the liver, while larger particles (400 nm) more heavily accumulated 
in the spleen.26 Liposomes of 100-200 nm achieved 4-fold tumoral accumulation compared 
to those that were larger or smaller. However, biodistribution investigation of polystyrene 
particles that were coated with d-α-tocopheryl poly(ethylene glycol) (1,000 Mn) succinate 
that ranged in size from 50-500 nm showed higher levels in both the liver spleen and  for 
larger particles compared to smaller particles.27 Further, the first polymeric micellar 
nanoparticle that has reached phase II clinical trials in the unites states is Genexol-PM 
[methoxy-PEG-poly(D,L-lactide)Taxol], comprised of a core containing Taxol-modified 
poly(lactide) and a corona of mPEG of 2000 Mn and sizes ranging 20-50 nm.28, 29  
The purpose of this study is to the effect of nanogel size and surface poly(ethylene 
glycol) content on whole body residence times and tumor tissue extravasation in mice 
bearing triple negative human mammary carcinomas. Our group has developed a versatile 
amphiphilic random copolymer-based nanogel that encompasses many of the desirable 
features of a drug delivery vehicle including particle size control, guest encapsulation, and 
cytosolic release.30-32 The copolymer forms micelle-type assemblies, encapsulating 
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hydrophobic guest molecules in aqueous media, which can then be core-crosslinked 
particle and quantifiably post-modified with PEG. While extensive work has investigated 
biodistribution profiles using PEG containing block copolymers, to our knowledge 
relatively little work has investigated random copolymers that are extensively post-
modified with PEG on their coronas. With the expectation that minor physicochemical 
differences can greatly impact the in vivo performance and profile, we aim to 
systematically modify polymer size (20-135 nm), length of PEG conjugated to the surface 
(1000, 2000, and 5000 Mn), and amount of PEG conjugated to the surface (0-50 mole %) 
to determine the parameters that can most significantly direct a nanogel to the desired 
tumor target. 
2.2 Results and Discussion 
2.2.1 Nanogel Synthesis and Characterization 
To afford nanogels with defined size and surface composition we utilized our 
reported self-crosslinking disulfide-based nanogels as the scaffold.30-32 We aimed to 
formulate nanogels of different sizes (28-135 nm), crosslink density (20-100%), corona 
PEG length (Mn 1000, 2000, and 5000), and extent of PEG functionalization (up to 50 mol 
%). Our polymeric nanogels were achieved using amphiphilic random copolymers that 
self-assemble into nanoscale aggregates with disulfide functionality that allows for both 
controlled guest entrapment and stimuli-responsive release. Redox-responsive guest 
release of nanoassemblies are of significant interest due to the relative concentrations of 
glutathione (GSH) in blood plasma (10 µM) compared to the cytosol (10 mM).33, 34 While 
stable encapsulation is observed at extracellular concentrations of GSH, these nanogels can 
release their therapeutic cargo following cellular internalization upon exposure to cytosolic 
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concentration of GSH. Further, fine control in particle size has been demonstrated using 
polymer molecular weight30, as well as both temperature30 and Hofmeister ions35 due to 
the lower critical solution temperature (LCST) and relative hydration or dehydration 
behavior of PEG. In our current work, we expanded on this platform to include surface 
post-conjugation with PEGs of different length in a controlled and quantifiable manner.  
Table 1. Characteristics of polymers prepared for nanogel formulation. 
Polymer Mna Ða OEG
b 
(Mole%) 
PDSb 
(Mole%) 
AEb 
(Mole%) 
P1 6.0 K 1.5 29 68 3 
P2 13 K 1.2 28 70 2 
P3 22 K 1.3 27 69 4 
a Estimated by GPC (THF) using PMMA as a standard. b Determined by NMR. 
 
The p(OEGMA-co-PDSMA-co-AEMA) random copolymers were synthesized by 
a reversible addition–fragmentation chain transfer (RAFT) copolymerization of monomers 
poly(ethylene glycol) methyl ether methacrylate (OEGMA), pyridyl disulfide ethyl 
methacrylate (PDSMA), 2-aminoethyl methacrylate hydrochloride (AEMA) (Scheme 1). 
After polymerization, the polymers were purified by dialysis against dichloromethane to 
remove unreacted monomers, then characterized by NMR and GPC (Table 1). We used 
the characteristic resonances of the 2-pyridylthio moieties of PDS (dHa = 8.42, dHb = 7.63, 
dHc = 7.07 ppm), methoxy moieties of OEG (dH = 3.34, ppm), and methylene moieties of 
AE (dH = 3.78-3.46 ppm) to calculate the relative ratios of the monomer ratios for 
OEG:PDS:AE, which were similar for all copolymers. A range of different molecular 
weights were prepared, similar to those previously published, to access nanogels of various 
sizes.30 The number-average molecular weight (Mn) and dispersity (Đ = Mw/Mn) of the 
copolymers was evaluated by GPC. The AE moieties were then used as a handle to 
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covalently conjugate the near IR probe, NHS ester functionalized cyanine 7. The reaction 
extent was determined to be nearly complete by evaluation of free amine using 
fluorescamine assay, suggesting the p(OEGMA-co-PDSMA-co-Cy7) random copolymers 
contains ~3 mole % near IR dye (Figure 18). 
 
Scheme 1. (A) Synthetic scheme of p(OEGMA-co-PDSMA-co-Cy7) nanogel precursors; 
(B) schematic representation and corresponding reaction scheme of nanogel formulation 
by first crosslinking of PDS group by reducing agent DTT, then post-modification with 
poly(ethylene glycol) methyl ether thiol through thiol-disulfide exchange. 
 
The NIR-labeled nanogels were formulated by first dispersing the p(OEGMA-co-
PDSMA-co-Cy7) random copolymers (P1, P2 or P3) in the aqueous phase (10 mg/mL), 
then either diluting, heating, or mixing with sodium sulfate or sodium carbonate and 
monitored by DLS to manipulate the size of the self-assembled aggregates (Table 3). Once 
the desired size was achieved, the aggregates were locked under those specific solution 
conditions through intra-aggregate disulfide crosslink formation. The covalent crosslinking 
is achieved by addition of a stoichiometric amount of reducing agent DL-dithiothreitol 
(DTT), which generates the corresponding quantity of free thiols on PDS moieties in the 
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aggregate interior, which then react with the remaining PDS moieties in the polymer chain. 
For these nanogels, crosslink densities were quantified using the reaction byproduct 2-
pyridinethione’s characteristic absorption peak at 343 nm (Figure 19). The nanogel 
solution can then be manipulated (i.e. dilution, concentration, mild salt or heat treatment) 
without any consequence to the particle’s size.  
 
Figure 9. Size distribution of (A) Size Series (B) Length PEG Series (C) Percent PEG 
Series (D) Small Size High PEG Series nanogels obtained by DLS measurements in water.  
 
Next, the remaining PDS handles of the nanogels were modified with mPEG thiols 
of Mn 1000, 2000, or 5000 through thiol-disulfide exchange reaction (Table 3). This post-
modification was quantified by absorbance using the reaction byproduct 2-pyridinethione 
as previously demonstrated with post-modification with thiol ligands (Figure 19).31, 36 A 
high reaction extent was achievable with PEG Mn 1000 and 2000, ranging from ~80-97% 
remaining PDS groups, however it was more limited at ~68-72% with PEG Mn 5000. 
Additional excess PEG 5000 did not increase the conjugation extent, likely due to steric 
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congestion, as these nanogels still contained the highest total surface ethylene glycol. Final 
sizes of nanogels were obtained using DLS (Figure 9). Post-modification to the nanogels, 
particularly with Mn 5000, often increased smaller particles by as much as 10-20 nm in 
diameter, leading to some unavoidable size discrepancy in comparing smaller particles 
with differing PEG length. Five series of nanogels were prepared chronologically based on 
in vivo findings: size, length PEG, percent PEG, and small size high PEG (Table 2).  
Table 2. Size and corona properties of p(OEGMA-co-PDSMA-co-Cy7) nanogels. 
Series Name Diameter (nm) PEG (Mn) PEG (mole%) 
Size 28 nm 28 ± 9 1000 27 
Size 50 nm 50 ± 14 1000 40 
Size 80 nm 80 ± 20 1000 45 
Size 135 nm 135 ± 31 1000 45 
Length PEG 36 nm-PEG1K 36 ± 10 1000 51 
Length PEG 56 nm-PEG2K 56 ± 16 2000 49 
Length PEG 58 nm-PEG5K 58 ± 17 5000 37 
Length PEG 78 nm-PEG1K 78 ± 23 1000 53 
Length PEG 78 nm-PEG2K 78 ± 22 2000 51 
Length PEG 79 nm-PEG5K 79 ± 28 5000 40 
Percent PEG 49 nm 29% PEG 49 ± 13 2000 29 
Percent PEG 44 nm 24% PEG 44 ± 11 2000 24 
Percent PEG 42 nm 18% PEG 42 ± 12 2000 18 
Percent PEG 34 nm 6% PEG 34 ± 8 2000 6 
Percent PEG 31 nm 0% PEG 31 ± 9 2000 0 
Small Size High PEG 36 nm 46% PEG 36 ± 11 2000 46 
Small Size High PEG 35 nm 43% PEG 35 ± 12 2000 43 
 
2.2.2 Tumor Cell Implantation and Growth 
Triple negative breast cancer does not express the genes for estrogen receptor (ER), 
progesterone receptor (PRE), or human epidermal growth factor receptor 2 (Her2/neu).37 
Aside from surgery and radiation, patient treatment commonly uses combinatorial 
chemotherapeutics including anthracyclines, taxanes, and platinum agents. Also, these 
patients are not candidates for endocrine therapies used to treat other more common forms 
of breast cancer.38 Triple negative breast cancers comprise 15-25% of breast cancer cases, 
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and have shorter median relapses and lower survival times. Nanoparticle-based 
therapeutics are attractive for treatment of triple negative breast cancer since they have the 
potential to increase target-specific delivery, weaken side effects, and are compatible with 
combinatorial therapy.  
Cultured triple negative breast cancer cell line MDA-MB-231-luc-D3H2LN were 
implanted (5x106 cells, 50% Matrigel®) subcutaneously low in the right flank of each 6-7 
week old animal on Day 0 and tumors grown until they reach the size of ~200-400 mg 
(target 300 mg). On Day 19-21, depending on tumor growth progress of mice model, the 
body weights were obtained and tumor burdens were determined from caliper 
measurements. The average weights and estimated tumor burdens were in a well-matched 
range for the first day of treatment and imaging for each series. Mice were triaged into 
groups (n=5 mice per group) with tumor burden within 10% overall mean, then dosed once 
with a 100 µL nanogel by intravenous injection for imaging on Day 0.  
2.2.3 In Vivo FMT Tissue Distribution 
Fluorescence Molecular Tomography (FMT) is an in vivo whole body quantitative 
imaging modality that uses red to near-infrared (NIR) light in a wavelength range of 700–
900 nm. The deep tissue penetration of light up to 5 cm thick allows for time-dependent 
and non-invasive characterization of small animal subjects treated with NIR fluorescent 
probes in a 3-dimensional manner with a resolution of 1-2 mm.39, 40 The minimal NIR 
autofluorescence from biological tissue allows for quantitative information and sub-
picomolar sensitivity with the appropriate choice of probe with NIR excitation wavelength, 
high molar absorption coefficient and fluorescence quantum yield.  Cyanine 7 probe was 
chosen for covalent conjugation to nanogels for its NIR excitation (lmax: 750 nm, e: 
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199000) and emission (773 nm). 
In FMT imaging for nanogel samples, the total whole body fluorescence was 
obtained at time 0, when signal distribution is attributed to the animal vasculature, and then 
monitored over time to assess both clearance and changes in the tissue distribution, 
including extravasation into specific tissues. For all nanogels, the total body probe 
decreased over time, but was still detectable at 72 hours after administration (Figure 10, 
12, and 14). The fluorescence values at the 0-hour imaging time point for each nanogel 
sample were normalized in their group average total whole body probe, which scanned 
shoulders to base of the tail, as 100% (Figure 11, 13, and 15).  The normalized percentages 
were calculated at each imaging time point, so that the percent retention of total body probe 
signal over 0-72 hours could be compared between nanogel samples, despite minor 
variation of fluorophore concentration between nanogel samples. Tissue-based 
quantification of fluorophore concentration was obtained by manual positioning and 
scanning over the regions of interest (ROI). Fluorescence signals were significant and 
localized to the various tissues, allowing for quantification in the tumor, liver, spleen, 
intestines, lung and heart. To normalize the obtained fluorescence values, the percent 
injected dose (%ID) in the tissue of the total body probe signal per imaging time point were 
reported. For the tumor ROI, the primary endpoints were the percent injected dose per gram 
(%ID/g) tumor and used as an indicator for percentage of nanogel that accumulates in the 
tumor.  
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Figure 10. Size series quantitative in vivo (A) retention of total body probe over 72 hours; 
(B) %ID/g tumor over 72 hours; (C) tissue distribution for tumor, liver, spleen, intestines, 
lungs, heart, left and right kidney of 28 nm nanogel, (D) 50 nm nanogel, (E) 80 nm nanogel 
and (F) 135 nm nanogel following intravenous administration obtained by FMT imaging. 
Data are given as mean ± standard deviation (n = 5). *Tumor values are given %ID/g tumor 
to normalize for any variations in mass (all group mean estimated tumor burden: 343 mg, 
range: 312-396 mg). 
2.2.3.1 Size Series 
The 28, 50, and 80 nm nanogels showed a pattern of accumulation following 
injection over time to a maximum %ID/g tumor at 24 to 48 hours, followed by a decrease 
at 72 hours (Figure 10). The 135 nm nanogel had a generally constant %ID/g tumor 
observed from 0-48 hours followed by an increase at 72 hours. From initial injection to 
nanogels peak maximum %ID/g, the group average tumor percent increased 7, 7, 5, and 
4% for the 28, 50, 80, and 135 nm nanogel, respectively. In general, the observed 
accumulation trend correlated to a decrease in nanogel size, which all had a measurable, 
but non-significant, overall increase in %ID/g. This accumulation over time was observed 
despite a contrasting monotonic decrease in the whole body, liver, lungs, intestines, spleen, 
and heart (Figure 10, 11). This suggests that the nanogels exhibit a selective behavior 
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towards accumulation the tumor compared to normal tissues. The peak maximum %ID/g 
tumor was 12% (48 hours), 9% (48 hours) and 12% (24 hours), and 9% (72 hours) for 
nanogels 28nm, 50nm, 80nm, and 135 nm, respectively.   
The retention of total body probe for all nanogels decreased over time, with 
generally the smaller particles achieving higher retention, which is similar to the tumor 
accumulation trends (Figure 10). The 28 nm nanogel had the highest percentage retention 
in total body probe over time, with 79% of total signal retained at 72 hours. The second, 
third, and fourth highest retention in probe at 72 hours was the 80, 50, and 135 nm nanogels 
with 73, 65, and 59% of total signal retained, respectively.  
The liver was consistently the tissue with the highest localization (Figure 10, 11). 
For the 28 nm nanogel the liver %ID was at a maximum of 45% at 6 hours post injection, 
which deceased to 26% at 72 hours (Figure 11). For the 50 nm nanogel, the liver %ID was 
at a maximum of 42% at 6 hours post injection, which deceased to 24% at 72 hours. The 
80 nm nanogel was at a maximum liver %ID of 44% at 6 hours post injection, which 
deceased to 27% at 72 hours. Lastly, the 135 nm nanogel liver %ID was at a maximum of 
42% 0 hours post injection, which deceased to 23% at 72 hours, which was the highest rate 
of decreasing liver concentration. For all nanogels, the intestines, lungs, heart, and spleen 
showed a much lower %ID and similar general monotonic decrease over the time studied.  
The kidneys, showed minimal and virtually non-detectable %ID with < 1% for all nanogels 
and all imaging time points. 
  45 
 
Figure 11. Size series quantitative in vivo (A) whole body probe signal, (B) %ID liver, (C) 
%ID spleen, (D) %ID intestine, (E) %ID lungs, (F) %ID heart, (G) %ID left kidney, and 
(H) %ID right kidney over 72 hours following intravenous administration obtained by FMT 
imaging. Data are given as mean ± standard deviation (n = 5). 
 
General results from this series suggest that smaller nanogels gave measurably 
greater tumor specificity with higher %ID/g, a greater tumoral accumulation over time, and 
had higher total body retention over the time studied. However, the we were cautious to 
make far-reaching conclusions in this preliminary series due to sample variability (Table 
3) and the statistical significance of differences in values of tumor accumulation were not 
deemed sufficient. These findings, however, motivated the further investigation of the 28 
nm and 80 nm nanogels. Therefore, nanogels of a smaller and larger size were made, then 
decorated with different lengths of PEG: Mn 1000, 2000, and 5000, to obtain nanogels 36 
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nm-PEG1K, 56 nm-PEG2K, 58 nm-PEG5K, 78 nm-PEG1K, 78 nm-PEG2K, and 79 nm-
PEG5K (Table 2). Notice that PEGylation of the smaller size particles caused a 
considerable diameter increase from Mn 1000 to Mn 5000, while understandably not 
appreciably affecting the larger sized particles (Figure 9).  
 
 
Figure 12. Length PEG series quantitative in vivo (A) retention of total body probe over 
72 hours; (B) %ID/g tumor over 72 hours; (C) tissue distribution for tumor, liver, spleen, 
intestines, lungs, heart, left and right kidney of 36 nm-PEG1K nanogel, (D) 56 nm-PEG2K 
nanogel, (E) 58 nm-PEG5K nanogel, (F) 78 nm-PEG1K nanogel, (G) 78 nm-PEG2K 
nanogel and (H) 79 nm-PEG5K nanogel following intravenous administration obtained by 
FMT imaging. Data are given as mean ± standard deviation (n = 5). •%ID is 70 ± 51, with 
high error due to values from one mouse in group. *Tumor values are given %ID/g tumor 
to normalize for any variations in mass (all group mean estimated tumor burden: 316 mg, 
range: 312-323 mg). 
2.2.3.2 Length PEG Series 
Smaller nanogels showed a pattern of accumulation over time to a maximum %ID/g 
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tumor at 48 hours, except the 36 nm-PEG1K nanogel which increased up to 72 hours, 
exhibiting a selective behavior towards accumulation the tumor (Figure 12). This 
accumulation over time was observed despite a contrasting monotonic decrease in the 
whole body, liver, lungs, intestines, spleen, and heart (Figure 12, 13). An exception would 
be a small increase in the intestines in the smaller nanogels (36 nm-PEG1K, 56 nm-
PEG2K, and 58 nm-PEG5K). Larger nanogel patterns were less clear, with maximum 
%ID/g tumor occurring at 72 hours for 78 nm-PEG1K and 6 hours for both 78 nm-PEG2K 
and 79 nm-PEG5K. 
In general, the observed accumulation trend correlated to a decrease in nanogel size. 
The tumors showed a measurable, but non-significant, overall increase in %ID/g at variable 
times post-injection, followed by monotonic decreases to 72 hours. Over the time studied, 
the group average tumor percentage increased 12, 20, 13, 4, 5, and 4% for the nanogels 36 
nm-PEG1K, 56 nm-PEG2K, 58 nm-PEG5K, 78 nm-PEG1K, 78 nm-PEG2K, and 79 nm-
PEG5K, respectively (Figure 12). The peak maximum %ID/g tumor was 14% (72 hours), 
22% (48 hours), 17% (48 hours), 6% (72 hours), 7% (6 hours), and 4% (6 hours) for 
nanogels 36 nm-PEG1K, 56 nm-PEG2K, 58 nm-PEG5K, 78 nm-PEG1K, 78 nm-PEG2K, 
79 nm-PEG5K respectively. This generally also suggests that smaller nanogels (originally 
28 nm) gave higher tumor specificity, with 2-3-fold the peak %ID/g obtained compared to 
larger nanogels.  
The retention of total body probe for all nanogels decreased over time, with the 
smaller particles achieving nearly 2-fold the percent retention in total body probe compared 
to the larger particles, regardless of PEG length (Figure 12). This was well-matched with 
tumor accumulation trends amongst nanogels. The 36 nm-PEG1K had the highest 
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percentage retention in total body probe over time, with 82% of total signal retained at 72 
hours. The 56 nm-PEG2K nanogel had the second highest percentage retention in total 
body probe over time, with 79% of total signal retained at 72 hours, and the 58 nm-PEG5K 
nanogel also had high retention with 75% of total signal retained at 72 hours. The 78 nm-
PEG1K, 78 nm-PEG2K, and 79 nm-PEG5K nanogel had 35, 38, and 29% of total signal 
retained at 72 hours, respectively. 
The tissue accumulation for these nanogels were slightly more variable.  Generally, 
the liver showed the highest %ID, followed by the lungs (Figure 12, 13). Of the smaller 
nanogels, the 36 nm-PEG1K nanogel had a liver %ID of 53% 0 hours post injection, which 
deceased to 34% at 48 hours. The variability at the 72-hour time point is due to one mouse 
in its group having a high liver intensity. The spleen, intestines, and left kidney also had 
one mouse introducing variability at the 72-hour measurement, impacting the general 
pattern of decrease over time (Figure 13), while %ID values were generally low. Amongst 
all nanogels the kidneys again showed minimal and virtually non-detectable (< 1) %ID. 
The 56 nm-PEG2K nanogel had a liver %ID of 46% at 6 hours post injection, which 
deceased monotonically to 22% at 72 hours. Some tissues did not show the same pattern 
of decrease over time. The lungs had an elevated percentage to 48 hours at 12%, and the 
intestines and spleen showed some increase (8% and 4%, respectively) to 48 hours. The 58 
nm-PEG5K nanogel had a liver %ID of 49% at 48 hours post injection, and decreased to 
32% at 72 hours, a greater decrease than other nanogels. The lungs for this nanogel also 
had an elevated percentage to 48 hours at 11%, as did the spleen (2%) to 48 hours, and the 
intestines (7%) to 72 hours. 
For the larger nanogels, regardless of PEG length, the liver had considerable %ID 
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decrease over time suggesting rapid clearance of these nanogels (Figure 12). The 78 nm-
PEG1K nanogel had a liver %ID of 59% 0 hours post injection and deceased to 16% at 72 
hours (Figure 13). The intestines showed consistently low values over 72 hours, while the 
spleen showed generally low and decreasing %ID over the time studied. The 78 nm-
PEG2K nanogel had a liver %ID of 34% at 0 hours post injection, and decreased to 8% at 
72 hours. The intestines showed some increase to 6 hours followed by decrease over 72 
hours, the spleen was relatively constant. The 79 nm-PEG5K nanogel had a liver %ID of 
66% at 0 hours post injection, which deceased to 14% at 72 hours. The intestines showed 
some increase to 6 hours followed by decrease over 72 hours. These nanogels also showed 
generally low and decreasing %ID for the lungs, heart, and kidney. 
The results suggested that smaller nanogels had greater tumor specificity with 
higher %ID/g tumor, propensity to accumulate over time, and retention of total body probe 
over the time studied. The PEG2K decorated nanogels of both sizes performed slightly 
better with higher peak %ID/g compared to their 1k and 5k counterparts. We were therefore 
interested in further evaluating smaller particles decorated with different mole percent of 
PEG2K, to evaluate if a threshold advantage could be identified. Nanogels of 31 nm were 
made then decorated with PEG2K (0-29 mole percent) (Table 2) to achieve sizes ranging 
31 to 49 nm (Figure 9). 
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Figure 13. Length PEG series quantitative in vivo (A) whole body probe signal, (B) %ID 
liver, (C) %ID spleen, (D) %ID intestine, (E) %ID lungs, (F) %ID heart, (G) %ID left 
kidney, and (H) %ID right kidney over 72 hours following intravenous administration 
obtained by FMT imaging. Data are given as mean ± standard deviation (n = 5). 
2.2.3.3 Percent PEG Series 
Based on the general consistency of tissue profiles for previous nanogels, for this 
series only the total body probe and %ID/g tumor were obtained and calculated to establish 
relative nanogel performance. In this series, the whole total body fluorophore concentration 
was readily detected following administration, which then had 50% clearance and decrease 
to near-background levels by 24-48 hours (Figure 14, 15). With one nanogel, 34 nm 6% 
PEG, the whole-body fluorophore concentration reached background levels at 6 hours. The 
retention in total body probe over 72 hours was low, with 15, 15, 14, 3, and 15% observed 
for nanogels 49 nm 29% PEG, 44 nm 24% PEG, 42 nm 18% PEG, 34 nm 6% PEG, and 31 
nm 0% PEG, respectively. Such a detrimental effect was attributed to these lower PEG 
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percentages compared to previous systems.   
Compared to previous nanogels tested, these nanogels had a highest %ID/g tumor 
immediately after injection and decreased over 72 hours post-administration (Figure 14). 
This suggested no propensity towards tumor specificity or accumulation. The 49 nm 29% 
PEG nanogel had the peak %ID/g tumor at 0 hours with 15%, however one mouse 
introduced large variability in this time point measurement which normalized at subsequent 
time points. The %ID/g tumor then had a monotonic decrease to 3% at 72 hours. The peak 
%ID/g tumor then followed the trend in decrease in percent PEG, with nanogels 44 nm 
24% PEG, 42 nm 18% PEG, 34 nm 6% PEG, and 31 nm 0% PEG obtaining peak %ID/g 
of 4, 3, 2, and 2%, respectively.  
We expect these very rapidly cleared and low tumor accumulating samples are 
highly correlated to their lower PEG percentages which are conjugated on their surface 
compared to previously tested samples. It was surprising to see a decrease of 10-20 mole% 
PEG could impart such a detrimental effect to these nanogels.  Based on observed animal 
excretions this result is expected to be due to clearance through the renal system. We 
therefore wanted to reexamine these smaller nanogels that would be comprised of even 
higher percentages of PEG2K conjugated to their surface. Two nanogels were prepared: 
36 nm 46% PEG and 35 nm 43% PEG for FMT analysis (Table 2, Figure 9). 
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Figure 14. Quantitative in vivo (A) retention of total body probe and (B) %ID/g tumor of 
Percent PEG series (tumor burden all groups means: 377 mg, n = 5, range: 363-404 mg) 
and (C) retention of total body probe and (D) %ID/g tumor of Small Size High PEG series 
(tumor burden all groups means: 294 mg, n = 5, range: 283-301 mg) following intravenous 
administration. *Statistically significant (P<0.05) increase in tumor %ID/g from 0 hour of 
administration. Representative 2D fluorescent images (lateral view) of female Harlan 
Beige Nude XID mice with subcutaneously implanted MDA-MB-231-luc-D3H2LN cell 
line in the right flank injected with (E) 100 µL saline and (F) 100 µL 36 nm 46% PEG 
nanogel. 
2.2.3.4 Small Size Higher PEG 
The 36 nm 46% nanogel PEG had the peak %ID/g tumor at 72 hours with 27% 
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(Figure 14). This nanogel had a statistically significant (P<0.05), monotonic increase in 
the tumor %ID/g from 11-27% from 0-72 hours post-administration, an additional 
accumulation of 17% over the study, which constitutes a 1.5-fold increase compared to the 
0-hour tumor signal. Representative 2D fluorescent images of a mouse injected with saline 
and a mouse injected with the 36 nm 46% nanogel this group showed the increase in 
fluorescence intensity in the tumor ROI over time when treated with nanogel. This nanogel 
also had the highest retention in total body probe throughout the study, with 94% of total 
signal retained at 72 hours. This signifies only 6% of the injected dose was lost through 
elimination. 
The 35 nm 43% PEG nanogel had a peak %ID/g tumor at 6 hours with 28%, the 
highest maximum percentage achieved throughout this whole study (Figure 14). This 
nanogel had a statistically significant (P<0.05), monotonic increase in the tumor %ID/g 
from 16-28% from 0-6 hours post-administration, an additional accumulation of 12% over 
6 hours, which constitutes a 0.8-fold increase compared to the 0-hour tumor signal. The 
%ID/g tumor then monotonically decreased to a final 15% at 72 hours. This nanogel had 
less retention over the test period, with 70% of total whole body probe remaining at 72 
hours. 
The results again suggested smaller nanogels performed better in both tumor 
specificity with high %ID/g, accumulation over time, and retention of total body probe 
over time, with prerequisite that is contains extensive PEGylation. These results again 
suggest that nanogel surface PEG modification can dramatically impact the tumor 
accumulation and circulation retention. These results were consistent with general 
conclusions from the size series and the PEG length series, and suggests that a PEG2K-
  54 
modification has thus far imparted the greatest advantage in tumor specificity.  
 
Figure 15. FMT imaging in vivo whole body probe signal of (A) Percent PEG series 
nanogels and (B) Small Size High PEG series nanogels 72 hours following intravenous. 
Data are given as mean ± standard deviation (n = 5). 
2.2.3.5 Liver Localization 
The nanogels evaluated for full tissue profiles (size series and length PEG series) 
had the highest %ID in the liver. For all nanogels, throughout 72 hours the liver displayed 
a monotonic decrease in probe concentration over time. In all cases the liver localization 
at initial injection was frequently above 40% (Figure 10, 12). In the case of smaller 
particles, the %ID in the liver decreased to ~20-30% over 72 hours, however with larger 
particles they decreased to as little as ~10% (Figure 11, 13). The pattern of highest 
accumulation in the liver with slow monotonic decrease suggests that the nanogels are 
being cleared through the liver through hepatic uptake and not through kidney filtration. 
Nanoparticles can become sequestered in one of the RES organs following surface 
absorption of proteins leading to opsonization and removal from the blood stream. Despite 
PEG improvements on circulation, it has been shown that RES clearance is often 
significant even in optimized PEGylated systems, with >50% of the ID residing in the liver 
and spleen after 48 hours.41-44 An additional contributor to this observation is that the 
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noncontiguous vasculature in the liver with fenestrae pore size (50-100 nm) allows 
nanoparticles to penetrate their endothelial wall and nonspecifically accumulate.26  
2.2.3.6 Other Tissue Localization 
The second highest tissue of localization at initial imaging was the lungs, while the 
spleen, intestines, and heart showed less though detectable and resolvable %ID (Figure 10, 
12). The kidneys, however, showed minimal and virtually non-detectable %ID with < 1% 
for all nanogels and all imagining time points. Very little observed kidney localization 
indicates hepatic metabolism and not renal elimination as the mechanism of clearance. 
Also, relatively little spleen localization was observed, which is not always the case in 
polymeric nanoparticles.25 The considerable lung localization and low splenic 
accumulation may indicate that lung macrophages may contribute to particle uptake,45 but 
also may be a result of the mechanical deformability of these heavily PEGylated particles.46  
“Softer” deformation-prone nanoparticles and hydrogels  with high water content have 
been shown to reduce accumulation in the spleen compared to those with hydrophobic or 
tightly crosslinked cores.25, 47, 48 Further, recent microfluidic blood capillary models have 
shown that deformability of particles may aid in transport through small capillaries like 
those in the lung.46 The tissue profile obtained with these nanogels may likewise be 
impacted by the deformable parameter of these particles.  
2.2.4 Toxicity 
Injection of 100 µL of all samples were well-tolerated and throughout imaging no 
abnormal side effects were observed. For one mouse treated with the 28 nm nanogel sample 
(size series), during necropsy an edema in the abdominal cavity was observed. One mouse 
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treated with 36 nm-PEG1K nanogel and one mouse treated with 56 nm-PEG2K nanogel 
had an enlarged spleen and tumor-like growth on the pancreas (PEG length series). 
Separate mice treated with 56 nm-PEG2K, 78 nm-PEG1K, and 78 nm-PEG2K also had 
enlarged spleens. During necropsy, one mouse treated with 36 nm 46% PEG nanogel (small 
size high PEG series) was observed as having an enlarged spleen. For all other mice used 
throughout this study, no unusual observations were made during necropsy. 
2.2.5 Ex Vivo Tissue Distribution 
The ex vivo quantification of the fluorescence signal in individual tissue 
homogenates from gross necropsy 72 hours post injection was reasonably consistent with 
the in vivo FMT analysis (Figure 16). Comparing across tissues of mice treated with the 
PEG length nanogel series, ex vivo homogenates showed the highest intensity in the liver 
in all groups, followed by the tumor and intestines. The smallest nanogel in this series had 
considerable error in the FMT values at the 72-hour time point due to irregular values 
obtained for one mouse, which was not observed in tissue homogenates. Plots of in vivo 
versus ex vivo results for tissues gave variable correlation, with R2 values of 0.90, 0.89, 
0.70, 0.76 and 0.34, for nanogels 56 nm-PEG2K, 58 nm-PEG5K, 78 nm-PEG1K, 78 nm-
PEG2K, and 79 nm-PEG5K, respectively (Figure 17). The tissue introducing the greatest 
correlation deviation is the intestines, which gave higher efficiency values for homogenates 
than FMT. Ex vivo results gave slightly lower florescence values for the lungs than 
expected, while the liver, tumor, spleen, lungs, heart, and kidney fluorescence intensities 
were in reasonable agreement. Further, a similar trend between nanogels was observed in 
the tumor at this time-point for both in vivo and ex vivo results. Aside from minor 
discrepancies in intestine signals, ex vivo findings provided additional confidence in the 
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reliability of tissue signal segmentation by in vivo FMT. FMT distribution has been shown 
to well correlated with ex vivo results,49, 50 however performance can be impacted by tissue 
optical properties and depth.51, 52 Live imaging can be used in combination with X-ray 
computed tomography, magnetic resonance imaging, or diffuse optical tomography to 
improve either structural imaging or optical property accuracy.53-55 
 
Figure 16. Length PEG series nanogels (A) ex vivo quantification of tissue fluorescence 
efficiency (radiance of subject/illumination intensity) following final imaging and gross 
necropsy at 72 hours, quantified using filter set: ex: 710-760 nm, em: 810-875 nm, and (B) 
in vivo FMT comparison at 72 hours. •%ID is 70 ± 51, with high error due to values from 
one mouse in group. Data are given as mean ± standard deviation (n = 5). 
 
 
Figure 17. Comparison between in vivo FMT and ex vivo homogenate results of 
biodistribution values for tumor, liver, lung, spleen, intestine, heart, left kidney, and right 
kidney tissues using mean value of nanogels (n=5 in group) 56 nm-PEG2K, 58 nm-PEG5K, 
78 nm-PEG1K, 78 nm-PEG2K, and 79 nm-PEG5K. 
R² = 0.90
R² = 0.89
R² = 0.70
R² = 0.76
R² = 0.34
-5
0
5
10
15
20
25
30
35
40
0 1 2 3 4 5 6 7 8 9 10
In
 V
ivo
 F
M
T 
(%
ID
)
Ex Vivo Homogenates (Efficiency×10^5)
56 nm-PEG2K
58 nm-PEG5K
78 nm-PEG1K
78 nm-PEG2K
79 nm-PEG5K
Linear  (56 nm-PEG2K)
Linear  (58 nm-PEG5K)
Linear  (78 nm-PEG1K)
Linear  (78 nm-PEG2K)
Linear  (79 nm-PEG5K)
R² = 0.90
R² = 0.89
R² = 0.70
R² = 0.75921
R² = 0.34
-5
0
5
10
15
20
25
30
35
40
0 1 2 3 4 5 6 7 8 9 10
In
 V
ivo
 F
M
T 
(%
ID
)
Ex Vivo Homogenates (Effici ncy×10^5)
56 nm-PEG2K
58 nm-PEG5K
78 nm-PEG1K
78 nm-PEG2K
79 nm-PEG5K
Linear  (56 nm-PEG2K)
Linear  (58 nm-PEG5K)
Linear  (78 nm-PEG1K)
Linear  (78 nm-PEG2K)
Linear  (79 nm-PEG5K)
  58 
2.3 Conclusion 
In summary, NIR-labeled nanogels of various size and PEG content were 
formulated and exhibited discernable performance trends by in vivo FMT imaging. Using 
the model of triple negative human mammary carcinomas (cell line MDA-MB-231-luc-
D3H2LN), we determined that smaller nanogels (~30 nm) with a high PEG conjugation 
(~50 mole %) of Mn 2000 length performed better in both tumor specificity with highest 
maximum %ID/g, a greater accumulation over time, and greater retention of total body 
probe. These conclusions were supported by the consistency of smaller particles with 
extensive PEG conjugation outperforming those that were larger or less PEGylated. 
Nanogels without extensive PEGylation were excreted faster, even at similar sizes to 
PEGylated nanogels which achieved greater total body retention and tumor specificity. 
Nanogels had the highest %ID in the liver throughout the time studied, however like other 
tissues displayed a monotonic decrease over time suggesting the nanogels are being cleared 
by hepatic metabolism and not through the kidneys. The %IDs observed in RES organs are 
consistent with reported findings on other optimized PEGylated nanomaterials. 41-44 The ex 
vivo quantification of individual tissues from gross necropsy at 72 hours post injection 
generally showed trends that correlated with the FMT analysis, providing additional 
confidence in the reliability of tissue signal segmentation in vivo. Injection of all samples 
were well-tolerated and throughout imaging no abnormal side effects were observed. 
During necropsy, among the 85 mice used throughout this study, some observations 
included one mice with an edema in the abdominal cavity, five mice with enlarged spleens, 
two mice with a tumor-like growth on the pancreas. For all other mice, no unusual 
observations were made during necropsy. Overall, we determine here that minor physical 
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and chemical differences in these nanogels greatly impacted in vivo performance. Given 
that the key versatility of these nanogels arises from the fact that the self-assembly strategy 
offers enormous tunability in the nanoparticle, these findings will guide the design of next 
generation of nanogels as therapeutic delivery vehicles for cancer therapy. 
2.4 Experimental 
2.4.1 Materials and Methods 
Poly(ethylene glycol) methyl ether methacrylate (MW 475 g/mol, OEGMA), 2-aminoethyl 
methacrylate hydrochloride (AEMA), D,L-dithiothreitol (DTT), 4-cyano-4-
(phenylcarbonothioylthio)pentanoic, cyanine 7 NHS ester (Cy7), poly(ethylene glycol) 
methyl ether thiol (average Mn 1000, 2000, and 5000), and other conventional reagents 
were obtained from commercial sources and without further purification, unless otherwise 
mentioned. AIBN (2,2’-azobis(2-methylpropionitrile) was purchased from Sigma Aldrich 
and purified by recrystallization. MDA-MB-231-luc-D3H2LN cells were obtained from 
Xenogen Corporation (Caliper Life Sciences). Pyridyl disulfide ethyl methacrylate 
(PDSMA) was prepared as previously reported.56 Polymers were synthesized using RAFT 
polymerization and purified by dialysis using a membrane with 3500 MWCO. 1H-NMR 
spectra were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton 
resonance of the deuterated solvent as the internal standard. Polymer molecular weights 
were estimated by gel permeation chromatography (GPC, Waters) using THF as eluent at 
a flow rate of 1 mL/min by a refractive index detector compared to PMMA standard. 
Dynamic light scattering (DLS) measurements were conducted using a Malvern Nano 
Zetasizer. UV-visible absorption spectra were recorded on a Varian spectrophotometer 
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(model EL 0112047). Near-IR probe was quantified using a NanoDrop 2000C 
spectrophotometer.  
2.4.2 Experimental Procedures 
 
Scheme 2. Synthetic reaction scheme of p(OEGMA-co-PDSMA-co-AEMA). 
 
Synthesis of random copolymer p(OEGMA-co-PDSMA-co-AEMA) P1: To a Schlenk-
flask, monomers PDSMA (1.160 g, 4.54 mmol), OEGMA (800 mg, 1.68 mmol), AEMA 
(23.6 mg, 0.20 mmol), chain transfer agent 4-cyano-4-(phenylcarbonothioylthio)pentanoic 
acid (47.2 mg, 0.17 mmol), and AIBN (5.6 mg, 0.034 mmol) were dissolved in DMF (4 
mL). The mixture was degassed by performing three freeze-pump-thaw cycles and filled 
with argon.  The reaction mixture was then sealed and transferred into a pre-heated oil bath 
at 70 °C and stirred for 24 h.  The reaction flask was submerged in an ice bath to quench 
the polymerization, then dialyzed against dichloromethane in MWCO 3500 membrane for 
48 hours to remove unreactive monomers. The solution was dried to yield the random 
copolymer P1 as a waxy oil. GPC (THF) Mn: 6 kDa. Ð: 1.5. 1H NMR (400 MHz, CDCl3) 
δ (ppm): 8.49, 7.71, 7.15, 4.35-4.01, 3.76-3.51, 3.39, 3.05, 2.26-1.73, 1.18-0.78. The molar 
ratio of the three monomers in the polymer were determined by relative integrations of the 
aromatic protons of PDS, methoxy protons of PEG, and methylene protons of AE to 
give 29:68:3 (OEG:PDS:AE).  
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Synthesis of random copolymer p(OEGMA-co-PDSMA-co-AEMA) P2: To a Schlenk-
flask, monomers PDSMA (510 mg, 2 mmol), OEGMA (352 mg, 0.74 mmol), AEMA (14.7 
mg, 0.089 mmol), chain transfer agent 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid 
(10.3 mg, 0.037 mmol), and AIBN (1.2 mg, 0.0037 mmol) were dissolved in DMF (1.8 
mL). The mixture was degassed by performing three freeze-pump-thaw cycles and filled 
with argon.  The reaction mixture was then sealed and transferred into a pre-heated oil bath 
at 65 °C and stirred for 18 h.  The reaction flask was submerged in an ice bath to quench 
the polymerization, then dialyzed against dichloromethane in MWCO 3500 membrane for 
48 hours to remove unreactive monomers. The solution was dried to yield the random 
copolymer P2 as a waxy oil. GPC (THF) Mn: 13 kDa. Ð: 1.2. 1H NMR (400 MHz, Acetone-
D6) δ (ppm): 8.45, 7.66, 7.10, 4.35-3.97, 3.77-3.49, 3.34, 2.95, 2.12-1.67, 1.14-0.77. The 
molar ratio of the three monomers in the polymer were determined by relative integrations 
of the aromatic protons of PDS, methoxy protons of PEG, and methylene protons of AE to 
give 28:70:2 (OEG:PDS:AE).  
 
Synthesis of random copolymer p(OEGMA-co-PDSMA-co-AEMA) P3: To a Schlenk-
flask, monomers PDSMA (402 mg, 1.57 mmol), OEGMA (269 mg, 0.57 mmol), AEMA 
(11.4 mg, 0.07 mmol), chain transfer agent 4-cyano-4-(phenylcarbonothioylthio)pentanoic 
acid (6.9 mg, 0.025 mmol), and AIBN (0.8 mg, 0.005 mmol) were dissolved in DMF (1.2 
mL). The mixture was degassed by performing three freeze-pump-thaw cycles and filled 
with argon.  The reaction mixture was then sealed and transferred into a pre-heated oil bath 
at 65 °C and stirred for 18 h.  The reaction flask was submerged in an ice bath to quench 
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the polymerization, then dialyzed against dichloromethane in MWCO 3500 membrane for 
48 hours to remove unreactive monomers. The solution was dried to yield the random 
copolymer P3 as a waxy oil. GPC (THF) Mn: 22 kDa. Ð: 1.3. 1H NMR (400 MHz, Acetone-
D6) δ (ppm): 8.42, 7.63, 7.07, 4.37-3.93, 3.78-3.46, 3.34, 2.99, 2.10-1.60, 1.13-0.74. The 
molar ratio of the three monomers in the polymer were determined by relative integrations 
of the aromatic protons of PDS, methoxy protons of PEG, and methylene protons of AE to 
give 27:69:4 (OEG:PDS:AE).  
 
Scheme 3. Synthetic reaction scheme of p(OEGMA-co-PDSMA-co-Cy7). 
 
Synthesis of p(OEGMA-co-PDSMA-co-Cy7) P1-P3: To round bottom flasks, 
the p(OEGMA-co-PDSMA-co-AEMA) polymers P1-P3 (200 mg, 0.022 mmol AE) 
separately, each with Cy7 NHS ester (22.2 mg, 0.032 mmol), were dissolved in DCM (3 
mL) and purged with argon. Then triethylamine (6.14 µL, 0.044 mmol) was added and the 
mixtures were stirred for 12 hours at ambient temperature. Mixtures were purified by 
dialysis against dichloromethane in a MWCO 3500 regenerated cellulose membrane for 48 
hours. The solutions were dried to yield the Cy7-labeled polymers p(OEGMA-co-
PDSMA-co-Cy7) P1-P3 as waxy oils.  
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Cy7 Conjugation Quantification of p(OEGMA-co-PDSMA-co-Cy7): The presence of 
unreacted amine of AEMA monomer was evaluated by using the Fluorescamine reaction. 
Nanogels solutions (1 mg/mL, 93 nM amine/AE monomer) of precursor polymer 
p(OEGMA-co-PDSMA- co-AEMA), or NG-AE, and Cy7 reacted polymer p(OEGMA-co-
PDSMA-co-Cy7), or NG-Cy7, were prepared in PBS buffer pH 7.4. In a 96 well (flat-
bottomed) plate PBS buffer pH 7.4 (150 µL) and sample solutions NG-AE or NG-Cy7 (20 
uL) were added to each well. A blank control was prepared containing PBS buffer pH 7.4 
(170 µL). Then, fluorescamine solution in DMSO (12 µL, 465 nM) was added to each well 
and the fluorescence was obtained using a Molecular Devices Spectramax M5 plate reader 
(excitation: 390 nm; emission 465 nm). Average fluorescence values and deviation were 
obtained from replicate readings (n=3). The background fluorescence values from the 
blank solution was subtracted from values fluorescence intensity obtained for NG-AE and 
NG-Cy7 and normalized. Assuming complete fluorescamine reaction with free amines, 
there are was about 12.8% the fluorescence for NG-Cy7 compared to of NG-AE, indicating 
about 12.8% remaining amines of the NG-Cy7 sample (Figure 18). Of a polymer 
containing 3 mole percent polymer, this is only 04% or negligible, so we considered the 
conjugation sufficient.   
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Figure 18. Fluorescamine normalized fluorescence of free amine reaction of nanogel NG-
AE from precursor polymer p(OEGMA-co-PDSMA- co-AEMA) and NG-Cy7 of polymer 
p(OEGMA-co-PDSMA-co-Cy7), or NG-Cy7. 
 
Synthesis and Formulation of NIR-labeled Nanogels: Random copolymers p(OEGMA-
co-PDSMA-co-AEMA) were synthesized by reversible addition-fragmentation chain-
transfer (RAFT) polymerization to yield three polymers of Mn: 6.0 kDa with Ð: 1.5, Mn: 
13 kDa with Ð: 1.2, and Mn:22 kDa with Ð: 1.3, with monomer ratios for OEG:PDS:AE 
of 29:68:3, 28:70:2, and 27:69:4, respectively (see Supporting Information). The polymer 
was reacted with NIR probe, Cy7 NHS ester, to give covalently labeled polymer 
p(OEGMA-co-PDSMA-co-Cy7). The polymer was made into an aqueous particle 
suspension (10 mg/mL) using repeated cool and sonicate cycles until the solution appeared 
dissolved. Smaller aggregates (20-30 nm) were achieved at 25 °C sometimes requiring 
dilution (Table 3). To achieve aggregates, the polymer solutions were heated (to 40-50 
°C), requiring the presence of sodium sulfate or sodium carbonate (1-15 mM) in some 
cases, until desired sizes of aggregate were obtained, similar to conditions previously 
reported.30, 35 The crosslinking density was determined using the previously reported 
procedure by calculating the amount of 2-pyridinethione byproduct using its molar 
extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm).30, 31, 34 UV-vis absorption 
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measurements were performed on 1000-fold dilutions of crosslinking reaction solutions. 
Crosslinking percentage was calculating by assumption that cleavage of two PDS units 
would produce two pyridinethione byproduct and one disulfide bond. Nanogels were then 
post-modified with poly(ethylene glycol)monomethyl ether thiol (mPEG thiol) (average 
Mn 1000, 2000, and 5000) using simple thiol-disulfide exchange using the remaining PDS 
groups of the nanogels. Typically, mPEG thiol was dissolved in a minimum volume water 
then reacted with crosslinked nanogel solution at PDS molar equivalencies of 1, 1.2, and 
2, for Mn 1000, 2000 and 5000, respectively, and stirred for 24 hours. For example, 
PEG(1000)-SH (27.5 mg, 0.0275 mmol) was dissolved in a minimum volume of water  
(170 µL) then added to the crosslinked nanogel solution (11.55 mg, 0.0275 mmol) and 
stirred for 24 hours. Pyridinethione concentration calculations using its molar extinction 
coefficient was supported by comparison with addition of excess DTT, to obtain 100% 
pyridinethione generation. The conjugation extent was then determined using UV-vis 
absorption by quantification of pyridinethione absorbance at 343 nm as previously 
described.30, 31, 36 Dynamic light scattering experiments to obtain particle size were 
performed by using a digital correlator and goniometer with a light source operating at 514 
nm. Final nanogel size measurements were obtained at 25 °C at a correlation time of 30 
seconds. Dust was removed by filtering the solution through 0.45 µm polycarbonate filter. 
Final polymeric nanogel concentrations were calculated using initial feed, and final probe 
concentrations were determined using a NanoDrop 2000C spectrophotometer to obtain the 
absorbance of Cy7 (lmax: 750, e: 199000). 
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Figure 19. UV-vis absorption Spectra of pyridinethione byproduct at 343 nm (A) 
crosslinking reaction with DTT and (B) PEG conjugation with poly(ethylene glycol) 
methyl ether thiol Mn 2000, each with comparison to 100% pyridinethione from reaction 
with excess DTT. 
 
Table 3. Nanogel formulation, crosslink (CL) and mPEG-thiol conjugation information.  
Name Polymer Formulation Conditions 
CL 
(mole%) 
PEG 
(Mn) 
PEG %  
(PDS) 
PEG 
(mole%) 
28 nm P2  5 mg/mL, 25 ºC 42 1000 97 27 
50 nm P1 10 mg/mL, 15 mM Na2SO4, 25 ºC 28 1000 95 40 
80 nm P2  5 mg/mL, 1 mM Na2CO3 50 ºC 14 1000 80 45 
135 nm P2 5 mg/mL, 2.5 mM Na2CO3, 50 ºC 14 1000 80 45 
36 nm 
PEG-1K P1  
10 mg/mL, 1.5 mM Na2SO4, 25 
ºC 16 1000 94 51 
56 nm 
PEG-2K P1 
10 mg/mL, 1.5 mM Na2SO4, 25 
ºC 16 2000 91 49 
58 nm 
PEG-5K P1 
10 mg/mL, 1.5 mM Na2SO4, 25 
ºC 16 5000 68 37 
78 nm 
PEG-1K P1 5 mg/ml, 1 mM Na2CO3, 50 ºC 14 1000 94 53 
78 nm 
PEG-2K P1  5 mg/ml, 1 mM Na2CO3, 50 ºC 14 2000 91 51 
79 nm 
PEG-5K P1  5 mg/ml, 1 mM Na2CO3, 50 ºC 14 5000 72 40 
49 nm 29% 
PEG P2 10 mg/mL, 40 ºC 21 2000 63 29 
44 nm 24% 
PEG P2 10 mg/mL, 40 ºC 26 2000 48 24 
42 nm 18% 
PEG P2 10 mg/mL, 40 ºC 36 2000 54 18 
34 nm 6% 
PEG P2  10 mg/mL, 40 ºC 58 2000 43 6 
31 nm 0% 
PEG P2 10 mg/mL, 40 ºC 68 2000 N/A 0 
36 nm 46% 
PEG P3  10 mg/mL, 2 mM Na2CO3, 25 ºC 14 2000 82 46 
35 nm 43% 
PEG P3 10 mg/mL, 2 mM Na2CO3, 25 ºC 21 2000 88 43 
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Final Nanogel Cy7 Probe Concentration: The Cy7 probe concentration in final nanogel 
solutions were obtained by UV-vis absorption measurements using its molar extinction 
coefficient (199000 M-1 cm-1 at 759 nm) at Near-IR probe was quantified using a 
NanoDrop 2000C spectrophotometer. Concentrations were calculated assuming a path 
length of 1 mm.  
 
Figure 20. UV-vis absorption Spectra of Cy7-conjugated nanogel obtained using a 
NanoDrop spectrophotometer. 
 
Table 4. Nanogel formulation conditions and final Cy7 and polymer concentrations for in 
vivo injection. 
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Cy7 Polymer Absorbance
Series Name Polymer (mg/mL) Cy7 (µM) 
Size 28 nm 5.1 38 
Size 50 nm 4 18 
Size 80 nm 4.5 13 
Size 135 nm 2.2 27 
Length PEG 36 nm-PEG1K 0.69 45 
Length PEG 56 nm-PEG2K 0.69 23 
Length PEG 58 nm-PEG5K 0.69 16.8 
Length PEG 78 nm-PEG1K 0.69 127 
Length PEG 78 nm-PEG2K 0.69 50 
Length PEG 79 nm-PEG5K 0.69 26.9 
Percent PEG 49 nm 29% PEG 2.5 88 
Percent PEG 44 nm 24% PEG 2.5 100 
Percent PEG 42 nm 18% PEG 2.5 96 
Percent PEG 34 nm 6% PEG 2.5 100 
Percent PEG 31 nm 0% PEG 2.5 150 
Small Size High PEG 36 nm 46% PEG 2.2 112 
Small Size High PEG 35 nm 43% PEG 2.2 727 
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Animals and Husbandry: All animal work was conducted by Molecular Imaging, Inc. 
This experiment used female Harlan Beige SCID mice (Hsd:NIHS-LystbgFoxn1nuBtkxid), 
which lack T, B, and NK cells, for size and length PEG series nanogels, female Harlan 
Nude mice (Hsd:AthymicNude-Fox1nu), which lack T cells, for percent PEG series 
nanogels, and female Harlan Beige Nude XID mice (Hsd:NIHS-Lystbg-JFox1nuBtkxid) for 
small sixe high PEG series nanogels that were all 6-7 weeks old at the time of implantation. 
Animals were fed ad libitum (water and irradiated Harlan 2918.15 Rodent Diet) and housed 
inside Biobubble® Clean Rooms with Bed-O’CobsTM bedding with an environment of 
70±2 °F and 30-70% humidity. All measurements and imaging were conducted in the 
bubble environment with filtered high efficiency particulate air and 100 air changes per 
hour. All animal procedures were carried out under compliance with National Institutes of 
Health (NIH) guidelines and with Molecular Imaging, Inc.’s (AAALAC accredited and 
PHS assured facility) Animal Care and Use Committee approval. 
 
Cell Preparation: MDA-MB-231-luc-D3H2LN cells were grown in Minimal Essential 
Media (MEM) with Earle's Balanced Salt Solution (EBSS) supplemented with 10% Fetal 
Bovine Serum (FBS), 1% penicillin-streptomycin-glutamine (PSG), 1% L-glutamine, 1% 
non-essential amino acids, and 1% sodium pyruvate. Cells were grown at 5% CO2 and 37 
°C and, after expansion, cells (passage 5) were suspended using trypsin 0.25% and 2.21 
mM EDTA in Hank's Balanced Salt Solution (HBSS) then trypsin was deactivated with 
complete growth media. Cells were counted using Trypan Blue exclusion and a 
hemacytometer then centrifuged (1,374 rpm, 8 min), decanted, then resuspended in serum-
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free media (2.5x107 cells/ml). On day 0, cells (5x106, 200 µL) with 50% Matrigel® were 
implanted subcutaneously low in the right flank of each animal using a 27-guage needle in 
the animals. Three thioglycolate cultures of tumor cells tested negative for gross bacterial 
contamination. Daily clinical observations were made and moribund or distressed animals 
or those bearing ulcerated, weeping, or excessive (>1 gram) tumors were euthanized.  
 
Measurements and Endpoints: Measurements were conducted using reported general 
principles.57-63 At the initiation of imaging (sample injection Day 0), animal body weights 
were recorded and tumor burden determined from caliper measurements of orthogonal 
length (L) and width (W) in mm, and using the prolate ellipsoid formula: (L x W2)/2 = 
tumor burden (mg). The primary endpoints for evaluation are total whole body probe signal 
and percent injected dose per gram of the tumor region of interest (%ID/g), and secondary 
endpoint are percent injected dose (%ID) for heart, lungs, liver, kidneys, spleen, and 
intestines. Percent injected dose is defined by the probe signal in the tissue divided by 1.15-
fold the total whole body probe signal [%ID/(1.15´ total whole probe signal)] to account 
for head mass, a common assumption.57 The percent injected dose per gram (%ID/g) is 
defined by %ID for the tumor region of interest (ROI) divided by the tumor weight in 
grams. 
 
Treatment: Following tumor implantation at Day 0, on Day 21 body weights were 
obtained and tumor burdens were determined from caliper measurements. For size series 
nanogels, the average SCID Beige mice weights (range of group means: 20.6- 21.2 g, all 
≥18.0 g) and estimated tumor burden (all groups means: 343 mg, range: 312-396 mg) were 
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in a well-matched range for the first day of treatment and imaging. For PEG length series 
nanogels, on Day 21 the average SCID Beige weights (range of group means: 19.4-20.4 g, 
all ≥17.8 g) and estimated tumor burden (all groups means: 316 mg, range: 312-323 mg) 
were in a well-matched range for the first day of treatment and imaging. For percent PEG 
series nanogels, the growth rate of tumors in the nude mice was slightly faster, with animal 
weights (range of group means: 20.9-22.6 g, all ≥19.0 g) and estimated tumor burden (all 
groups means: 377 mg, range: 363-404 mg) were in a well-matched range and, still within 
the historical norms for this model, ready for treatment and imaging at Day 19. Similarly, 
for small size high PEG series nanogels the beige nude mice on Day 19 were a little larger 
(range of group means: 20.6-22.4 g, all ≥19.3 g) and estimated tumor burden (all groups 
means: 294 mg, range: 283-301 mg) were in a well-matched range for the first day of 
treatment and imaging. Mice were triaged into groups so that the tumor burden was within 
10% of the overall mean. Following weight and tumor burden measurements, mice were 
dosed once with a single injection of 100 µL nanogel solution in endotoxin free water for 
imaging on Day 0 (n=5 mice per nanogel solution were treated in each group).  
 
Fluorescence Molecular Tomography: Following sample injection, mice were 
individually imaged in vivo at 0, 6, 24, 48 and 72 hours by 3D FMT using the Perkin-Elmer 
FMT 2500TM LX Quantitative Tomography Imaging System. Just prior and throughout 
imaging mice were anesthetized with 2% isoflurane gas, then placed in the supine position 
in the imaging cassette, which was then was inserted to the heated (37 °C) docking system 
in the FMT imaging chamber. Prior to scanning the fluorescence scan region was manually 
positioned from the shoulders to base of tail for full body imaging (representative images 
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Figure 14). Total whole body signal was increased by 15% to account for body mass from 
non-imaged head.57 Specific regions of interest were scanned by manual positioning over 
the regions of interest using a medium source density (3 mm). Obtained images were 
analyzed using Perkin-Elmer TrueQuant software.  
 
Ex Vivo Imaging: Following final imaging at 72 hours, gross necropsy was performed and 
ex vivo images were acquired. On an IVIS 50 2D reflectance fluorescence images were 
obtained using the Indocyanine Green (ICG) filter set (ex:710-760 nm, em: 810-875 nm). 
Several hundred counts from each tissue were observable without saturation using 20 
seconds of exposure and large binning off CCD camera chip, and image analysis was 
performed using Living Image software (Caliper Life Sciences, Hopkinton, MA). The 
signal intensities of each tissue were quantified by efficiency (radiance of 
subject/illumination intensity). 
 
Assessment of Side Effects: Throughout tumor growth and sample treatment animals were 
observed for clinical signs daily. Following treatment and euthanasia, or in the case of any 
inadvertent death, animals were necropsied for general assessment and specific organ 
toxicity including edema or enlargement. For each animal, the existence or absence of 
tumor metastases was recorded. 
 
Statistics: Data are expressed as mean ± standard deviation of the five mice tested per 
sample. Significance of data was analyzed using one-way analysis of variance (ANOVA), 
and post-hoc analysis by the method of Holm-Sidak. A Kruskall-Wallace ANOVA by 
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ranks with post-hoc analysis was performed if the data did not pass normality or equal 
variance testing, by the method of Tukey. Statistical comparisons were performed for the 
total body probe between time points within each group, and between groups at each time 
point.  Statistical comparisons of %ID/g tumor were performed between time points within 
each group, and between groups at each time point. Likewise, statistical comparisons of 
%ID of individual tissues were performed between time points within each group, and 
between groups at each time point. Statistically significant differences were set at p values 
≤ 0.05, and calculated using SigmaPlot 12.0 software. 
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CHAPTER 3 
 
EVALUATION OF EFFICACY AND SAFETY OF DOCETAXEL-LOADED 
NANOGELS IN MICE BEARING TRIPLE NEGATIVE HUMAN MAMMARY 
CARCINOMA 
3.1 Introduction 
Hydrophobic therapeutic molecules can suffer from poor bioavailability, hydrolytic 
or enzymatic instability, and non-specific treatment leading to side effects, low efficacy, 
short half-life, and frequent administration.1,2 Many therapeutic candidates fail during 
development due to poor tolerability or efficacy from these complications. Formulation of 
drugs through encapsulation, conjugation, emulsion, or nanocrystalline methods can 
enhance their pharmacokinetic and pharmacodynamics properties through aqueous 
suspension and shielding the active compound during transport.3 However, development 
of drug delivery systems that satisfy a multitude of criteria remains a technical challenge.4 
Several factors can diminish the performance of therapeutic formulations, including non-
specific accumulation in healthy tissues, clearance, protein binding, and degradation.5-7  
Nano-scale formulations have attracted increased attention in the treatment of solid 
tumor type cancers due to the discovery of the enhanced permeability and retention (EPR) 
effect.8, 9 Nanoparticles can migrate through fenestrated neovasculature and accumulate in 
tumors, and content retention is aided by poor lymphatic drainage.10 To this end, a variety 
of nano-scale morphologies have been explored to enhance tumor delivery and protect 
therapeutic contents, including micelles, liposomes, and polymeric nanoparticles. Some 
examples of chemotherapeutic formulations include protein complexes such as 
Abraxane,11 micelle formulations such as NK105 and Genexol,12,13 and polymer conjugates 
such as Opaxio and Cellax.14-18  
Taxane chemotherapeutics such as such as paclitaxel (PTX) and docetaxel (Doc) 
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are frequently used to treat a common cancer indications including breast, non-small cell 
lung cancer, and prostate cancer.19 However, their solvent-based formulations induce 
systemic side effects from non-specificity, including neuropathy and neutropenia. 
Commonly used formulations such as solubilizing agent Cremophor EL can induce 
hypersensitivity responses in patients. Docetaxel has received increased interest from the 
Polysorbate 80 formulation, which has reduced toxicity and improved clinical results, but 
can still cause hypersensitivity responses.19-21 
For hydrophobic drugs, liposomes can be limited by their lipid bilayer capacity, 
and can be loaded to a higher extent with aqueously soluble or amphiphilic drugs, such as 
doxorubicin.22-25 Further, stability in serum is a concern because encapsulated hydrophobic 
contents can be subject to burst release in liposomal structures.22 Micelles, formed through 
self-assembly of small molecule amphiphiles or detergents, are better candidates for 
suspension of hydrophobic contents, however they often suffer from high critical 
aggregation concentrations (CACs) and poor mechanical stability. Polymeric nanoparticles 
that form micelle-type aggregates, however, generally have greater stability and low CAC 
values, making them good candidates for use as nano-containers.26 
 Genexol and NK105 are polymeric micelle-type formulations that non-covalently 
encapsulate PTX and have shown improved pharmacokinetics and efficacy compared to 
free PTX in preclinical models.12, 13, 27 However, in clinical trials, drug release in plasma 
and adsorption to proteins such as serum albumin and alpha-1-glycoprotein led to reduced 
tumor efficacy and pharmacokinetic profiles like those of free PTX. Non-covalent systems 
have also been explored with Doc, including encapsulation in PLA-PEG block copolymer 
assemblies, with surface ligand decoration for the binding of prostate-specific membrane 
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antigen on prostate cancer cells as well as non-prostate solid tumor neovasculature.28 In 
preclinical evaluation, this system demonstrated enhanced accumulation and tumor growth 
suppression after 12 hours in tumor bearing mice, compared to solvent-based Doc 
formulations. Further, the plasma concentrations of the Doc-loaded targeted nanoparticle 
after 24 hours were 100-fold compared to solvent based Doc formulations.  
Alternatively, the covalent conjugation of taxanes to polymeric delivery vehicles 
has been explored in efforts to limit drug partitioning and avoid side effects.6,29 Some drug-
conjugate systems have suffered lower efficacy compared to solubilizing agent-based 
taxanes administered at the same dose.30 One system, Opaxio, a conjugate of PTX and 
polyglutamate, was well tolerated and showed improved efficacy over PTX, but ultimately 
suffered from degradation in serum, non-specific distribution to the liver, spleen, kidney, 
and heart, and did not exhibit improvement over classic chemotherapy.14-16 A taxane-
polymer conjugate comprised PEGylated cellulose-Doc has also been explored for 
antitumor efficacy.17 This amphiphilic micelle-type aggregate, Cellax, exhibited 5.5-fold 
tumor uptake and improved efficacy compared to Taxotere, a Polysorbate 80 formulation, 
and exhibited tumor retention for several days. Cellax demonstrated greater safety with 
less non-specific accumulation in the kidney, lung and heart compared to Taxotere. The 
formulation was then evaluated in different tumor models (EMT-6, B16F10, PC3, and 
MDA-MB-231), and variability in efficacy was observed, which was directly associated 
with extent of tumor uptake of each model.18 
We have developed a drug delivery platform based on an amphiphilic random 
copolymer capable of self-assembly, encapsulation of hydrophobic contents, and core 
chemical crosslinking. This nanogel design can address limitations of existing systems due 
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to its highly tailorable size, crosslink percentage, and post-formulation surface PEGylation. 
We have previously shown that the circulation time and tumor accumulation of these 
particles can be improved by PEGylation of their surfaces. Here, we aimed to evaluate the 
preclinical in vivo therapeutic efficacy of Doc loaded nanogels in triple negative breast 
cancer models MDA-MB-231 xenograft, PDX BR1458, PDX BR1474, and PDX BR1282 
in BALB/c nude mice. Triple negative breast cancer is often treated with combinatorial 
chemotherapeutics including anthracyclines, taxanes, and platinum agents. 31 Triple 
negative breast cancer does not express the genes for estrogen receptor (ER), progesterone 
receptor (PRE), or human epidermal growth factor receptor 2 (Her2/neu), and is not a 
candidate for endocrine therapies used to treat other more common forms of breast 
cancer.32 Triple negative breast cancers comprise 15-25% of breast cancer cases, and have 
shorter median relapses and lower survival times. Therefore, nanoparticle-based 
therapeutics are attractive for treatment of triple negative breast cancer due to their 
potential to increase target-specific delivery, weaken side effects, and compatibility with 
combinatorial therapy. 
3.2 Results and Discussion 
 The objective of this study was to evaluate the in vivo efficacy of Doc loaded 
nanogels in triple negative human breast cancer models in BALB/c nude mice. The 
therapeutic efficacy of two nanogels (NG1 and NG2) loaded with Doc was studied in four 
triple negative breast cancer models: MDA-MB-231 xenograft, PDX BR1458, PDX 
BR1474, and PDX BR1282. Efficacy nanogels were studied in the four models, where each 
model uses 3 arms with 10 mice each.  The three arms include: 1.) dose of compound (Doc 
loaded nanogel), 2.) negative control, and 3.) Doc positive control. The desirable Doc 
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dosage schedule was 10 mg/kg/week. The dosing will be 4 injections/week for up to 3 
weeks, or 10 mg/kG QWx3, where QW = once a week. 
3.2.1 Synthesis and Formulation of Docetaxel-Loaded Nanogels 
 All nanogel characteristics (polymer Mn and monomer composition, as well as 
particle size, crosslink density, PEG post-modification) were motivated on previously 
obtained biodistribution results. Previously, the biodistribution nanogels were comprised 
of a 21.6 K polymer with, monomer ratio PDS:OEG:Cy7 near IR tag of 69:28:3. Aqueous 
polymer solutions were used to generate 30 nm precursor nanogels, covalently crosslinked 
20-30%  then post modified with PEG thiols (Mn 2,000) to reach sizes ranging from 
approximately 30-40 nm. Among other nanogels tested, these samples obtained the highest 
maximum %ID/g tumor over a 72-hour period. Encapsulation efforts in these nanogels, 
however, yielded poor Doc loading, with 0.4-0.5 weight percent achieved. Extensive 
precipitation of the drug was observed during the PEGylation step of formulation, which 
severely compromised the hydrophobicity of the particle core. Therefore, alternative 
designs were pursued to with the aim to compromise particle size and PEG content 
parameters with higher guest encapsulation.  
 To achieve this, a strategy for post-modification with PEG on the hydrophilic OEG 
moieties of the polymer assembly, rather than on hydrophobic PDS moieties, was pursued. 
Orthogonal NHS ester-amine coupling chemistry was chosen as the method to post 
functionalize the polymer with PEG due to its aqueous phase compatibility. To this end, a 
random copolymer was synthesized with amine functionality on the terminus of OEG units 
in the polymer (Scheme 4). To optimize aggregation characteristics, random copolymers 
with various amine composition were made from synthesis of precursors p[(BocNH-OEG8-
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MA)-co-PDSMA] by RAFT polymerization, and characterized by 1H NMR spectroscopy.  
Monomer ratios were determined by relative integrations of the aromatic protons of PDS 
and ethylene protons of BocNH-OEG to give 28:72, 34:66, and 46:54 BocNH-OEG:PDS 
for the three polymers. The polymers were determined to have similar molecular weights 
by GPC with Mn 14.7 kDa Ð:1.29, Mn 15.8 kDa Ð:1.4, and Mn 18.7 kDa Ð:1.3, 
respectively. The Boc groups were removed by TFA to yield random copolymers p[(NH2-
OEG8-MA)-co-PDSMA 28:72, 34:66, and 46:54. The polymers were then post modified 
with alkane thiol to substitute half of remaining PDS groups that would not be used for 
crosslinking, to generate random copolymers p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] 28:36:36, 24:33:33, 46:27:27 for NH2-OEG:PDS:Dodecyl, as determined by 
relative integrations of the aromatic protons of PDS, ethylene protons of NH2-OEG, and 
ethylene protons of dodecyl.  
 
Scheme 4. Synthesis of surface functionalizable amphiphilic random copolymer p[(NH2-
OEG8-MA)-co-PDSMA-co-Dodecyl]. 
 
 The aggregation characteristics of polymers where then monitored by DLS. The 
polymers were made into an aqueous particle suspension (10 mg/mL) using repeated chill 
and sonicate cycles. Doc was loaded by dissolving 5 weight % in acetone and adding it to 
the polymer solution at a 1:1 volume ratio for acetone:water and left stirring open to 
atmosphere until the acetone evaporated. Aggregates of ~20 nm were achieved at 25 °C 
with polymer containing 46% NH2-OEG, but less than 10 nm for 28 and 34% NH2-OEG 
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(Figure 21). Upon heating the solutions to 45 °C, 46% NH2-OEG aggregates did not 
increase above 20 nm while 28 and 34% NH2-OEG increased slightly to ~10 nm, so 
crosslinking with DTT was performed at 45 °C. Following crosslinking, post-conjugation 
was achieved with PEG(2000)-NHS ester (Scheme 5). Nanogel were standardized to 1´ 
PBS pH 7.4 by addition of 10´ PBS buffer, then brought to pH 8-8.5, and poly(ethylene 
glycol) methyl ether N-hydroxy succinimide ester (average Mn 2000) was added. The 
solution was stirred for 48 hours at ambient temperature, and, following dialysis 
purification, was characterized to be 31, 32, and 25 nm for polymers 28, 34% 46% NH2-
OEG.  
 
Scheme 5. Synthesis of surface functionalizable amphiphilic random copolymer p[(NH2-
OEG8-MA)-co-PDSMA-co-Dodecyl]. 
 
Table 5. Characteristics of amine monomer variation random copolymers p[(NH2-OEG8-
MA)-co-PDSMA-co-Dodecyl] and resultant nanogel. 
NH2-
OEG 
PDS Dodecyl Mn Ð Conditions Size (nm) 
28 36 36 14744 K 1.29 10 mg/mL, 45°C 31 
34 33 33 15839 K 1.35 10 mg/mL, 45°C 32 
46 27 27 18711 K 1.38 10 mg/mL, 45°C 25 
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Figure 21. DLS sizes of amine monomer (NH2-OEG) variation aggregates A) Docetaxel-
loaded aggregates, B) temperature responsiveness of 46% NH2-OEG, C) temperature 
responsiveness of 34% NH2-OEG, D) crosslinked aggregates, and E) PEGylated final 
nanogel sizes, with NG1, NG2, NG3 representing 28% NH2-OEG, 34% NH2-OEG and 
46% NH2-OEG polymers, respectively.  
  
 From this amine monomer variation, we established that any of these NH2-OEG 
ratios could achieve appropriate target sizes with temperature manipulation. Moving 
forward we aimed to vary the crosslink to dodecyl ratio to investigate any effects on 
encapsulation efficiency, with ~34% NH2-OEG polymer. Precursor polymer p[(BocNH-
OEG8-MA)-co-PDSMA] of Mn 16 kDa Ð:1.2, and monomer ratio 36:64 BocNH-
OEG:PDS was synthesized, then post modified with 2-dodecanethiol to various extents. 
Polymers p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] were determined to be 36:64:0, 
36:51:13, 36:42:22, and 36:37:27 for BocNH-OEG:PDS:Dodecyl. TFA removal of Boc 
groups then yielded p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] polymers of the same 
respective ratios. After aggregate suspension and Doc loading (5 weight %), the two 
polymers containing 0 and 13% Dodecyl could not be manipulated with temperature or 
Hoffmeister salts to achieve target sizes. However, ~20 nm aggregates were achieved with 
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10 mg/mL at 40 °C and 13 or 22 mM Na2CO3 for 22 and 27% Dodecyl, respectively 
(Figure 22, Table 6). 
 
Figure 22. DLS sizes of A) 10 mg/mL aggregates, B) temperature responsiveness of DOC-
loaded 22% Dodecyl, C) temperature responsiveness of DOC-loaded 27% Dodecyl, D) 
replicates of crosslinked 22% DOC Dodecyl and 27% DOC Dodecyl. 
 
Table 6. Characteristics of dodecyl monomer variation random copolymers p[(NH2-OEG8-
MA)-co-PDSMA-co-Dodecyl]. 
NH2-OEG PDS Dodecyl Mn Ð Conditions Size (nm) 
36 64 0 16.2 K 1.2 N/A N/A 
36 15 16.2 16.2 K 1.2 N/A N/A 
36 42 22 16.2 K 1.2 10 mg/mL, 40 °C, 13 mM Na2CO3 20 nm 
36 37 27 16.2 K 1.2 10 mg/mL, 40 °C, 22 mM Na2CO3 20 nm 
 
 The Doc loading in these nanogels were then evaluated by HPLC. To do this, a 
calibration curve of area under the curve (AUC) of absorbance at 214 nm of various Doc 
concentrations was prepared (Figure 23). Docetaxel solutions in methanol were injected 
at a set volume (20 µL) to and characterized by HPLC using a C18 column (4.6 mm × 10 
cm, 2.7 µm particle size) using a gradient mobile phase of acetonitrile 0% to 70% 
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acetonitrile in water, both containing 0.05% (v/v) trifluoroacetic acid, monitoring 
absorbance of 214 nm at a flow rate of 1 mL/min. Docetaxel showed consistent retention 
time of 16.6 min so that AUC for 214 absorbance could be compared for different 
concentrations of injections. The linear fit for 0.01-1 mg/mL Doc, performed in triplicate, 
gave R2=0.99. Thus, concentrations of Doc could be calculated for unknown samples using 
obtained AUC for absorbance of 214 nm at 16.6 min. These values were obtained by 
disrupting aggregate encapsulation integrity by adding acetone (1:1 volume %) to nanogel 
solutions, then characterizing HPLC results of 20 µL of this solution. Nanogels with 22 
and 27% dodecyl, prepared in duplicate, achieved average Doc loads of 0.9 and 1.23%, 
respectively (Table 7). With feeds or 5 weight %, this suggests that efficiency was low, 
with 18 and 25% for nanogels with 22 and 27% dodecyl, respectively. 
 
Figure 23. HPLC A) calibration curve of docetaxel from absorbance at 214 nm and B) 
chromatogram overlays of 0.01-1 mg/mL docetaxel injection with retention time of 16.6 
min. 
 
Table 7. Docetaxel loading in dodecyl monomer variation random copolymers p[(NH2-
OEG8-MA)-co-PDSMA-co-Dodecyl]. 
Dodecyl 
(%) 
Doc Feed  
(wt %) 
Doc Load 
(wt %) 
Efficiency (%) 
22 5 0.90 ± 0.07 18 ± 1 
27 5 1.55 ± 0.46 25 ± 9 
 
 From these findings, we estimated encapsulation would be approximately 1 weight 
% for nanogels of this composition. With the efficacy plan of four models, with 10 mice 
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each at docetaxel doses desired was 10 mg/kg/week (mouse is approximately 20 g), and 
two test nanogels, we estimated 2.5 g of polymer would be required for each nanogel to 
encapsulate sufficient Doc. Larger scale random copolymer p[(BocNH-OEG8-MA)-co-
PDSMA] was synthesized by reversible addition-fragmentation chain-transfer (RAFT) 
polymerization to yield a Mn of 20.7 kDa. Ð: 1.2 and monomer ratio of 39:61 (BocNH-
OEG8:PDS). The polymer was then post modified with alkane thiol to substitute PDS 
groups that would not be used for crosslinking, to generate random copolymers p[(BocNH-
OEG8-MA)-co-PDSMA-co-Dodecyl] 1 and p[(BocNH-OEG8-MA)-co-PDSMA-co-
Dodecyl] 2, The molar ratio of the three monomers was determined by relative integrations 
of the aromatic protons of PDS, methoxy protons of OEG, and ethylene protons of dodecyl 
to give 39:37:24 (BocNH-OEG8-MA:PDS:Dodecyl) and 36:22:36 (BocNH-OEG8-
MA:PDS:Dodecyl), for 1 and 2 respectively. Then Boc groups were removed by using 
TFA, to yield random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 1 and 
p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 2 with ratios 39:37:24 (NH2-
OEG:PDS:Dodecyl) and 36:22:36 (NH2-OEG:PDS:Dodecyl), for 1 and 2 respectively. 
Table 8. Characteristics of random copolymers p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] and aggregates for efficacy studies. 
NH2-OEG PDS Dodecyl Mn Ð Conditions Size (nm) 
36 22 36 20.7 K 1.1 40 mg/mL, 70 °C, 20 mM Na2CO3 18 nm 
 
The random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] were made 
into an aqueous particle suspension (40 mg/mL) using repeated chill and sonicate cycles 
(Figure 24, Table 8). Docetaxel was loaded into sample NG1 by dissolving 5 weight % in 
acetone and adding it to the polymer solution at a 1:1 volume ratio for acetone:water and 
left stirring open to atmosphere until the acetone evaporated. Control C1 was not loaded 
with docetaxel. Aggregates of ~20 nm were achieved at 40 mg/mL, 70 °C, and 20 mM 
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Na2CO3 and crosslinked at that size with DTT, and quantified as 100% by UV-vis 
spectroscopy by release of 2-pyridinethione at 343 nm. Nanogels were standardized to 1´ 
PBS pH 7.4 by addition of 10´ PBS buffer, then brought to pH 8-8.5, and poly(ethylene 
glycol) methyl ether N-hydroxy succinimide ester (average Mn 2000) was added. The 
solution was stirred for 72 hours at ambient temperature, and, following dialysis 
purification, was characterized to be 35 nm and 43 nm for nanogels NG1 and C1, 
respectively. The Doc load in NG1 was characterized by HPLC as described above, and 
determined to by 1.1 weight %, and efficiency of 22%. NG1 was concentrated using 
Spectra/Gel Absorbent to 0.5 mg/mL drug (44.3 mg/mL polymer) so that a 100 µL animal 
injection would be the appropriate dosage. C1, empty nanogel control, was then 
concentrated to the same polymer concentration for continuity. 
 
Figure 24. DLS sizes of A) 40 mg/mL Doc-loaded NG1 and empty C1, B) crosslinked 
NG1 and C1, and C) PEG-conjugated NG1 and C1. UV-vis absorbance spectra of crosslink 
reaction for D) NG1 and E) C1. 
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The formulation of a second nanogel with slightly varied dodecyl:PDS (i.e. 
dodecyl:crosslink), gave aggregates that were larger than 100 nm and highly disperse, and 
manipulations to concentration and temperature of assembly could not achieve target 
aggregate sizes. An alternative non-PEGylated nanogel was quickly prepared for testing. 
Random copolymer p(OEGMA-co-PDSMA) was synthesized by reversible addition-
fragmentation chain-transfer (RAFT) polymerization to yield a Mn of 21.7 kDa. Ð: 1.2, 
and monomer ratio of 34:66 (OEG:PDS) (Scheme 6). The polymer was then post modified 
with alkane thiol to substitute PDS groups that would not be used for crosslinking, to 
generate random copolymer p(OEGMA-co-PDSMA-co-Dodecyl). The molar ratio of the 
three monomers was determined by relative integrations of the aromatic protons of PDS, 
methoxy protons of OEG, and ethylene protons of dodecyl to give 34:34:32 
(OEG:PDS:Dodecyl). The polymer was made into an aqueous particle suspension (40 
mg/mL) using repeated chill and sonicate cycles until the solution appeared dissolved. 
Aggregates of around 20 nm were achieved at 25 °C, then docetaxel was loaded by 
dissolving 5 weight % in acetone and adding it to the polymer solution at a 1:1 volume 
ratio for acetone:water and left stirring open to atmosphere until the acetone evaporated to 
create NG2 (Figure 25, Table 9). Following evaporation, Nanogels NG2 was crosslinked 
using reducing agent DTT to lock their nanogel size. Crosslink was quantified by release 
of byproduct 2-pyridinethione by its absorption at 343 nm by UV-vis spectroscopy. 
Following dialysis, Doc loading was quantified by HPLC against the obtained calibration 
curve loading of 0.59 weight percent, a 12% loading efficiency, was achieved for nanogel 
NG2. This nanogel was concentrated using Spectra/Gel Absorbent to 0.5 mg/mL drug (84.6 
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mg/mL polymer) so that a 100 µL animal injection would be the appropriate dosage (Table 
10).  
 
Scheme 6. Synthesis of  amphiphilic random copolymer p(OEGMA-co-PDSMA-co-
Dodecyl). 
 
Table 9. Characteristics of random copolymers p(OEGMA-co-PDSMA-co-Dodecyl) and 
aggregates for efficacy studies. 
OEG PDS Dodecyl Mn Ð Conditions Size (nm) 
34 34 32 21.7 K 1.2 40 mg/mL, 25 °C 24 nm 
 
 
Figure 25. Sample NG2 A) DLS size and B) crosslinking quantification by UV-vis 
absorbance. 
 
Table 10. Sample information of Nanogels NG1, C1, and NG2 for in vivo efficacy studies. 
Nanogel Size 
(nm) 
Doc Load 
(wt %) 
Doc 
(mg/mL) 
Doc  
(mM) 
Nanogel 
(mg/mL) 
Volume 
(mL) 
Drug 
(total mg) 
Nanogel 
(total g) 
NG1 35 1.1 0.5 0.62 44.3 57.6 28.8 2.552 
C1 43 0 0 0 44.3 57.6 0 2.552 
NG2 24 0.59 0.5 0.62 84.6 33.6 16.7 2.841 
 
3.2.2 Efficacy Study Results Model MDA-MB-231 
Due to sample limitations, dosages of docetaxel were adjusted. For model MDA-
MB-231 only NG1 and its negative control C1 were tested at a dosage of 8 mg/kg/week 
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for up to 3 weeks. Treatments with nanogel were initiated when the mean tumor size 
reached 152 mm3. The sample administration for model MDA-MB-231 is shown in 
experimental (Table 19). Mice were treated with 100 µL of nanogel sample per injection, 
2 mg/kg per injection, and their tumor growth, inhibition, and total body weights were 
monitored over the treatment period. From the tumor growth curves and tumor growth 
curves (Figure 26, Table 11), NG1 did not demonstrate any significant anti-tumor activity 
against the orthotopic MDA-MB-231 human breast cancer xenograft model. Free 
docetaxel inhibited tumor growth by 25% at 24 days of treatment. No adverse effects on 
body weight was observed with NG1 or C1, however (Figure 26). 
 
Figure 26. Treatment with C1, NG1, and Docetaxel on orthotopic MDA-MB-231 
xenograft model groups A) mean tumor volume B) % inhibition tumor volume C) mean 
body weight, and D) percent change body weight over 21 days (Mean ± SEM, n = 10 
female Musculus BALB/c nude mice). 
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Table 11. Antitumor Activity on the Treatment of Orthotopic MDA-MB-231 Human 
Breast Cancer Xenograft Model 
Treatment Tumor size (mm
3)a 
on day 0 of treatment 
Tumor size (mm3)a 
at termination T/C (%) P value
b 
G1 C1 (0 mg/kg) 151.5 ± 6.5 1111 ± 60 -- -- 
G2 NG1 (2 mg/kg) 151.5 ± 7.2 1317 ± 114 118.5 0.130 
G3 Docetaxel (2 mg/kg) 151.5 ± 7.1 838 ± 63 75.4 0.006 
Note: a. Mean ± SEM; b. Inhibition of test (T) NG1 or Docetaxel compared with the control 
(C1) at termination; c. compared to control (C1) at termination. 
3.2.3 Efficacy Study Results Model BR1474 
 For model BR1474 also, only NG1 and its negative control C1 were tested at the 
same dosage of 8 mg/kg/week for up to 3 weeks. Once the mean tumor size reached 150 
mm3, nanogel treatment was initiated. The sample administration for model BR1474 is 
shown in experimental (Table 20). Mice were treated with 100 µL of nanogel sample per 
injection, 2 mg/kg/week, and their tumor growth, inhibition, and total body weights were 
monitored over the treatment period. From the tumor growth curves and tumor growth 
curves (Figure 27, Table 12), NG1 did not demonstrate any significant anti-tumor activity 
against the subcutaneous PDX BR1474 human breast cancer model. Free docetaxel 
inhibited tumor growth by 25% at 24 days of treatment. No adverse effects on body weight 
was observed with NG1 or C1, however (Figure 27). 
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Figure 27. Treatment with C1, NG1, and Docetaxel on subcutaneous PDX BR1474 
model groups A) mean tumor volume B) % inhibition tumor volume C) mean body 
weight, and D) percent change body weight over 24 days (Mean ± SEM, n = 10 female 
Musculus BALB/c nude mice). 
 
Table 12. Antitumor Activity of in the Treatment of Breast PDX Model BR1474 
Treatment Tumor size (mm
3)a 
on day 0 of treatment 
Tumor size (mm3)a 
on day 24 of treatment T/C (%)
b P valuec 
G1 C1 (0 mg/kg) 149.7 ± 9.1 588.0 ± 83.3 - - 
G2 NG1 (2 mg/kg) 149.7 ± 8.8 637.5 ± 50.6 108.42 0.836 
G3 Docetaxel (2 mg/kg) 149.7 ± 9.2 441.4 ± 42.3 75.07 0.228 
Note: a. Mean ± SEM; b. Inhibition of test (T) NG1 or Docetaxel compared with the control 
(C1) at termination; c. compared to control (C1) at termination. 
 
3.2.4 Efficacy Study Results Model BR1282 
Dosages were then increased to 12 mg/kg/week for model BR1282 in an effort to 
improve antitumor activity. Both NG1 and NG2 were tested for this model. Once the mean 
tumor size reached 150 mm3, nanogel treatment was initiated. The sample administration 
for model BR1282 is shown in experimental (Table 21). Mice were treated with 100 µL 
of nanogel sample per injection, 3 mg/kg/week, and their tumor growth, inhibition, and 
total body weights were monitored over the treatment period (Figure 28, Table 13). After 
2 weeks of dosing no significant tumor inhibition was observed for NG1 (about 3%) 
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compared to free docetaxel (95%). However, tumor inhibition of about 17% was observed 
with NG2. The test compound NG2 at 3 mg/kg therefore showed minor antitumor activity 
in subcutaneous breast PDX models BR1282. The study was terminated at 2 weeks due to 
adverse effects to body mass observed in free Docetaxel samples, however this dosage in 
the nanogels were well tolerated (Figure 28).   
 
Figure 28. Treatment with C1, NG1, NG2, and Docetaxel on subcutaneous PDX BR1282 
model groups A) mean tumor volume B) % inhibition tumor volume C) mean body weight, 
and D) percent change body weight over 14 days (Mean ± SEM, n = 10 female Musculus 
BALB/c nude mice). 
 
Table 13. Antitumor Activity of in the Treatment of Breast PDX Model BR1282 
Treatment Tumor size (mm
3)a 
on day 0 of treatment 
Tumor size (mm3)a 
on day 14 of treatment T/C (%)
b P valuec 
G1 C1 (0 mg/kg) 150.2 ± 8.0 1917.7 ± 101.2 - - 
G2 NG1 (3 mg/kg) 150.2 ± 7.8 1869.2 ± 124.1 97.47 0.990 
G3 Docetaxel (3 mg/kg) 150.2 ± 8.9 92.3 ± 20.0 4.81 <0.001 
G4 NG2 (3 mg/kg) 150.2 ± 8.4 1593.6 ± 120.3 83.10 0.206 
Note: a. Mean ± SEM; b. Inhibition of test (T) NG1 or Docetaxel compared with the control 
(C1) at termination; c. compared to control (C1) at termination 
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3.2.5 Efficacy Study Results Model BR1458 
For model BR1458 dosing was returned to 8 mg/kg/week for up to 3 weeks due to 
sample limitations. Both NG1 and NG2 were tested for this model. Once the mean tumor 
size reached 153 mm3, nanogel treatment was initiated. The sample administration for 
model BR1458 is shown in experimental (Table 22). Mice were treated with 100 µL of 
nanogel sample per injection, 2 mg/kg/week, and their tumor growth, inhibition, and total 
body weights were monitored over the treatment period (Figure 29, Table 14). For this 
model, both NG1 and NG2 exhibited some antitumor effect (Figure 29). At day 24 the 
percent tumor inhibition was approximately 31% for NG1 and 44% for NG2, compared to 
76% for free docetaxel. The efficacy of these nanogels was observed without any adverse 
effects observed for body weight, however was not an improvement in tumor inhibition 
compared to free docetaxel (Figure X). 
 
Figure 29. Treatment with C1, NG1, NG2, and Docetaxel on subcutaneous PDX BR1458 
model groups A) mean tumor volume B) % inhibition tumor volume C) mean body weight, 
and D) percent change body weight over 24 days (Mean ± SEM, n = 10 female Musculus 
BALB/c nude mice). 
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Table 14. Antitumor Activity of in the Treatment of Breast PDX Model BR1458 
Treatment Tumor size (mm
3)a 
on day 0 of treatment 
Tumor size (mm3)a 
on day 14 of treatment T/C (%)
b P valuec 
G1 C1 (0 mg/kg) 153.2 ± 21.5 1305.5 ± 155.2 - - 
G2 NG1 (2 mg/kg) 153.0 ± 21.1 1744.1 ± 331.8 133.60 0.913 
G3 Docetaxel (2 mg/kg) 153.1 ± 20.8 484.2 ± 80.8 37.09 0.001 
G4 NG2 (2 mg/kg) 153.0 ± 20.9 987.8 ± 166.5 75.66 0.467 
Note: a. Mean ± SEM; b. Inhibition of test (T) NG1 or Docetaxel compared with the control 
(C1) at termination; c. compared to control (C1) at termination. 
 
3.3 Conclusion 
In this study, the therapeutic efficacy of docetaxel-loaded nanogels were evaluated 
in the treatment of human mammary orthotopic MDA-MB-231 xenograft model, and 
subcutaneous PDX models BR1474 BR1282 and BR1458. Polymeric nanogels were 
synthesized, optimized in terms of monomer composition and particle size, and docetaxel 
load was quantified by HPLC. Tumor-bearing mice were then treated with regimens of 
nanogels and any tumor inhibition or adverse effects were monitored. The results of these 
studies showed some anti-tumor activity for NG2 in model BR1282 and anti-tumor activity 
both NG1 and NG2 for model BR1458. These initial results obtained for these particles 
may have several opportunities for improvement in the future. The tunability in particle 
size, surface composition, and guest encapsulation allows for greater optimization in 
investigation of tumor inhibition. Furthermore, the opportunity for active targeting may 
further improve the tumor cell uptake and tumor inhibition with these docetaxel-loaded 
particles. 
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3.4 Experimental 
3.4.1 Materials and Methods 
Methacryloyl chloride, O-(hydroxyl)-O′-[2-(Boc-amino)ethyl]heptaethylene glycol 
(BocNH-OEG8-OH), D,L-dithiothreitol (DTT), 1-dodecanethiol, poly(ethylene glycol) 
methyl ether N-hydroxy succinimide ester (average Mn 2000), 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid, trifluoroacetic acid, and other 
conventional reagents were obtained from commercial sources and without further 
purification, unless otherwise mentioned. AIBN (2,2’-azobis(2-methylpropionitrile) was 
purchased from Sigma Aldrich and purified by recrystallization. Pyridyl disulfide ethyl 
methacrylate (PDSMA) was prepared as previously reported.44 Docetaxel was for nanogel 
encapsulation was obtained by TCI, while free docetaxel was obtained by Jiang Su Heng 
Rui Medicine Co. Ltd, Lot no.: 15081816 (light yellow-yellow clear viscous liquid, 20 mg 
in 0.5ml/vial, stored at 4 ºC). Polymers were synthesized using RAFT polymerization and 
purified by dialysis using a membrane with 3500 MWCO. 1H-NMR spectra were recorded 
on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of the 
deuterated solvent as the internal standard. Polymer molecular weights were estimated by 
gel permeation chromatography (GPC, Waters) using THF as eluent at a flow rate of 1 
mL/min by a refractive index detector compared to PMMA standard. Dynamic light 
scattering (DLS) measurements were conducted using a Malvern Nanozetasizer. UV-
visible absorption spectra were recorded on a PerkinElmer Lambda 35 UV/Vis 
Spectrophotometer. Docetaxel calibration was conducted by High performance liquid 
chromatography was conducted using a Shimadzu Prominence Modular HPLC. 
Separations were performed using a C18 column (4.6 mm × 10 cm, 2.7 µm particle size) 
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using a gradient mobile phase of acetonitrile, both containing 0.05% (v/v) trifluoroacetic 
acid, monitoring absorbance of 214 nm at a flow rate of 1 mL/min. 
3.4.2 Experimental Procedures 
Synthesis of monomer BocNH-OEG8-MA: To a round bottom flask BocNH-OEG8-OH 
(3.0 g, 6.38 mmol) and triethylamine (1.08 mL, 7.67 mmol) were dissolved in DCM and 
under argon at ambient temperature. Then methacryloyl chloride (0.749, 7.67 mmol) was 
added dropwise and allowed to stir for 10 hours. The crude reaction was dried under 
reduced pressure, then purified by Combiflash column chromatography using ethyl acetate: 
methanol 95:5 as eluent. The pure product BocNH-OEG8-MA was isolated as a clear oil 
(90% yield) and analyzed by 1H NMR (400 MHz, CDCl3) δ (ppm): 6.11 (s, 1H, CH), 5.56 
(s, 1H, CH), 5.04 (s, 1H, NH), 4.29 (t, J = 4.84 Hz, 2H, CH2), 3.37 (t, J = 4.84 Hz, 2H, 
CH2), 3.64 (m, 24H, 12´CH2), 3.52 (t, J = 4.72 Hz, 2H, CH2), 3.31 (q, J = 5.04 Hz, 2H, 
CH2), 1.94 (s, 3H, CH3), 1.43 (s, 9H, 3´CH3). 
 
Figure 30. 1H-NMR spectrum of monomer BocNH-OEG8-MA.  
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Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] A (28:72): To a 
Schlenk-flask, monomers PDSMA (203 mg, 0.79 mmol), BocNH-OEG8-MA (183 mg, 
0.34 mmol), chain transfer agent 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (6.2 mg, 0.015 mmol), and AIBN 
(0.5 mg, 0.003 mmol) were dissolved in THF (0.5 mL). The mixture was degassed by 
performing three freeze-pump-thaw cycles and filled with argon.  The reaction mixture was 
then sealed and transferred into a pre-heated oil bath at 65 °C and stirred for 24 h.  The 
reaction flask was submerged in an ice bath to quench the polymerization, then dialyzed 
against dichloromethane in MWCO 3500 membrane for 48 hours to remove unreacted 
monomers. The solution was dried to yield the random copolymer as an oil. GPC (THF) 
Mn: 14.7 kDa. Ð: 1.3. 1H NMR (400 MHz, CDCl3) δ: 8.38, 7.60, 7.03, 5.03, 4.46-3.88, 
3.87-3.32, 3.23, 2.96, 2.20-1.58, 1.37, 1.27-0.63 ppm. The molar ratio of the two monomers 
in the polymer were determined by relative integrations of the aromatic protons of PDS 
and methylene protons of OEG to give 28:72 (BocNH-OEG8-MA:PDS).  
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Figure 31. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] 
A (28:72). 
 
Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] B (34:66): To a 
Schlenk-flask, monomers PDSMA (134 mg, 0.52 mmol), BocNH-OEG8-MA (188 mg, 
0.33 mmol), chain transfer agent 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (4.8 mg, 0.012 mmol), and AIBN 
(0.4 mg, 0.0024 mmol) were dissolved in THF (0.5 mL). The mixture was degassed by 
performing three freeze-pump-thaw cycles and filled with argon.  The reaction mixture was 
then sealed and transferred into a pre-heated oil bath at 65 °C and stirred for 24 h.  The 
reaction flask was submerged in an ice bath to quench the polymerization, then dialyzed 
against dichloromethane in MWCO 3500 membrane for 48 hours to remove unreacted 
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monomers. The solution was dried to yield the random copolymer as an oil. GPC (THF) 
Mn: 15.8 kDa. Ð: 1.4. 1H NMR (400 MHz, CDCl3) δ: 8.40, 7.61, 7.05, 5.04, 4.33-3.87, 
3.82-3.33, 3.24, 2.97, 2.09-1.51, 1.38, 1.09-0.64 ppm. The molar ratio of the two monomers 
in the polymer were determined by relative integrations of the aromatic protons of PDS 
and methylene protons of OEG to give 34:66 (BocNH-OEG8-MA:PDS).  
 
Figure 32. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] 
B (34:66). 
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mL). The mixture was degassed by performing three freeze-pump-thaw cycles and filled 
with argon.  The reaction mixture was then sealed and transferred into a pre-heated oil bath 
at 65 °C and stirred for 24 h.  The reaction flask was submerged in an ice bath to quench 
the polymerization, then dialyzed against dichloromethane in MWCO 3500 membrane for 
48 hours to remove unreacted monomers. The solution was dried to yield the random 
copolymer as an oil. GPC (THF) Mn: 18.7 kDa. Ð: 1.3. 1H NMR (400 MHz, CDCl3) δ: 
8.44, 7.65, 7.09, 5.07, 4.37-3.93, 3.85-3.37, 3.28, 3.00, 2.12-1.59, 1.41, 1.29-0.70 ppm. 
The molar ratio of the two monomers in the polymer were determined by relative 
integrations of the aromatic protons of PDS and methylene protons of OEG to give 46:54 
(BocNH-OEG8-MA:PDS).  
 
Figure 33. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] 
C (46:54). 
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Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA] A (28:72): To 
a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA] A (300 mg) was 
dissolved in DCM (1.5 mL) and purged with argon. Then trifluoroacetic acid (1.5 mL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
evaporated under reduced pressure, then purified by dialysis against dichloromethane then 
acetone in a MWCO 3500 regenerated cellulose membrane for 48 hours. The solution was 
dried to yield p[(NH2-OEG8-MA)-co-PDSMA] as a waxy oil. 1H NMR (400 MHz, CDCl3) 
δ: 8.45, 7.69, 7.12, 4.42-3.94, 3.87-3.37, 3.15, 3.09, 2.12-1.58, 1.32-0.62 ppm. The reaction 
completion was confirmed by the disappearance of Boc group (δ: 1.38 ppm). 
 
Figure 34. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA] A 
(28:72). 
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dissolved in DCM (1.5 mL) and purged with argon. Then trifluoroacetic acid (1.5 mL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
evaporated under reduced pressure, then purified by dialysis against dichloromethane then 
acetone in a MWCO 3500 regenerated cellulose membrane for 48 hours. The solution was 
dried to yield p[(NH2-OEG8-MA)-co-PDSMA] as a waxy oil. 1H NMR (400 MHz, CDCl3) 
δ: 8.46, 7.67, 7.12, 4.37-3.97, 4.85-3.41, 3.17, 3.03, 2.11-1.71, 1.20-0.75 ppm. The reaction 
completion was confirmed by the disappearance of Boc group (δ: 1.21 ppm). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA] C (46:54): To 
a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA] C (160 mg) was 
dissolved in DCM (1.5 mL) and purged with argon. Then trifluoroacetic acid (1.5 mL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
evaporated under reduced pressure, then purified by dialysis against dichloromethane then 
acetone in a MWCO 3500 regenerated cellulose membrane for 48 hours. The solution was 
dried to yield p[(NH2-OEG8-MA)-co-PDSMA] as a waxy oil. 1H NMR (400 MHz, CDCl3) 
δ: 8.45, 7.69, 7.12, 4.36-3.94, 3.87-3.40, 3.24-2.92, 2.11-1.54, 1.13-0.71 ppm. The reaction 
completion was confirmed by the disappearance of Boc group (δ: 1.21 ppm). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] A 
(28:36:36): To a round bottom flask polymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] A (40 mg, 0.09 mmol PDS) and 1-dodecanethiol (6.2 µL, 0.045 mmol) was 
dissolved in DCM (2 mL) and purged with argon. Then glacial acetic acid (3 µL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
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purified by dialysis against dichloromethane in a MWCO 3500 regenerated cellulose 
membrane for 72 hours. The solution was dried to yield p[(NH2-OEG8-MA)-co-PDSMA-
co-Dodecyl] as a waxy oil. 1H NMR (400 MHz, CDCl3) δ: 8.48, 7.79, 7.27, 4.43-4.07, 
3.91-3.56, 3.29, 3.21, 3.06, 2.85, 1.94, 1.79, 1.36, 1.24-0.80 ppm. The molar ratio of the 
three monomers in the polymer were determined by relative integrations of the aromatic 
protons of PDS, methylene protons of OEG, and methylene protons of dodecyl to 
give 28:36:36 (NH2-OEG8-MA:PDS:Dodecyl). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] B 
(34:33:33): To a round bottom flask polymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] B (40 mg, 0.083 mmol PDS) and 1-dodecanethiol (5.7 µL, 0.041 mmol) was 
dissolved in DCM (2 mL) and purged with argon. Then glacial acetic acid (3 µL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
purified by dialysis against dichloromethane in a MWCO 3500 regenerated cellulose 
membrane for 72 hours. The solution was dried to yield p[(NH2-OEG8-MA)-co-PDSMA-
co-Dodecyl] as a waxy oil. 1H NMR (400 MHz, CDCl3) δ: 8.46, 7.83, 7.21, 4.46-4.07, 
3.94-3.57, 3.29, 3.23, 3.06, 2.86, 1.79, 1.36, 1.22-0.82 ppm. The molar ratio of the three 
monomers in the polymer were determined by relative integrations of the aromatic protons 
of PDS, methylene protons of OEG, and methylene protons of dodecyl to give 34:33:33 
(NH2-OEG8-MA:PDS:Dodecyl). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] C 
(46:27:26): To a round bottom flask polymer p[(NH2-OEG8-MA)-co-PDSMA-co-
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Dodecyl] C (40 mg, 0.068 mmol PDS) and 1-dodecanethiol (4.7 µL, 0.034 mmol) was 
dissolved in DCM (2 mL) and purged with argon. Then glacial acetic acid (3 µL) was 
added and the mixture was stirred for 12 hours at ambient temperature. The mixture was 
purified by dialysis against dichloromethane in a MWCO 3500 regenerated cellulose 
membrane for 72 hours. The solution was dried to yield p[(NH2-OEG8-MA)-co-PDSMA-
co-Dodecyl] as a waxy oil. 1H NMR (400 MHz, CDCl3) δ: 8.46, 7.83, 721, 4.43-4.08, 3.94-
3.56, 3.30, 3.23, 3.06, 2.85, 1.78, 1.36, 1.23-0.80 ppm. The molar ratio of the three 
monomers in the polymer were determined by relative integrations of the aromatic protons 
of PDS, methylene protons of OEG, and methylene protons of dodecyl to give 46:27:26 
(NH2-OEG8-MA:PDS:Dodecyl). 
 
Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] (36:64): To a 
Schlenk-flask, monomers PDSMA (1.005 g, 3.93 mmol), BocNH-OEG8-MA (1.411 g, 
2.62 mmol), chain transfer agent 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (48.5 mg, 0.12 mmol), and AIBN 
(3.9 mg, 0.023 mmol) were dissolved in THF (4 mL). The mixture was degassed by 
performing three freeze-pump-thaw cycles and filled with argon.  The reaction mixture was 
then sealed and transferred into a pre-heated oil bath at 65 °C and stirred for 24 h.  The 
reaction flask was submerged in an ice bath to quench the polymerization, then dialyzed 
against dichloromethane in MWCO 3500 membrane for 48 hours to remove unreacted 
monomers. The solution was dried to yield the random copolymer as an oil. GPC (THF) 
Mn: 16.0 kDa. Ð: 1.3. 1H NMR (400 MHz, CDCl3) δ: 8.44, 7.65, 7.09, 5.08, 4.34-3.92, 
3.89-3.36, 3.29, 3.00, 2.08-1.57, 1.42, 1.31-0.67 ppm. The molar ratio of the two monomers 
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in the polymer were determined by relative integrations of the aromatic protons of PDS 
and methylene protons of OEG to give 36:64 (BocNH-OEG8-MA:PDS).  
 
Figure 35. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] 
(36:64). 
 
Synthesis of random copolymers p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] 13-
27: To a round bottom flask polymer each p[(BocNH-OEG8-MA)-co-PDSMA] 36:34 (160 
mg, 2.8 mmol PDS) and separately 1-dodecanethiol (14.3 µL, 0.59 mmol; 27.8 µL, 1.1 
mmol; 40.9 µL, 1.7 mmol) was dissolved in DCM (3 mL) and purged with argon. Then 
glacial acetic acid (15 µL) was added to each and the mixtures were stirred for 48 hours at 
ambient temperature. The mixture was purified by dialysis against dichloromethane in a 
MWCO 3500 regenerated cellulose membrane for 48 hours. The solutions were dried to 
yield p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] polymers as a waxy oils. 1H NMR 
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Dodecyl 13% (400 MHz, CDCl3) δ: 8.44, 7.66, 7.09, 5.07, 4.36-3.95, 3.84-3.41, 3.29, 3.00, 
2.83, 2.65, 2.10-1.51, 1.42, 1.23, 1.13-0.68 ppm. 1H NMR Dodecyl 22% (400 MHz, 
CDCl3) δ: 8.44, 7.66, 7.09, 5.07, 4.34-3.93, 3.77-3.42, 3.28, 3.00, 2.83, 2.65, 2.05-1.51, 
1.41, 1.23, 1.15-0.66 ppm. 1H NMR Dodecyl 27% (400 MHz, CDCl3) δ: 8.45, 7.66, 7.10, 
5.06, 4.38-3.94, 3.80-3.43, 3.29, 3.01, 2.83, 2.66, 2.05-1.50, 1.42, 1.23, 1.14-0.64 ppm. 
The molar ratio of the three monomers in each polymer were determined by relative 
integrations of the aromatic protons of PDS, methylene protons of OEG, and methylene 
protons of dodecyl to give each 36:51:13, 36:42:22, and 36:37:27 (BocNH-OEG8-
MA:PDS:Dodecyl). 
 
Figure 36. 1H-NMR spectrum of random copolymers p[(BocNH-OEG8-MA)-co-PDSMA-
co-Dodecyl] (36:51:13). 
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Figure 37. 1H-NMR spectrum of random copolymers p[(BocNH-OEG8-MA)-co-PDSMA-
co-Dodecyl] (36:42:22). 
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Figure 38. 1H-NMR spectrum of random copolymers p[(BocNH-OEG8-MA)-co-PDSMA-
co-Dodecyl] (36:37:27). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 13-27: 
To a round bottom flask polymers p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] 
Dodecyl 0, 13, 22, and 27% (140 mg) were each dissolved in DCM (3 mL) and purged 
with argon. Then trifluoroacetic acid (3 mL) was added and the mixtures were stirred for 
12 hours at ambient temperature. The mixtures were evaporated under reduced pressure, 
then purified by dialysis against dichloromethane then acetone in a MWCO 3500 
regenerated cellulose membrane for 48 hours. The solutions were dried to yield polymers 
p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] as waxy oils. 1H NMR Dodecyl 0% (400 
MHz, Methanol-D4) δ: 8.46, 7.84, 7.26, 4.43-4.03, 3.91-3.51, 3.34, 3.18, 2.3-1.77, 1.45-
0.79 ppm. 1H NMR Dodecyl 13% (400 MHz, Methanol-D4) δ: 8.45, 7.83, 7.25, 4.50-4.00, 
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3.90-3.43, 3.17, 3.98, 2.75, 2.28-1.54, 1.29, 1.21-0.73 ppm. 1H NMR Dodecyl 22% (400 
MHz, Acetone-D6) δ: 8.52, 7.86, 7.28, 4.49-4.07, 3.82-3.54, 3.30, 3.21, 3.03, 2.80, 2.28-
1.54, 1.72, 1.31, 1.22-0.82 ppm. 1H NMR Dodecyl 27% (400 MHz, Acetone-D6) δ: 8.51, 
7.85, 7.27, 4.50-4.05, 3.97, 3.87, 3.70, 3.62, 3.29, 3.21, 3.02, 2.79,1.72, 1.30, 1.20-0.78 
ppm. The reaction completions were confirmed by the disappearance of Boc group (δ: 1.21 
ppm). 
 
Figure 39. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] (36:64). 
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Figure 40. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] (36:51:13). 
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Figure 41. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] (36:42:22). 
 
O
O
H2N
O
O
S
S
O
N
7
x y
O
S
S
O z
9
a
b, c
d e, f, g
i
g
k
r, r’, r’’
n, n’, n’’
e f
j
j
k l m
m
l
a
d
h
h
i
c
b
n n’ n’’
p
o
o
p
r’’r’r
r
  115 
 
Figure 42. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] (36:42:22). (36:37:27). 
 
Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] (39:61) large 
scale: To a Schlenk-flask, monomers PDSMA (3.678 g, 14.4 mmol), BocNH-OEG8-MA 
(5.161 g, 9.60 mmol), chain transfer agent 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (108 mg, 0.268 mmol), and AIBN 
(8.8 mg, 0.054 mmol) were dissolved in THF (12 mL). The mixture was degassed by 
performing three freeze-pump-thaw cycles and filled with argon.  The reaction mixture was 
then sealed and transferred into a pre-heated oil bath at 65 °C and stirred for 24 h.  The 
reaction flask was submerged in an ice bath to quench the polymerization, then dialyzed 
against dichloromethane in MWCO 3500 membrane for 48 hours to remove unreacted 
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monomers. The solution was dried to yield the random copolymer as an oil. GPC (THF) 
Mn: 20.7 kDa. Ð: 1.2. 1H NMR (400 MHz, CDCl3) δ: 8.43, 7.65, 7.09, 5.05, 4.32-3.93, 
3.73-3.42, 3.28, 3.00, 2.11-1.62, 1.41, 1.17-0.70 ppm. The molar ratio of the two monomers 
in the polymer were determined by relative integrations of the aromatic protons of PDS 
and methylene protons of OEG to give 39:61 (BocNH-OEG8-MA:PDS).  
 
Figure 43. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA] 
(39:61) large scale. 
 
Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] 1 
(39:37:24): To a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA] (3.67 g, 
6.8 mmol PDS) and 1-dodecanethiol (0.656 mL, 2.7 mmol) was dissolved in DCM (3 mL) 
and purged with argon. Then glacial acetic acid (332 µL) was added and the mixture was 
stirred for 48 hours at ambient temperature. The mixture was purified by dialysis against 
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dichloromethane in a MWCO 3500 regenerated cellulose membrane for 72 hours. The 
solution was dried to yield p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] as a waxy oil. 
1H NMR (400 MHz, CDCl3) δ: 8.48, 7.69, 7.13, 5.11, 4.36-3.98, 3.78-3.42, 3.32, 3.05, 
2.87, 2.69, 2.10-1.72, 1.66, 1.44, 1.26, 1.16-0.70 ppm. The molar ratio of the three 
monomers in the polymer were determined by relative integrations of the aromatic protons 
of PDS, methylene protons of OEG, and methylene protons of dodecyl to give 39:37:24 
(BocNH-OEG8-MA:PDS:Dodecyl). 
 
Figure 44. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA-
co-Dodecyl] 1 (39:37:24). 
 
Synthesis of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] 2 
(36:22:36): To a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA] (3.67 g, 
6.8 mmol PDS) and 1-dodecanethiol (0.984 mL, 4.1 mmol) was dissolved in DCM (25 
mL) and purged with argon. Then glacial acetic acid (332 µL) was added and the mixture 
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was stirred for 48 hours at ambient temperature. The mixture was purified by dialysis 
against dichloromethane in a MWCO 3500 regenerated cellulose membrane for 72 hours. 
The solution was dried to yield p[(BocNH-OEG8-MA)-co-PDSMA-co-Dodecyl] as a waxy 
oil. 1H NMR (400 MHz, CDCl3) δ: 8.43, 7.65, 7.09, 5.09, 4.34-3.90, 3.82-3.37, 3.25, 2.99, 
2.82, 2.64, 2.05-1.50, 1.39, 1.21, 1.10-0.60 ppm. The molar ratio of the three monomers in 
the polymer were determined by relative integrations of the aromatic protons of PDS, 
methylene protons of OEG, and methylene protons of dodecyl to give 36:22:36 (BocNH-
OEG8-MA:PDS:Dodecyl). 
 
Figure 45. 1H-NMR spectrum of random copolymer p[(BocNH-OEG8-MA)-co-PDSMA-
co-Dodecyl] 2 (36:22:36). 
 
Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 1 
(39:37:24): To a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA-co-
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Dodecyl] 1 (4.366 g) was dissolved in DCM (16 mL) and purged with argon. Then 
trifluoroacetic acid (6 mL) was added and the mixture was stirred for 12 hours at ambient 
temperature. The mixture was evaporated under reduced pressure, then purified by dialysis 
against dichloromethane then acetone in a MWCO 3500 regenerated cellulose membrane 
for 48 hours. The solution was dried to yield p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 
as a waxy oil. 1H NMR (400 MHz, Acetone-D6) δ: 8.52, 7.86, 7.28, 4.55-4.05, 4.03-3.53, 
3.30, 3.20, 3.03, 2.80, 2.0-1.52, 1.31, 1.21-0.77 ppm. The reaction completion was 
confirmed by the disappearance of Boc group (δ: 1.21 ppm). 
 
Figure 46. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] 1 (39:37:24). 
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Synthesis of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 2 
(36:22:36): To a round bottom flask polymer p[(BocNH-OEG8-MA)-co-PDSMA-co-
Dodecyl] 2 (4.4 g) was dissolved in DCM (16 mL) and purged with argon. Then 
trifluoroacetic acid (6 mL) was added and the mixture was stirred for 12 hours at ambient 
temperature. The mixture was evaporated under reduced pressure, then purified by dialysis 
against dichloromethane then acetone in a MWCO 3500 regenerated cellulose membrane 
for 48 hours. The solution was dried to yield p[(NH2-OEG8-MA)-co-PDSMA-co-Dodecyl] 
as a waxy oil. 1H NMR (400 MHz, Acetone-D6) δ: 8.52, 7.85, 7.28, 4.46-4.04, 4.00-3.53, 
3.29, 3.20, 3.02, 2.80, 2.04-1.81, 1.73, 1.31, 1.21-0.77 ppm. The reaction completion was 
confirmed by the disappearance of Boc group (δ: 1.21 ppm). 
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Figure 47. 1H-NMR spectrum of random copolymer p[(NH2-OEG8-MA)-co-PDSMA-co-
Dodecyl] 2 (36:22:36). 
 
Synthesis of random copolymer p(OEGMA-co-PDSMA): To a Schlenk-flask, 
monomers PDSMA (3.8 g, 14.9 mmol), OEGMA (2.76 g,  5.5 mmol), chain transfer agent 
4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (111 mg, 0.276 mmol), 
and AIBN (9.1 mg, 0.055 mmol) were dissolved in THF (10 mL). The mixture was 
degassed by performing three freeze-pump-thaw cycles and filled with argon.  The reaction 
mixture was then sealed and transferred into a pre-heated oil bath at 65 °C and stirred for 
24 h.  The reaction flask was submerged in an ice bath to quench the polymerization, then 
dialyzed against dichloromethane in MWCO 3500 membrane for 48 hours to remove 
unreactive monomers. The solution was dried to yield the random copolymer as an oil. 
O
O
H2N
O
O
S
S
O
N
7
x y
O
S
S
O z
9
i
g
k
e f
j m
l
a
d
h
c
b
n n’ n’’
o
p
r’’r’r
r
a
b, c
d
e, f, g
r, r’, r’’
n, n’, n’’
i
k l m
h
i
p
o
j
  122 
GPC (THF) Mn: 21.7 kDa. Ð: 1.2. 1H NMR (400 MHz, Acetone-D6) δ: 8.47, 7.79, 7.20, 
4.37-4.00, 3.72-3.41, 3.34, 3.13, 2.14-1.77, 1.36-0.82 ppm. The molar ratio of the two 
monomers in the polymer were determined by relative integrations of the aromatic protons 
of PDS and methoxy protons of OEG to give 34:66 (OEG:PDS).  
 
Figure 48. 1H-NMR spectrum of random copolymer p(OEGMA-co-PDSMA). 
 
Synthesis of random copolymer p(OEGMA-co-PDSMA-co-Dodecyl): To a round 
bottom flask polymer p(OEGMA-co-PDSMA) (6.121 g, 12.6 mmol PDS) and 1-
dodecanethiol (1.825 mL, 7.56 mmol) was dissolved in DCM (100 mL) and purged with 
argon. Then glacial acetic acid (600 µL) was added and the mixture was stirred for 48 hours 
at ambient temperature. The mixture was purified by dialysis against dichloromethane then 
acetone in a MWCO 3500 regenerated cellulose membrane for 48 hours. The solution was 
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dried to yield p(OEGMA-co-PDSMA-co-Dodecyl) as a waxy oil. 1H NMR (400 MHz, 
Acetone-D6) δ: 8.52, 7.87, 7.29, 4.43-4.03, 3.82-3.45, 3.32, 3.22, 4.04, 2.82, 1.95, 1.75, 
1.337. 1.25-0.85. The molar ratio of the three monomers in the polymer were determined 
by relative integrations of the aromatic protons of PDS, methoxy protons of OEG, and 
ethylene protons of dodecyl to give 34:34:32 (OEG:PDS:Dodecyl). 
 
Figure 49. 1H-NMR spectrum of random copolymer p(OEGMA-co-PDSMA-co-
Dodecyl). 
 
Formulation of Nanogels: Dynamic light scattering experiments to obtain particle size 
were performed by using a digital correlator and goniometer with a light source operating 
at 514 nm. Final nanogel size measurements were obtained at 25 °C at a correlation time 
of 30 seconds. Dust was removed by filtering the solution through 0.45 µm polycarbonate 
filter. Final polymeric nanogel concentrations were calculated using initial feed, and final 
docetaxel concentrations were determined HPLC. 
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PEG-NHS ester Conjugation: Nanogel in aqueous solution were standardized to 1´ PBS 
pH 7.4 by addition of 10´ PBS buffer, then brought to pH 8-8.5 with 1 M NaOH. To this 
solution, poly(ethylene glycol) methyl ether N-hydroxy succinimide ester (average Mn 
2000) (g, mmol, 5 equivalents to nanogel NH2-OEG monomer) was added, and stirred for 
48 hours at ambient temperature. Nanogels were purified by dialysis against a cellulose 
membrane with 8-10 kDa MWCO.  
 
Nanogel Crosslinking: The crosslinking was quantified using the previously reported 
procedure34 by monitoring the amount of 2-pyridinethione byproduct produced from DTT 
addition using its molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm).35 UV-vis 
absorption measurements were obtained on 1000-fold crosslinking reaction dilutions. The 
assumption that cleavage of two PDS units would produce two pyridinethione byproduct 
and one disulfide bond was made to calculate crosslink density.  
 
Quantification of Docetaxel Load: Docetaxel loads were determined by analytical HPLC, 
using a C18 column (4.6 mm × 10 cm, 2.7 µm particle size) using a gradient mobile phase 
of acetonitrile 0% to 70% acetonitrile in water, both containing 0.05% (v/v) trifluoroacetic 
acid, monitoring absorbance of 214 nm at a flow rate of 1 mL/min. A calibration curve was 
prepared by Docetaxel by obtaining AUC for 214 absorbance at consistent retention time 
of 16.6 min for the drug, for 0.01-1 mg/mL doc, performed in triplicate. The linear fit for 
AUC vs Doc concentration gave R2=0.99. Thus, concentrations of Doc could be calculated 
for unknown samples using obtained AUC for absorbance of 214 nm at 16.6 min. These 
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values were obtained by disrupting aggregate encapsulation integrity by adding acetone 
(1:1 volume %) to nanogel solutions, then characterizing HPLC results of 20 µL of this 
solution. 
 
Animals and Husbandry: All animal work was conducted by Crown Biosciences, Inc. 
All experiments used female Musculus BALB/c nude mice supplied by Shanghai 
Lingchang Bio-Technology Co. Ltd (LC, Shanghai, China). At the time of inoculation 
animals were 7-8 weeks for MDA-MB-231 model, 9-10 weeks old for BR1282 model, 11-
12 weeks old for BR1458 model, and 13-14 weeks old for BR 1474 model. Their body 
weights were 17-22 g. Animals were fed ad libitum (reverse osmosis autoclaved water and 
Co60 irradiation sterilized dry granule food) and housed inside individually ventilated cage 
(IVC) systems with corn cob bedding, 5 animals in each cage, and an environment of 21-
26 °C and 30-70% humidity. All procedures involving use and care of animals were 
performed in compliance with the Institutional Animal Care and Use Committee (IACUC) 
of CrownBio, Inc. and in accordance with regulations of the Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC). 
 
Cell Preparation and Tumor Inoculation: MDA-MB-231 cells were grown and 
maintained in in vitro culture in L-15 medium supplemented with 10% fetal bovine serum 
(heat inactivated) at 37 ºC in 100% air. Tumor cells were subcultured twice per week, and 
cells in exponential growth phase were harvested and for tumor inoculation. On day 0, 
MDA-MB-231 tumor cells (1 x 107) in PBS with 50% Matrigel® (100 µL) were inoculated 
subcutaneously at right mammary pad of each animal for tumor development. Fragments 
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of tumor tissues (2-3 mm in diameter) were harvested from stock mice inoculated with 
breast PDX model BR1282, BR1458 or BR1474 and inoculated subcutaneously at the right 
flank into each BALB/c nude for tumor development  
 
Measurements and Endpoints: Following tumor inoculation, all animals body weights 
were obtained and tumor volumes calculated using caliper measurements. Throughout 
treatment tumor volumes were measured twice weekly and expressed in mm3 using the 
formula: V = 0.5 a × b2 where a and b are the length and width of the tumor, respectively. 
Systematic error was minimized by randomizing animals prior to treatment into specified 
groups by minimal variation in tumor volume using StudyDirectorTM software (Studylog 
Systems, Inc. CA, USA). The primary endpoints for the study is tumor growth inhibition 
(TGI), which is an indication of antitumor effectiveness. The inhibition is expressed as TGI 
(%) =100 × (1-T/C), where the mean tumor volume (or weight) for the treated (T) and 
control (C) were obtained on a given day. Tumor sizes are given in Tables 15-18. 
Table 15. Tumor Sizes in the Different Treatment Groups in MDA-MB-231 Study 
Days 
Tumor Volume (mm3) 
C1 (0 mg/kg) NG1 (2 mg/kg) Docetaxel (2 mg/kg) 
0 151.5 ± 6.5 151.5 ± 7.2 151.5 ± 7.1 
3 326.1 ± 24.2 297.5 ± 19.0 292.0 ± 25.7 
7 426.9 ± 23.3 422.0 ± 31.1 390.6 ± 29.7 
10 562.6 ± 28.8 520.2 ± 39.3 475.0 ± 46.4 
14 680.7 ± 35.9 707.6 ± 48.0 606.4 ± 44.9 
17 831.0 ± 40.6 885.5 ± 58.0 688.9 ± 58.0 
21 1111.5 ± 60.1 1316.6 ± 114.5 838.1 ± 63.0 
Note: data expressed as Mean ± SEM 
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Table 16. Tumor Sizes in the Different Treatment Groups in BR1282 Study.  
Days 
Tumor Volume (mm3) 
C1 (0 mg/kg) NG1 (3 mg/kg) Docetaxel (3 mg/kg) NG2 (3 mg/kg) 
0 150.2 ± 8.0 150.2 ± 7.8 150.2 ± 8.9 150.2 ± 8.4 
4 433.3 ± 32.8 453.6 ± 33.5 263.5 ± 17.9 392.9 ± 18.0 
7 832.2 ± 50.1 810.0 ± 54.1 153.6 ± 15.4 714.7 ± 45.7 
11 1527.3 ± 98.0 1403.6 ± 81.0 116.5 ± 20.8 1230.3 ± 97.1 
14 1917.7 ± 101.2 1869.2 ± 124.1 92.3 ± 20.0 1593.6 ± 120.3 
Note: data expressed as Mean ± SEM. *One animal in C1 group was sacrificed on Day 12 
after the first treatment due to tumor volume >2000mm3. 
 
Table 17. Tumor Sizes in the Different Treatment Groups in BR1458 Study. 
Days 
Tumor Volume (mm3) 
C1 (0 mg/kg) NG1 (2 mg/kg) Docetaxel (2 mg/kg) NG2 (2 mg/kg) 
0 153.2 ± 21.5 153.0 ± 21.1 153.1 ± 20.8 153.0 ± 20.9 
4 437.5 ± 57.5 417.3 ± 67.5 297.2 ± 39.9 348.7 ± 51.5 
7 689.2 ± 63.8 801.5 ± 136.5 405.1 ± 55.8 546.6 ± 84.3 
11 1117.4 ± 133.6 1339.8 ± 230.8 433.2 ± 70.9 746.8 ± 125.7 
14 1305.5 ± 155.2 1744.1 ± 331.8 484.2 ± 80.8 987.8 ± 166.5 
18 1916.2 ± 199.6 1661.7 ± 310.0 530.3 ± 86.3 1195.7 ± 201.5 
21 1886.2 ± 142.4 1140.7 ± 192.1 538.2 ± 89.7 1530.4 ± 267.5 
24 2294.0 ± 198.7 1571.7 ± 258.5 562.1 ± 97.8 1278.2 ± 301.3 
Note: data expressed as Mean ± SEM 
     *There were animals being sacrificed from day 18 after the first treatment due to tumor 
volume >2000mm3. 
 
Table 18. Tumor Sizes in the Different Treatment Groups in BR1474 Study. 
Days 
Tumor Volume (mm3) 
C1 (0 mg/kg) NG1 (2 mg/kg) Docetaxel (2 mg/kg) 
0 149.7 ± 9.1 149.7 ± 8.8 149.7 ± 9.2 
3 172.5 ± 11.3 177.0 ± 10.7 179.0 ± 12.9 
7 237.7 ± 17.5 248.9 ± 18.1 218.8 ± 16.4 
10 288.5 ± 26.0 316.9 ± 21.3 268.4 ± 19.8 
14 357.9 ± 44.3 360.4 ± 21.8 269.1 ± 23.5 
17 445.1 ± 62.0 487.2 ± 40.7 358.1 ± 29.5 
21 512.2 ± 73.1 563.5 ± 45.6 403.1 ± 39.8 
24 588.0 ± 83.3 637.5 ± 50.6 441.4 ± 42.3 
Note: data expressed as Mean ± SEM 
 
Treatment: Treatment was initiated with the group mean tumor size reached 152, 150, 
153, and 150 mm3 for tumor models MDA-MB-231, BR1282, BR1458, and BR1474 
respectively. Nanogels and docetaxel solutions were administered to the tumor-bearing 
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mice according to the regimens in Tables 19-22. Stock docetaxel (0.02 mL, 40 mg/mL) 
was diluted to 0.06 mL with 13% ethanol solution, then 1.52 mL saline to make a final 1.6 
mL of 0.5 mg/mL dosing solution, same as test nanogel concentrations. All dosing, tumor 
measurements, and body weight measurement were conducted in a Laminar Flow Cabinet. 
The MDA-MB-231, BR1474, BR1282, and BR1458 studies were terminated after dosing 
on Day 21, Day 24, Day 14, and Day 24, respectively. 
Table 19. Treatment administration schedule for MDA-MB-231 bearing mice. 
Group N Treatment Dose (mg/kg) 
Dosing 
Volume 
(mL/kg) 
Dosing 
Route Schedule 
1 10 C1 0 4 i.v. 4 days on 3 days off/week x 3 weeks 
2 10 NG1 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
3 10 Docetaxel 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
 
Table 20. Treatment administration schedule for BR1474 bearing mice. 
Group N Treatment Dose (mg/kg) 
Dosing 
Volume 
(mL/kg) 
Dosing 
Route Schedule 
1 10 C1 0 4 i.v. 4 days on 3 days off/week x 3 weeks 
2 10 NG1 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
3 10 Docetaxel 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
 
Table 21. Treatment administration schedule for BR1282 bearing mice. 
Group N Treatment Dose (mg/kg) 
Dosing 
Volume 
(mL/kg) 
Dosing 
Route Schedule 
1 10 C1 0 6 i.v. 4 days on 3 days off/week x 2 weeks 
2 10 NG1 3 6 i.v. 4 days on 3 days off/week x 2 weeks 
3 10 Docetaxel 3 6 i.v. 4 days on 3 days off/week x 2 weeks 
4 10 NG2 3 6 i.v. 4 days on 3 days off/week x 2 weeks 
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Table 22. Treatment administration schedule for BR1458 bearing mice. 
Group N Treatment Dose (mg/kg) 
Dosing 
Volume 
(mL/kg) 
Dosing 
Route Schedule 
1 10 C1 0 4 i.v. 4 days on 3 days off/week x 3 weeks 
2 10 NG1 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
3 10 Docetaxel 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
4 10 NG2 2 4 i.v. 4 days on 3 days off/week x 3 weeks 
 
Assessment of Side Effects: Throughout tumor growth animals were observed for 
morbidity and mortality daily. Throughout the study the animals were routinely checked 
for clinical signs of tumor growth or treatment effects on mobility, food and water 
consumption, body weight gain or loss (measured twice weekly), eye/hair matting and any 
other unusual observations. Any observed clinical signs and death were recorded.  
 
Statistics: Statistical analysis of MDA-MB-231 was evaluated using Independent-Samples 
T Test. All data were analyzed in SPSS (Statistical Product and Service Solutions) version 
18.0 (IBM, Armonk, NY, U.S.). Analysis of BR1282 (day 14 TV) was conducted using a 
one-way ANOVA and comparisons using Games-Howell. Statistical analysis of BR1458 
(day 14 TV) and BR1474 (day 28 TV) was conducted using a one-way ANOVA and Tukey 
HSD. Log transformation was performed for homogeneity of variances when necessary. 
Statistically significant differences were set at p values ≤ 0.05. 
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CHAPTER 4 
 
MATRIX METALLOPROTEINASE-9 RESPONSIVE NANOGELS FOR 
PROXIMAL SURFACE CONVERSION AND ACTIVATED CELLULAR 
UPTAKE 
4.1 Introduction 
A nanoscopic drug delivery platform that can maintain long blood circulation times 
without compromising selective and rapid target tissue internalization is still a big 
challenge in obtaining desired therapeutic profiles for clinical applications. The passive 
mechanism by which nanoscale systems diffuse and accumulate in tumor tissue is a result 
of fenestrated hypervasculature from angiogenesis and a deficient lymphatic drainage. 1 
Albeit somewhat controversial, 2-4 this enhanced permeation and retention (EPR) effect 
drives the development of particles with long circulation characteristics. In the 
development of passive nanocarriers, poly(ethylene glycol) polymers (PEG) have been 
shown to achieve non-fouling characteristics for nanoparticles by reducing non-specific 
interactions and protein adsorption to their surfaces.5, 6 The grafting, conjugation, or 
adsorption of PEG on the surface of macromolecules has been shown to reduce the extent 
of phagocytic elimination by the reticular endothelial system (RES) and achieve extended 
blood circulation half-lives. 7-13 
Passive nanogels inherently lack the ability to distinguish healthy tissues from 
diseased ones, and their stealth surface properties can inhibit cellular interaction resulting 
in reduced endosomolytic activity.14, 15 Active targeting aims to address these points 
through enhancement or specificity of cellular internalization. Active uptake is often 
pursued through one of two ways: i) targeting of unique cell-surface receptors or ii) 
enhanced cellular interaction with cationic materials. The former aims to improve 
specificity of receptor-mediated endocytosis through cancer cell surface receptors and 
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antigens.16-20 Various systems have been explored for active targeting including the 
incorporation of cell-penetrating peptides,21,22 targeting peptides,23 monoclonal 
antibodies,24,25,26 or small molecules.27,28,29 Concerns for in vivo surface decoration of such 
ligands is that they can limit their stealth surface, resulting in RES recognition and 
clearance,30 and their tumor penetration.31 Further, internalization through receptor 
mediated endocytosis can lead to therapeutic decomposition in the lysosome.32 The later 
cationic strategy is due to enhanced charge-charge interaction with the anionic 
phospholipid bilayer of cell membranes, resulting in adsorptive endocytosis at a higher rate 
than neutral or anionic formulations.33,34 Many polycationic nanocarriers have been 
developed with the aim of improved cellular internalization of therapeutic contents, 
particularly with anionic nucleotide-based or nucleic acid therapeutics such as siRNA, 
mRNA, and DNA.35 Systemic administration of cationic nanomaterials however, result in 
indiscriminate cellular internalizations, nonspecific adsorption of serum proteins, and short 
circulation half-lives due to rapid RES clearance.36-38 
This dilemma can be addressed by developing passive “smart” nanocarriers that 
become “active” in response to specific stimulus proximal to the disease site. Many 
externally applied stimuli have been explored (e.g. light, temperature),39 however tumor-
specific endogenous stimuli can exploit inherent physiological biochemical differences in 
cancerous tissues.40 Such stimuli that are intrinsic to the extracellular tumor 
microenvironment include decreased pH and enzyme dysregulation. Nanocarriers with pH-
sensitivity have been well explored because lactate production from anerobic glycolysis 
under hypoxic conditions in tumors causes a pH decrease (6.2-6.9).42 Nanoscopic systems 
that can generate positive charge or shed surface PEG in response to mildly acidic 
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conditions have been demonstrated to facilitate phagocytosis.42-48 One disadvantage of pH 
dependent strategies is that inflammatory regions also have mildly acidic hypoxic 
environments. Further, hypoxia can be variable in incidence and severity, in some cases 
irregularly affecting regions distant from the nutritive vasculature where oxygen diffusion 
is limited and the tumor outgrows its blood supply.49, 50  
The dysregulation of enzymes however, is common to many tumor types and can 
be highly specific to the local microenvironment.51,52 The overexpression of matrix 
metalloproteinases (MMPs), zinc-dependent proteases that degrade the extracellular 
matrix, has been observed in various cancers and are associated with tumor invasiveness, 
metastasis, and angiogenesis.53 Furthermore, these tumor-associated proteases are 
expressed at the angiogenic invasive anterior of tumors where nanoparticles may more 
easily access and accumulate, supporting their candidacy as proximal activators of 
nanoparticles. Variable supramolecular designs in the protease-induced activation of 
nanoparticles have been pursued.54-64 Extracellularly overexpressed MMPs have been used 
to improve cell uptake through exposure of cationic polymeric block54,55, cationic cell 
penetrating peptide56, 57, or through revealing underlying ligands58-60. Other approaches 
have used MMPs to decrease particle hydrodynamic radius61, or induce nanoparticle 
morphological changes62 and disassembly63, 64 to result in extracellular therapeutic release. 
Here, we investigate an abridged protease activation strategy that explores the 
generation of peptide N-termini on the particle surface to enhance cellular uptake. This 
strategy can be achieved by simply installing a protease-cleavable substrate to a particle at 
its C-terminus that is shielded by PEG at its N-terminus (Scheme 7). Therefore, peptide 
hydrolysis by a relevant enzyme, here MMP-9, removes the PEG shield to reveal a 
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polyamine-type surface from N-termini. The resultant “active” nanogel is expected to 
internalize more rapidly than its PEGylated parent “passive” nanogel due to charge 
conversion, reduced steric stabilization, and resultant enhanced membrane interactions. 
Such a design is versatile and flexible in that the peptide substrate can dictate the sensitivity 
and specificity of MMP cleavage, or be adapted to the known MMP types in a target tissue 
of interest. Further, the formulation is modular in nature such that the enzyme-responsive 
feature is post-conjugated to the pre-formed nanogel surface, allowing for facile substrate 
amendment and versatility in molecular design. This study focuses on proof-of-concept 
formulation and characterization of an MMP-9-responsive nanogel delivery platform that 
offers potential for tumor-specific delivery of chemotherapeutics. 
 
Scheme 7. A) Schematic representation of MMP-9 responsive nanogel and resulting 
activated cell uptake and GSH release, and B) structural representation of polymer 
nanogels and stimuli-responsiveness. 
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4.2 Results and Discussion 
4.2.1 Enzyme-Responsive Substrate Synthesis and Proteolysis Validation 
Key elements of the suggested nanocarrier are the polymeric nanogel responsible 
for guest incorporation and intracellular guest release, along with the post-modifiable 
enzyme responsive substrate that will facilitate cellular internalization. The matrix 
metalloproteinase-9 responsive peptide-poly(ethylene glycol) monomethyl ether (Mw 350 
and 750 g/mol) substrates, mPEG(350)- GPLG¯LLGC(NH2) and mPEG(750)-
GPLG¯LLGC(NH2), were inspired from collagenous peptide sequences that were shown 
to be hydrolyzed by type IV collagenases, or MMP-9 between the Gly-Leu bond.65, 66  Of 
those investigated, the sequence AcPLG¯LLG-OC2H5 was found to be the best substrate 
for MMP-9, with a similar turnover number (kcat) to denatured collagen and a specific 
activity of 80 µmol/mg/h.65 A minimum of six amino acid residues and peptide charge 
neutrality was found to exhibit more rapid gelatinolytic activity than peptides comprised 
of less amino acid residues or charged residues.  From N- to C-terminus, the substrate for 
this study was thus designed to contain PEG, an additional glycine residue, the validated 
PLG¯LLG sequence, and an amide-neutralized cysteine. Two PEG lengths were explored 
with the expectation that a shorter length may have greater enzyme accessibility, however 
if proteolysis is sufficient, longer lengths may engender greater difference in cellular 
interaction from its “passive” to “active” state. The MMP-9 cleavable PEG-peptide 
conjugates mPEG(350)-GPLG¯LLGC(NH2) and mPEG(750)-GPLG¯LLGC(NH2) were 
made using solid phase peptide synthesis, purified by high performance liquid 
chromatography, and characterized using electrospray ionization (ESI) and matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry (Figure 66, 67).  
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Prior to nanogel conjugation, proteolytic susceptibility of substrates by MMP-9 was 
evaluated. Synthesized substrates mPEG(350)-GPLG¯LLGC(NH2) and mPEG(750)-
GPLG¯LLGC(NH2) were incubated with MMP-9 and characterized by liquid 
chromatography mass spectrometry (LCMS). For both substrates, chromatographic 
separation of unreacted substrate from digested products was achieved and products were 
identified (Figure 71). For mPEG(350)-GPLG¯LLGC(NH2) the unreacted substrate 
eluted at 36-39 min and has a distribution of peaks separated by 44 Da, the mass of one 
ethylene glycol unit, that is centered at m/z 1020 ([M+H]+, M=1019 g/mol) (Figure 50). 
The expected product LLGC(NH2) eluted at 15-16 minutes with m/z 404 ([M+H]+, M=403 
g/mol), and mPEG(350)-GPLG eluted at 25-31 minutes with a distribution of peaks 
separated by 44 Da centered at m/z 635 ([M+H]+, M=634 g/mol). The 44 Da mass 
difference between each peak indicates the repeating ethylene glycol units, which further 
validate the structure of the cleaved product. Some disulfide LLGC dimer was also 
observed, which likely occurred during peptide incubation. Likewise, for mPEG(750)-
GPLG¯LLGC(NH2), the unreacted substrate eluted at 39-40 min with m/z 1328 ([M+H]+, 
M=1327 g/mol). The expected product LLGC(NH2) eluted at 15-17 minutes with m/z 404, 
and product mPEG(750)-GPLG eluted at 25-35 minutes with m/z 987 ([M+H]+, M=986 
g/mol). The absence of other products supports the specificity of MMP-9 cleavage between 
the Gly-Leu bond. 
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Figure 50. LC-MS ESI characterization of A) mPEG(350)-GPLGLLGC(NH2) 1) starting 
material and MMP-9 cleavage products 2) mPEG(350)-GPLG and 3) LLGC(NH2). ESI 
characterization of B) mPEG(750)-GPLGLLGC(NH2) 1) starting material and MMP-9 
cleavage products 2) mPEG(750)-GPLG and 3) LLGC(NH2). 
4.2.2 Matrix Metalloproteinase-Responsive Nanogel Synthesis and Characterization 
To afford nanoparticles with MMP-9 responsive characteristics, we utilized the 
previously reported self-crosslinking disulfide-based nanogel scaffold.67 The polymeric 
nanogels are achieved using amphiphilic random copolymers that self-assemble into 
nanoscale aggregates with disulfide functionality that allows for both controlled guest 
entrapment and stimuli-responsive release. Redox-responsive guest release from 
nanoassemblies are of significant interest due to their sensitivity to concentrations of 
glutathione (GSH) in blood plasma (10 µM) compared to the cytosol (10 mM).67-69  While 
stable encapsulation is observed at extracellular GSH concentrations, these nanogels 
release their therapeutic cargo following cellular internalization and exposure to cytosolic 
concentrations of GSH. In this work, we expanded this platform to include a second 
stimuli-responsive feature at the particle surface, which can modify its cell interaction and 
facilitate cellular uptake. 
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The p(OEGMA-co-PDSMA) random copolymer used for nanogel formation was 
synthesized by a reversible addition–fragmentation chain transfer (RAFT) polymerization 
of monomers poly(ethylene glycol) methyl ether methacrylate (OEGMA) and 
pyridyldisulfide ethyl methacrylate (PDSMA). After polymerization, the polymer was 
purified by dialysis against dichloromethane to remove unreacted monomers, then 
characterized by NMR and GPC (Figure 61, 62). We used the characteristic resonances of 
the 2-pyridylthio moieties of PDSMA (dHa = 8.45, dHb = 7.66, and dHc = 7.10 ppm) and 
methoxy moieties of OEGMA (dHd = 3.37 ppm) to calculate the relative ratios of the 
monomer incorporated in the polymer as 7:3 PDS to OEG. The GPC obtained number-
average molecular weight (Mn) and dispersity (Đ = Mw/Mn) of the copolymer was 31.9 
kDa and 1.4, respectively.  
The nanogel was then formulated by dispersing the p(OEGMA-co-PDSMA) 
random copolymer in an aqueous phase in the presence of Na2SO4 (25 mM) to form ~20 
nm self-assembled aggregates. The aggregates were then locked in conformation through 
intra-aggregate disulfide crosslink formation (Scheme 8). The covalent crosslinking is 
achieved via the addition of a sub-stoichiometric amount of reducing agent, DL-
dithiothreitol (DTT), which generates the corresponding quantity of free thiols on PDS 
moieties within the aggregate interior, which then react with remaining activated PDS 
moieties in the polymer chain. For these nanogels, we used 12.5 mol% DTT, relative to 
PDS in the aggregates, to result in 25% crosslinked nanogels. The crosslinking for resultant 
Bare-NG was quantified by the reaction byproduct 2-pyridinethione using its characteristic 
absorption peak at 343 nm (Figure 69).  
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Scheme 8. A) Schematic representation of polymeric nanogel formation, and B) structural 
representation of polymer nanogels synthesis with structure of substrates. 
 
Next, nanogels were decorated with either mPEG(350)-GPLG¯LLGC(NH2), 
mPEG(750)-GPLG¯LLGC(NH2), or positive control LLGC(NH2) through a thiol-
disulfide exchange reaction between the cysteine thiols of the peptide and PDS groups of 
the nanogel (Scheme 8). Peptides dissolved in methanol were added to the aqueous 
crosslinked nanogels and post modification was quantified by absorbance using the 
reaction byproduct 2-pyridinethione (Figure 69). The resulting nanogels denoted 
mPEG350-NG, mPEG750-NG, and LLGC-NG contained ~30% peptide functionalization 
respective to PDS, for each mPEG(350)-GPLG¯LLGC(NH2), mPEG(750)-
GPLG¯LLGC(NH2), and LLGC(NH2), respectively (Table 23). Conjugation efficiency 
for LLGC(NH2) was 73%, while the conjugation efficiencies for mPEG(350)-
GPLG¯LLGC(NH2) and mPEG(750)-GPLG¯LLGC(NH2) were 64% and 56%, 
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respectively. Nanogels were purified by dialysis and MALDI characterization of nanogel 
confirmed removal of free peptide (Figure 51). Post-modification of the peptides to the 
nanogels did not appreciably change the particle sizes, or cause any observable 
precipitation or aggregation as characterized by DLS (Figure 51). Due to the known lower 
critical solution temperature (LCST) characteristics of PEG, the temperature 
responsiveness of these nanogels were characterized by DLS. Size transitions were 
observed well above 37 °C, suggesting nanoparticle integrity at biologically-relevant 
conditions (Figure 70). 
Table 23. Characterization of substrate-functionalized nanogels. 
Sample 
 
Crosslink 
(% PDS) Substrate Identity 
Substrate 
(% PDS) 
Size 
(nm) 
Bare NG 24 -- N/A 16 
mPEG350-NG 24 mPEG350-GPLGLLGC(NH2) 32 18 
mPEG750-NG 24 mPEG750-GPLGLLGC(NH2) 28 18 
LLGC-NG 24 LLGC(NH2) 33 16 
 
4.2.3 Surface-Conversional Validation and Quantification 
The proteolytic capability of MMP-9 to cleave peptide from the nanogel surface 
was confirmed using MALDI-MS. On a substrate decorated particle surface, we expect 
MMP-9 proteolysis to generate free mPEG-GPLG in solution while LLGC(NH2) remains 
conjugated to the particle by the C-terminal cysteine. The nanogels were incubated with 
active MMP-9 at 37 °C for 24 hours in PBS pH 7.4. Following this incubation, any free 
cleaved peptide was isolated for analysis using 3 kDa centrifuge filtration.  The centrifuged 
solutions were then mixed with matrix solutions containing CHCA and characterized by 
MALDI-MS. As a control, nanogels not incubated with MMP-9 were characterized to 
demonstrate that masses corresponding to free substrates were not observed prior to 
proteolysis, while their cleavage products were evident following MMP-9 treatment 
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(Figure 51). MALDI analysis of mPEG350-NG incubated with MMP-9 generated a 
distribution of peaks separated by 44 Da that is centered at m/z 767, which correlates to 
[M+H]+ of product mPEG8-GPLG. MMP-9 mediated mPEG750-NG proteolysis also 
exhibited a distribution of peaks separated by 44 Da with a distribution maxima of m/z 
1,141, which correlates to [M+Na]+ of product mPEG16-GPLG. For both nanogels, these 
proteolysis products have a slightly higher PEG distribution shift than observed on free 
substrate. This slight change can be attributed to either preferential conjugation of longer 
PEG species to the particle due to enhanced aqueous solubility, or higher MALDI 
ionization efficiency of the longer PEG species.  
 
Figure 51. DLS sizes by volume of A) Bare NG and substrate-modified nanogels and B) 
MMP-9 responsive NGs mPEG350-NG and mPEG750-NG before and after MMP (54 nM) 
treatment. C) MALDI characterization of substrate containing nanogels 1) mPEG350-NG, 
2) mPEG350-NG pretreated with MMP-9 (54 nM), 3) mPEG750-NG, 4) mPE7350-NG 
pretreated with MMP-9 (54 nM). 
 
We then investigated the generation free amines on the nanogel surfaces by MMP-
9 proteolysis and aimed to quantify the reaction using a fluorescamine assay. In this assay, 
non-fluorescent fluorescamine (4-phenylspiro[furan-2(3H), 1'-phthalan]-3,3'-dione) reacts 
directly with primary amines to form a fluorescent product (390 nm excitation, 465 nm 
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emission). Previous reports have observed near complete reaction between lysines and N-
terminus of peptides with fluorescamine.72 Because fluorescence is proportional to the 
quantity of free amines present, this assay is often used to detect and quantify proteins with 
high sensitivity.72-74 The fluorescamine assay has been frequently used to monitor 
supramolecular processes as well, such as characterization of poly(L-lysine)-DNA 
complexes that are post-modified a multivalent polymer.73 Likewise, we expect the N-
termini generated by MMP-9 proteolysis on a nanogel surface to be quantifiable using the 
fluorescamine assay. 
 Here we used the positive control nanogel, modified with 33% LLGC(NH2), to 
demonstrate the reaction between fluorescamine and a modeled MMP-9 created N-
terminus. Moreover, the fluorescence generated is proportional to the concentration of N-
termini present from the functionalized peptide. Because the fluorescamine reaction is 
highly efficient, the fluorescence from this sample can be assumed to represent a nanogel 
with 100% cleavage. A concentration dependent calibration curve was generated using 3 
molar excess of fluorescamine in DMSO with various concentrations of LLGC-NG 
(mg/mL) PBS buffer pH 7.4 and monitoring the fluorescence intensity (Figure 52). The 
fluorescamine assay confirmed that the fluorescence intensity was linearly proportional to 
the concentration of LLGC-NG, and appropriate for quantification of N-termini in solution. 
Nanogels were incubated with low nanomolar concentrations of MMP-9 (0.54-5.4 
nM) to evaluate responsivity to levels reported in plasma (50-500 ng/mL) for various 
cancers.74-76 There have been significant efforts to determine plasma or serum 
concentrations of MMP-9 to discern cancer progression and prognosis significance. Local 
tumor concentrations are expectedly higher, and cell culture of different cancer lines report 
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MMP-9 excretions in the high nanomolar to low micromolar range.63, 77 This is 
heterogeneous across different tumor types78, so we assigned an MMP-9 concentration of 
54 nM (5 µg/mL) as a conservative estimate to evaluate responsivity at tumor-relevant 
extracellular matrix concentrations. To understand concentration affects, mPEG350-NG 
and mPEG750-NG nanogels were incubated with 0.54, 5.4, and 54 nM MMP-9, and at 
determined time points quenched, purified by 100 kDa dialysis, then reacted with 
fluorescamine for quantification. Obtained fluorescence intensities were calculated against 
the linear fit of LLGC-NG to determine percentage of N-termini, i.e. cleavage, generated 
by MMP-9.  
 
Figure 52. Fluorescamine assay results for MMP-9 substrate cleave percent by A) 
concentration and B) time for nanogels (avg. ± std, n=3 repeat), and C) fluorescence 
calibration of LLGC-NG (avg. ± std, n=4 measurements). D) Mean zeta potential of 
nanogels conjugated with increasing LLGC% (avg. ± std, n=3 measurements). D) Mean 
zeta potential of mPEG350-NG and mPEG750-NG before and after MMP-9 treatment 
(avg. ± std, n=3 measurements). F) Confirmation of MMP-9 activity over the 24-hour 
experiment, expressed as normalized RFU/s with 8 hours ProMMP-9 activation with 
APMA as time 0 of nanogel incubation (avg. ± std, n=2 repeat).  
 
Nanogels incubated without MMP-9 showed negligible fluorescence, confirming 
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the expected absence of amines on the starting material (Figure 52). At 0.54 nM MMP-9, 
negligible (~1%) cleavage was observed for both mPEG350-NG and mPEG750-NG after 
a 24-hour incubation, which were similar in value to those obtained for 0 nM MMP-9. At 
moderate concentrations (5.4 nM), as expected low cleavage values were still obtained, 
with ~4% for both nanogels. Under extracellular relevant concentrations of MMP-9 (54 
nM), 30±6% of the substrate was cleaved from the mPEG350-NG nanogel surface after 24 
hours. For mPEG750-NG, however, approximately half the amount of cleavage was 
obtained, with 14±1% cleaved at 24 hours. To evaluate this result, time dependent cleavage 
of 54 nM MMP-9 was obtained. This analysis showed that much higher cleavage occurred 
with mPEG350-NG compared to mPEG750-NG, however was progressive over the full 24 
hours for both systems. We hypothesize that this difference is due to substrate accessibility, 
as it is expected that the longer PEG lengths can cause more steric hindrance and restrict 
the extent of protease-mediated substrate cleavage.  
We were also interested in evaluating this surface conversional property by 
examining nanocarrier zeta potential change. Precursor Bare NG and substrate-decorated 
nanogels mPEG350-NG and mPEG750-NG gave zeta potentials of -21 mV, -22 mV and -
17 mV, respectively (Figure 52). Although the negative zeta potential of anticipated 
neutral PEG surface seems unexpected, several reports indicate PEG-decorated 
nanostructures do have negative zeta potentials.42, 79, 80 The cause of this, however, is thus 
far unclear. Nanogels were then decorated with increasing amounts of amine terminus 
containing peptide LLGC(NH2) to test the veracity of the amine terminus to inflict a 
positive zeta potential on these nanogels. Indeed, conjugation of LLGC(NH2) developed a 
positive charge, with zeta potential becoming more neutral at -1 mV for 7% conjugation 
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and +18 mV for 16% conjugation, which did not become more positive with higher peptide 
conjugation. This guided our rationale that even small amounts of this substrate could 
impact the surface charge of these nanogels. The zeta potentials of mPEG350-NG did 
indeed become less negative after incubation with MMP-9, with a mean zeta potential of 
+6 mV after 24 hours of treatment. This suggests a significant shift in surface character 
from the initial value of -22 mV. Measurably positive surface charge was not achieved with 
mPEG750-NG, with maximum value of -1 mV after 24 hour MMP-9 incubation. This is 
consistent with the lower cleavage extent observed by fluorescamine assay on this particle, 
further supporting that accessibility of the protease to substrate limited the surface-
conversion capability.  
4.2.4 Guest Encapsulation and Stimuli-Responsive Release 
For this nanocarrier, guest encapsulation under both stimuli GSH and MMP-9 was 
evaluated. To test the structural stability and guest release in response to stimuli, nanogels 
encapsulated with a model hydrophobic guest 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindocarbocyanine perchlorate (DiI) were prepared for mPEG350-NG, 
mPEG750-NG, and Bare NG to serve as a MMP-9 non-responsive control (Figure 53). 
Due to the hydrophobicity of DiI, we expect any dye release from the nanogels interior to 
result in precipitation and resulting fluorescence decrease. Nanogels were prepared in TNC 
buffer, pH 7.4, and the fluorescence of DiI was monitored over time in response to GSH, 
ProMMP-9 to serve as non-catalytic protein control, or MMP-9 at various concentrations. 
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Figure 53. UV-visible spectra of crosslinking of A) Bare NG, and post modification with 
substrates to give B) mPEG350-NG and B) mPEG750-NG compared to excess DTT for 
maximum release byproduct 2-pyridinethione (lmax = 343 nm) in nanogels loaded with DiI 
(lmax = 558 nm). 
 
The trends in guest release were similar for Bare-NG, mPEG350-NG, and 
mPEG750-NG (Figure 54). In all cases, the nanogel control, which is exposed to no 
stimulus, exhibited some release over 48 hours, with 4±3, 13±7, and 8±4% for Bare-NG, 
mPEG350-NG, and mPEG750-NG, respectively (Table 24). This release is likely due to 
loss of any adsorbed or poorly encapsulated DiI from buffer dilution. We investigated the 
release capabilities under cytosolic redox conditions and as expected, the disulfide-based 
nanogel crosslinks were responsive to reduced glutathione. Over a 48-hour period, we 
observed 51±3, 42±1, and 48±1% release of encapsulated DiI in the presence of 10 mM 
GSH at pH 7.4, for Bare-NG, mPEG350-NG, and mPEG750-NG, respectively (Figure 
54). Release values in response to extracellular reduced GSH concentrations (10 µM) were 
similar to the controls, supporting low responsivity to extracellular GSH levels.  
0
0.2
0.4
0.6
0.8
1
300 350 400 450 500 550 600
Ab
so
rb
an
ce
Wavelength (nm)
Bare NG(DiI)
Bare NG(DiI) excess DTT
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
300 350 400 450 500 550 600
Ab
so
rb
an
ce
Wavelength (nm)
mPEG350-NG(DiI)
mPEG350-NG(DiI) excess DTT
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
300 350 400 450 500 550 600
Ab
so
rb
an
ce
Wavelength (nm)
mPEG750-NG(DiI)
mPEG570-NG(DiI) excess DTT
A B C
  149 
 
Figure 54. Guest release based on normalized fluorescence for nanogels A) Bare over 48 
hours in response to GSH (10 mM and 10 µM), ProMMP-9 (54 nM), and MMP-9 (0.54, 
5.4, and 54 nM) compared to no stimulus control, and B) corresponding DLS of nanogel 
sizes upon exposure to MMP-9 (54 nM) and GSH (10 mM) and serial dilution. C) Guest 
release and D) DLS plots of mPEG350-NG upon exposure to stimuli, and E) guest release 
and F) DLS plots of mPEG750-NG upon exposure to stimuli. 
 
Unexpectedly, we also observed some release by MMP-9 with values of 42±3, 
41±1, and 41±2% at 48 hours for Bare-NG, mPEG350-NG, and mPEG750-NG, 
respectively (Figure 54). This was heavily dependent on MMP-9 concentration, with far 
less release observed at serum concentration of MMP (5.4 nM), and values similar to 
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controls at 0.54 nM. Furthermore, this release was not observed with the inactive 
proenzyme, ProMMP-9, with 6±7, 4±2, and 2±1% at 48 hours for 54 nM for nanogels 
Bare-NG, mPEG350-NG, and mPEG750-NG, respectively, which was irrespective of 
concentration, (Figure 55). This suggests that the release mediated by MMP-9 is not due 
to general non-specific protein interaction with the nanogels, but unique to MMP-9 
catalytic activity with the nanogels. However, this is not a result of the MMP-responsive 
substrates, as the same result was observed with the non-MMP-responsive Bare NG. 
Further, DLS characterization of the nanogels was executed under severe dilution 
conditions (1000-fold) and we observed maintained particle integrity of MMP-9 (54 nM) 
treated nanogels, while those treated with 10 mM GSH lost its aggregation capability 
(Figure 54). One possibility for observed release is that the protease could exhibit some 
esterase activity, cleaving ester bonds in the polymer structure. This could be easily 
avoided for these nanogels through use of acrylamide rather than methacrylate-based 
monomers. Some premature extracellular guest release would still be unique to tumor-
relevant high protease concentrations, and therefore in the target region and may not be of 
concern. 
Table 24. Guest release % for A) Bare NG B) mPEG350-NG, and C) mPEG750-NG at 
48 h. 
 Control 
GSH 
(10 µM) 
GSH 
(10 mM) 
ProMMP 
(.54 nM) 
ProMMP 
(5.4 nM) 
ProMMP 
(54 nM) 
MMP 
(.54 nM) 
MMP 
(5.4 nM) 
MMP 
(54 nM) 
A 3.5±3.3 6.4±0.2 50.9 ±3.2 4.6±0.4 5.8±0.3 6.3±6.6 5.3±2.6 12.7±0.6 41.6±2.5 
B 13.3±6.6 10.2±4.8 42.0±1.0 6.7±1.4 5.7±0.2 3.8±1.6 12.5±4.8 17.4±0.6 41.3±1.3 
C 7.8±4.3 10.6±1.0 48.2±0.7 3.4±1.8 1.6±0.8 2.1±0.9 2.8±8.3 12.3±1.2 41.3±1.7 
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Figure 55. Guest release based on normalized fluorescence for nanogels A) Bare NG B) 
mPEG350-NG, and C) mPEG750-NG over 48 hours in response to ProMMP-9 (0.54, 
5.4, and 54 nM) compared to no stimulus control. D) Activty of MMP-9 monitored in 
TTC and TNC buffer over 33 hours (8 hour APMA activation is 0 hour of nanogel 
incubation). 
4.2.5 Cellular Uptake Analysis 
Confocal microscopy was used to evaluate whether the nanogels were taken up by 
human HeLa cells at an enhanced rate following MMP-9 treatment. Cytotoxicity of these 
nanogels was evaluated for the HeLa cell line using the MTT cytotoxicity assay, 
demonstrating >70% viability even up to 1 mg/mL (Figure 56). To monitor the in vitro 
cellular uptake, nanogels were first covalently modified with 5% thiol-modified 
fluorescein label. Negative “passive” controls mPEG350-NG(F) (fluorescein) and 
mPEG750-NG(F), amine-decorated positive control LLGC-NG(F), and test samples 
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MMP-treated mPEG350-NG(F) Active and mPEG750-NG(F) Active were all prepared 
with fluorescein tag and were the same size by DLS (Figure 57). 
 
Figure 56. MTT toxicity assay with nanogels mPEG350-NG and mPEG350-NG compared 
to positive control (PBS) and negative control (trypsin). 
 
 
Figure 57. Fluorescein-modified nanogel A) structure and B) sizes by DLS for confocal 
Microscopy. 
 
Nanogels were incubated with HeLa cells for 2 hours before confocal imaging, and 
NG uptake was observed using laser excitation at 488 nm. Consistent with expectations, 
from microscopy images “passive” PEG-decorated mPEG350-NG(F) showed much lower 
cellular uptake than amine-decorated LLGC-NG(F) (Figure 58). This result supported our 
anticipation that the poly-amine character from N-termini could be sufficient in modifying 
the adsorption of nanogels on cellular membranes. Indeed, once treated with MMP-9, 
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mPEG350-NG(F) Active exhibited uptake much more reminiscent of positive control 
LLGC-NG(F). Therefore, the extent of enzymatic proteolysis achieved on this nanogel was 
sufficient to achieve a surface-conversion and alter its cellular uptake. The results are likely 
a combination of PEG reduction of endosomolytic activity and improved charge-charge 
adsorption of polyvalent amines on the phospholipid bilayer of cells. Microscopy z-stack 
images at 100´ objective supported these results (Figure 59). Nanogel mPEG750-NG(F), 
however, did not exhibit an observable difference in uptake following MMP-9 treatment, 
which shows that the extent of cleavage that occurs on these particles is crucial in obtaining 
this improved cell-membrane interaction. These results were supported quantitatively by 
flow cytometry, which showed highest fluorescence intensities of FITC in HeLa cells with 
positive control LLGC-NG, and a greater fluorescence intensity for mPEG350-NG Active 
compared to mPEG350-NG (Figure 58). Consistent with microscopy observations, 
mPEG750-NG did not show uptake enhancement following MMP activation, with similar 
median FITC fluorescence intensities. It is possible that either higher protease 
concentrations or longer incubation times could improve the extent of MMP-9 surface 
charge turnover for longer PEG nanogel, but these results suggest a fine balance is required 
between substrate PEG shielding and enzyme accessibility to achieve the “passive” to 
“active” conversion.    
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Figure 58. Confocal microscopy images using a 40´ objective of composite (left) with 
nucleus (blue 405 nm) and fluorescein-labeled NG (green, 488 nm), and composite with 
brightfield (right) image overlays of HeLa cells after 2-hour incubation with A) no sample, 
and fluorescein-labeled nanogels B) LLGC-NG(F) positive control, C) mPEG350-NG(F), 
D) mPEG350-NG(F) Active, E) mPEG750-NG(F), F) mPEG750-NG(F) Active. Flow 
cytometric histogram profiles of FITC fluorescence intensity for HeLa cells incubated with 
LLGC-NG(F) and G) mPEG350-NG(F) and mPEG350-NG(F) Active, and H) mPEG750-
NG(F) and mPEG750-NG(F) Active. 
 
 
Figure 59. Confocal microscopy 100´ composite (left) and brightfield (right) images of 
HeLa cells after 2-hour incubation with fluorescein-labeled nanogels A) LLGC-NG(F), B) 
mPEG350-NG(F), C) mPEG350-NG(F) Active. Two images represented for each.   
A
B
C
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We then investigated the internalization behavior of DiI-encapsulated mPEG350-
NG before and after MMP treatment to determine the capability to deliver a hydrophobic 
guest. This was of interest due to observed DiI release from nanogels under high 
concentrations of MMP-9. DiI loaded mPEG350-NG was activated with MMP-9, then 
purified by 100 kDa dialysis and filtration to remove any released free DiI prior to confocal 
analysis. A loss of ~20% of DiI was observed by absorbance spectra (lmax = 558 nm) 
following MMP-9 activation compared to untreated control (Figure 60). Nanogels were 
incubated with HeLa cells for 2 hours at the same nanogel concentration (0.1 mg/mL) so 
that comparative uptake could be evaluated despite the DiI loss. Uptake was observed by 
confocal microscopy using laser excitation at 540 nm. Even with less fluorophore guest, 
significantly different cellular uptake was observed for mPEG350-NG(DiI) and 
mPEG350-NG(DiI) active. These results suggest that the higher internalization is not due 
to guest quantity or extracellular leakage, but from the greater uptake of MMP-9 activated 
nanogels, consistent with fluorescein-labeled nanogel results. The enhanced delivery of a 
hydrophobic guest illustrates the potential for the protease-activation strategy to improve 
the internalization of therapeutic cargo in MMP-rich environments.  
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Figure 60. Confocal microscopy images using a 40´ objective of composite (left) with 
nucleus (blue 405 nm) and DiI-loaded NG (red, 540 nm), and composite with brightfield 
(right) image overlays of HeLa cells after 2-hour incubation with A) mPEG350-NG(DiI) 
and B) mPEG350-NG(DiI) Active. C) UV-visible absorbance spectra of DiI 
encapsulation before and after MMP-9 activation. Dye release calculated from decrease 
in absorbance at lmax 558 nm. 
 
4.3 Conclusion 
In summary, we report on a nanogel capable of converting its surface properties 
from a passive PEGylated particle to an active amine decorated particle in the presence of 
MMP-9, a protease frequently observed in the tumor extracellular environment. We have 
shown that: (i) the incorporation of MMP-9 substrate on the nanogel surface can lead to a 
MMP-9 dependent surface conversion from PEG to N-termini, (ii) this conversion is 
dependent on time and the concentration of MMP-9 present, and circulation concentrations 
of MMP-9 were inadequate while tumor extracellular concentrations of MMP-9 were 
adequate in achieving surface conversion, (iii) the surface conversion process can be used 
to enhance nanocarrier cellular uptake specifically under desired MMP-9 upregulated 
environments, and (iv) this surface proteolysis on the particle does not lead to nanogel 
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disassembly, while the intracellular concentrations of reducing glutathione do cause 
disassembly. 
Considering the molecular design, we expect that the sensitivity and specificity of 
peptidase response can be modified based on the identity of the proteolysis-susceptible 
peptide incorporated. Because this strategy of N-terminus generation can be achieved by 
simply installing the substrate to the particle at its C-terminus, it allows for flexible 
sequence selection and adaptation to the appropriate upregulated MMPs or other proteases 
in the target tissue. The modular formulation achieved by post-assembly modification with 
substrate using thiol-disulfide exchange allows for facile incorporation of a variety of 
responsive sequences, opening a variety of avenues for the design of these protease-
responsive surface conversional nanogels.   
4.4 Experimental 
4.4.1 Materials and Methods 
Polyethylene glycol monomethyl ether (average MW 350 and 750 g/mol) , 4-
aminophenylmercuric acetate (APMA), methacryloyl chloride, 2-mercaptoethanol, 
poly(ethyleneglycol) monomethyl ether methacylate (OEGMA; MW 500 g/mol), 4-cyano-
4-(phenylcarbonothioylthio)pentanoic acid, chromium trioxide, sulfuric acid, 
trifluoroacetic acid, triisopropylsilane, 1,2-ethanedithiol, DL-dithiothreitol (DTT), 2-(4-
amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI), fluorescein isothiocyanate 
isomer 1 (FITC), cystamine dihydrochloride, trimethylamine, tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), piperidine solution 
and fluorescamine were purchased from Sigma Aldrich and used without further 
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purification. AIBN (2,2’-azobis(2-methylpropionitrile) was purchased from Sigma Aldrich 
and purified by recrystallization. Amino acids and Rink Amide AM resin (100-200 mesh) 
for solid phase peptide synthesis were purchased from EMD Millipore. ProMMP-9 was 
purchased from BioLegend Inc. Fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2 
was purchased from R&D Systems, Inc. Solvents, Dulbecco's modified Eagle's medium 
(DMEM), fetal bovine serum (FBS), trypsin-EDTA (0.5%, no phenol red) were purchased 
from Fisher Scientific. Penicillin-streptomycin-glutamine (100x) solution, PBS 7.4, and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from 
Thermo Fisher Scientific. Pyridyl disulfide ethyl methacrylate (PDSMA) was prepared as 
previously reported.81 Polymers were synthesized using RAFT polymerization and purified 
by dialysis using a membrane with 3500 MWCO. 1H-NMR spectra were recorded on a 
400 MHz Bruker NMR spectrometer using the residual proton resonance of the deuterated 
solvent as the internal standard. Polymer molecular weights were estimated by gel 
permeation chromatography (GPC, Waters) using THF as eluent at a flow rate of 1 mL/min 
by a refractive index detector compared to poly(methyl methacrylate) (PMMA) standard. 
UV-visible absorption spectra were recorded on a PerkinElmer Lambda 35 UV/Vis 
Spectrophotometer. High performance liquid chromatography was conducted using a 
Shimadzu Prominence Modular HPLC. 
4.4.2 Experimental Procedures 
Synthesis of random copolymer p(OEGMA-co-PDSMA): To a Schlenk-flask, 
monomers PDSMA (5 g, 19.58 mmol) and OEGMA (3.625 g, 7.25 mmol), RAFT reagent 
4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (60 mg, 0.362 mmol), and initiator 
AIBN (12 mg, 0.0731 mmol) were dissolved in DMF (10 mL). The mixture was degassed 
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by performing three freeze-pump-thaw cycles and filled with argon.  The reaction mixture 
was then sealed and transferred into a pre-heated oil bath at 70 °C and stirred for 18 h.  The 
reaction flask was submerged in an ice bath to quench the polymerization, then dialyzed 
against dichloromethane in a MWCO 3500 regenerated cellulose membrane for 48 hours 
to remove unreacted monomers. The solution was dried to yield the random copolymer as 
an oil. GPC (THF) Mn: 31.9 KDa; Ð: 1.4. 1H NMR (400 MHz, CDCl3) δ (ppm): 8.45, 7.66, 
7.10, 4.37-3.94, 3.76-3.47, 3.37, 3.01, 2.15-1.56, 1.14-0.65. The molar ratio of the two 
monomers in the polymer was determined by the relative integrations of the aromatic 
protons of PDS and methoxy protons of oligoethylene glycol to give 3:7 (OEG:PDS). 
 
Figure 61. 1H-NMR spectrum of random copolymer p(OEGMA-co-PDSMA). 
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Figure 62. GPC (THF) for polymer p(OEGMA-co-PDSMA) Mn: 31.9 KDa; Ð 1.4. 
 
Synthesis of mPEG(350) carboxylic acid: Poly(ethylene glycol) monomethyl ether 
carboxylates were prepared from Jones’ Oxidation of poly(ethylene glycol) monomethyl 
ether following previously published procedures.82-84 Jones’ Reagent (1.25 M) was 
prepared by dissolving chromium trioxide (5 g, 50 mmol) in 35.7 mL of water at 10 °C 
with stirring, to which 4.36 mL of concentrated sulfuric acid was added in small portions. 
The solution was stirred for ten minutes then allowed to reach room temperature. 
Poly(ethylene glycol) monomethyl ether MW 350 (4 g, 11.43 mmol) was dissolved in 250 
mL acetone and 1.25 M Jones’ Reagent (18.3 mL, 22.86 mmol) was added in a single 
portion and stirred at room temperature for 12 hours. The solution was filtered to remove 
excess chromium salts, then evaporated under reduced pressure to remove acetone. The 
green-blue oil was then dissolved in dichloromethane, dried with anhydrous Na2SO4, and 
filtered to remove remaining chromium salts. The solution was dried to yield the 
poly(ethylene glycol) monomethyl ether carboxylic acid (MW 350) as an oil with 99% 
yield. 1H NMR (400 MHz, CDCl3) δ (ppm): 4.16 (s, 2H, CH2), 3.88-3.49 (m, 27H, 
13´CH2), 3.38 (s, 3H, CH3). MALDI characterization confirmed product conversion, with 
distribution of 44 Da centered around m/z 419.55 ([M+Na]+, M=396.5 g/mol) (Figure 63, 
65). 
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Figure 63. 1H-NMR spectrum of random copolymer mPEG(350) carboxylic acid. 
 
Synthesis of mPEG(750) carboxylic acid: Polyethylene glycol monomethyl ether MW 
750 (5 g, 6.667 mmol) was dissolved in 250 mL acetone and 1.25 M Jones’ Reagent (10.7 
mL, 13.33 mmol) was added in a single portion and stirred at room temperature for 12 
hours. The solution was filtered to remove excess chromium salts, then evaporated under 
reduced pressure to remove acetone. The green-blue oil was then dissolved in 
dichloromethane (100 mL), dried with anhydrous Na2SO4, and filtered to remove 
remaining chromium salts. The solution was dried to yield the Poly(ethylene glycol) 
monomethyl ether carboxylic acid (MW 350) as an oil with quantitative yield. 1H NMR 
(400 MHz, CDCl3) δ (ppm): 4.12 (s, 2H, CH2), 3.85-3.42 (m, 60H, 30´CH2), 3.34 (s, 3H, 
CH3). MALDI characterization confirmed product conversion, with distribution of 44 Da 
centered around m/z 729.33 ([M+Na]+, M=706.3 g/mol) (Figure 64, 65).  
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Figure 64. 1H-NMR spectrum of random copolymer mPEG(750) carboxylic acid. 
 
Figure 65. MALDI characterization of A) mPEG(350) carboxylic acid and B) mPEG(750) 
carboxylic acid. 
 
Synthesis of mPEG(350 and 750)-GPLG¯LLGC(NH2): The MMP-9 cleavable peptide 
(GPLG¯LLGC(NH2); arrow indicates expected MMP-9 cleavage site) was synthesized 
through standard Fmoc-based solid phase techniques on a rink amide AM resin (500 mg, 
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0.71 mmol/g loading, 100-200 mesh). Fmoc deprotection was achieved using 20% 
piperidine in DMF (10 mL) for 20 minutes. Amino acid couplings were achieved by adding 
Fmoc-protected amino acid (1.06 mmol), HATU (405 mg, 1.06 mmol), and N,N-
diisopropylethylamine (190 µL, 1.06 mmol) in DMF (3.55 mL, 0.3 M amino acid) to the 
resin for 45 minutes. Following each Fmoc deprotection or amino acid coupling, the resin 
was washed three times with DMF then DCM and then monitored by the Kaiser test. 
Following the final Fmoc deprotection, either poly(ethylene glycol) monomethyl ether 
carboxylic acid MW 350 (901 mg, 2.475 mmol) or poly(ethylene glycol) monomethyl ether 
carboxylic acid MW 750 (1.891 g, 2.475 mmol), with HATU (972 mg, 2.475 mmol), and 
N,N-diisopropylethylamine (547 µL, 2.475 mmol) to each was dissolved in DMF (8.52 mL 
0.3 M carboxylic acid) and added for coupling. The poly(ethylene glycol) monomethyl 
ether carboxylic acids were left to react for 12 hours, then unreacted reagents were washed 
from the resin several times with DMF then DCM then monitored by the Kaiser test. The 
resin was rinsed with DCM and methanol, then dried under vacuum. The PEG-peptide was 
cleaved from the resin in by incubation in a solution containing trifluoroacetic acid (6.312 
mL), 1,2-ethanedithiol (226 µL), triisopropylsilane (129 µL), and water (250 µL), for 6 
hours, then filtered and washed two times with small portions of trifluoroacetic acid. The 
combined filtrates were evaporated under reduced pressure then precipitated with 10-fold 
volume of cold diethyl ether. The crude precipitate was dissolved in a minimum amount of 
DCM then precipitated again in diethyl ether several times. The substrates were purified 
using HPLC on a semi-preparatory C18 column (10 mm x 25 cm, 10 µm particle size) 
using a gradient mobile phase of acetonitrile 0% to 70% acetonitrile in water, both 
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containing 0.05% (v/v) trifluoroacetic acid, monitoring absorbance of 214 nm at a flow 
rate of 5 mL/min.  
 
Scheme 9. Synthetic scheme of solid phase peptide synthesis of mPEG(350)-
GPLGLLGC(NH2) and mPEG(750)-GPLGLLGC(NH2). 
 
Characterization of mPEG(350)-GPLGLLGC(NH2) and mPEG(750)-
GPLGLLGC(NH2): The peptide mPEG(350)-GPLGLLGC(NH2) purity was confirmed 
to be 96%, and the peptide mPEG(750)-GPLGLLGC(NH2) purity was confirmed to be 
91% by analytical HPLC using a C18 column (4.6 mm × 10 cm, 2.7 µm particle size) using 
a gradient mobile phase of acetonitrile 0% to 50% acetonitrile in water, both containing 
0.05% (v/v) trifluoroacetic acid, monitoring absorbance of 214 nm at a flow rate of 1 
mL/min (Figure 66). The peptide identities were characterized using ESI Mass 
spectrometry. Mass analysis was carried out on a Bruker AmaZon (Billerica, MA) 
quadrupole ion trap mass spectrometer equipped with an electrospray ionization source. 
Typically, the electrospray needle voltage was kept at ∼4 kV, and the capillary temperature 
was set at 220 °C.  In mass spectrometry characterization of both mPEG(350)- and 
mPEG(750)-GPLGLLGC(NH2), distributions were observed with shifts of m/z 44, 
consistent with differences in 44 g/mol for one ethylene glycol unit due to the 
polydispersity of the poly(ethylene glycol) in the substrates. For mPEG(350)-
GPLGLLGC(NH2), the distribution centered around about m/z 1020, which coorelates to 
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[M+H]+ for expected M of 1019 g/mol and indicates a substrate with an average of 5 
ethylene glycol units. The other peaks shifted by m/z of 44 span about ±5 ethylene glycol 
units. The second distribution observed in the spectrum at m/z 1042 correspond to [M+Na]+ 
of the same product. Also observed is an [M+H]2+ distribution of the same product. From 
this spectrum, we can conclude the absence of any significant PEG-peptide impurities. 
Similarly, for mPEG(750)-GPLGLLGC(NH2), the distribution centered around about m/z 
of 1350.6 correlates to [M+Na]+ for expected mass 1327.6 g/mol, and indicates a substrate 
with an average of 12 ethylene glycol units. The other peaks shifted by 44 Da suggests 
about ±7 ethylene glycol units. Also observed is an [M+2Na]2+ distribution of the same 
product. Likewise, from this spectrum, we can conclude the absence of any significant 
PEG-peptide impurities. 
 
Figure 66. Substrate mPEG(350)-GPLGLLGC(NH2) A) ESI MS chromatogram and B) 
reverse phase HPLC chromatogram, and substrate mPEG(750)-GPLGLLGC(NH2) C) ESI 
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MS chromatogram and D) reverse phase HPLC chromatogram. 
 
 
 
Figure 67. Substrate A) mPEG(350)-GPLGLLGC(NH2) MALDI MS chromatogram and 
B) mPEG(750)-GPLGLLGC(NH2) MALDI MS chromatogram. 
 
 
Synthesis of LLGC(NH2): The MMP-9 cleavage product peptide LLGC(NH2) was 
synthesized through standard Fmoc-based solid phase techniques on a rink amide AM resin 
resin (0.2 g, 0.71 mmol/g loading, 100-200 mesh). As described above, Fmoc deprotection 
was attained using 20% piperidine (5 mL), and amino acid coupling were achieved using 
Fmoc-protected amino acid (0.4125 mmol), HATU (162 mg, 0.4125 mmol), and N,N-
diisopropylethylamine (76.2 µL, 0.4125 mmol) in DMF (1.42 mL, 0.3 M amino acid). 
Following the final Fmoc deprotection, the resin was rinsed with DCM and methanol, then 
dried under vacuum. The peptide was cleaved from the resin by incubation in a solution 
containing TFA (1.052 mL), water (41.7 µL), 1,2-ethanedithiol 37.7 µL) and 
triisopropylsilane (21.5 µL) for 3 hours, then isolated by diethyl ether precipitation as 
described above. The peptide was purified using HPLC on a semi-preparatory C18 column 
(10 mm x 25 cm, 10 µm particle size) using a gradient mobile phase of acetonitrile 0% to 
70% acetonitrile in water, both containing 0.05% (v/v) trifluoroacetic acid, monitoring 
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absorbance of 214 nm and flow rate 5 ml/min.  
 
Scheme 10. Synthetic scheme of peptide of LLGC(NH2). 
 
LLGC(NH2) Characterization: The peptide purity was confirmed to be 97% by analytical 
HPLC using a C18 column (4.6 mm × 10 cm, 2.7 µm particle size) (Figure 68). The peptide 
identity was characterized using ESI Mass spectrometry, and the observed peaks at m/z of 
404.2 matches [M+H]+ for expected mass of 403 g/mol. A second smaller peak at m/z 
805.4 matches [(2M-2H)+H]+ for disulfide formation of the product as a dimer.  
 
Figure 68. A) Reverse phase HPLC chromatogram of peptide LLCG in 0-70% acetonitrile 
at 214 nm in water, B) ESI MS of peptide LLGC. 
 
 
Synthesis of thiol-modified FITC: Fluorescein isothiocyanate (FITC) (61 mg, 0.158 
mmol), cystamine dihydrochloride (19 mg, 0.079 mmol) and triethylamine (110 µL, 0.788 
mmol) were dissolved in DMSO (1.2 mL) and stirred for 4 hours. Then tris(2-
carboxyethyl)phosphine hydrochloride (54 mg, 0.188 mmol) was added and stirred for 1 
hour. The mixture was precipitated in diethyl ether and then washed with water. The 
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resultant crude fluorescein-cysteamine was used for nanogel labeling without further 
purification. 
 
Formulation of Nanogels: Deionized water was added to the polymer (10 mg/mL) and 
made into a particle suspension using repeated chill and sonicate cycles until the solution 
appeared dissolved. Particles of about 20 nm were achieved by chemically crosslinking 
this equilibrium assembly of the polymer at 25 °C in 25 mM Na2SO4 using a calculated 
amount of DTT for 1 hour as reducing agent as previously reported.67, 85 Crosslinking was 
determined to be 25 mole percent PDS by calculating the amount of byproduct, 2-
pyridinethione, using its molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm)86 
using UV-Vis spectroscopy. Dynamic light scattering (DLS) experiments to obtain particle 
size were performed by using a digital correlator and goniometer with a light source 
operating at 514 nm using a Malvern Nanozetasizer-ZS. Final nanogel size measurements 
were obtained at 25 °C at a correlation time of 30 seconds. Dust was removed by filtering 
the solution through 0.45 µm polycarbonate filter. For each sample, 3 readings were 
recorded averaging 10 runs for the same sample. 
 
PEG-Peptide conjugation to nanogels: The substrates mPEG(350)-GPLG¯LLGC(NH2) 
(53.3 mg, 54.6 µmol), or mPEG(750)-GPLG¯LLGC(NH2) (72.7 mg, 54.6 µmol) were each 
dissolved in methanol (100 µL) and added separately to 5 mL of aqueous crosslinked 
nanogel (Bare NG) solutions (10 mg/mL, 109.3 µmol PDS) and stirred open to the 
atmosphere for 12 hours to allow the methanol to evaporate. The peptide LLGC(NH2) (3.97 
mg, 9.84 µmol) was added to 1 mL of aqueous crosslinked nanogel solution (10 mg/mL, 
21.9 µmol PDS) and stirred for 12 hours. The conjugation extent for each mPEG350-NG, 
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mPEG350-NG, and LLGC-NG, was quantified by UV-Vis spectroscopy by calculating the 
amount of generated byproduct 2-pyridinethione (Figure 69). Unconjugated peptide and 
2-pyridinethione byproduct was removed by dialysis against DI water in a 100 KDa 
MWCO cellulose dialysis membrane for 48 hours. DLS of peptide-conjugated nanogels 
were obtained in phosphate buffer pH 7.4 at a concentration of 2.5 mg/mL. 
 
Figure 69. DLS sizes of Bare NG and substrate-modified nanogels by A) number, B) 
volume, and C) intensity. Absorption spectra of D) nanogel crosslinking, E) mPEG(350)-
GPLGLLGC conjugation, F) mPEG(750)-GPLGLLGC conjugation, and G) LLGC 
conjugation, represented with excess DTT for 100% 2-pyridinethione byproduct release 
for comparison. Note: for LLGC conjugation, free 2-pyridinethione from crosslinking was 
removed prior to conjugation, so lower absorption is observed respective to excess DTT. 
 
LCST Determination of Nanogels: Dynamic light scattering (DLS) experiments to obtain 
temperature dependent nanogel size. The stability of these crosslinked and PEG-peptide 
decorated nanogels were evaluated at biologically-relevant conditions due to the lower 
critical solution temperature (LCST) characteristic of PEG. Final nanogel size 
measurements in PBS buffer pH 7.4 were obtained at 25-65 °C at a correlation time of 30 
seconds. Dust was removed by filtering the solution through 0.45 µm polycarbonate filter. 
For each sample, 3 readings were recorded averaging 10 runs for the same sample. For 
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mPEG(350)-NG the LCST transition was observed at 45 °C, and for mPEG(750)-NG the 
LCST transition was observed at 59 °C, both well above biological temperatures (Figure 
70). 
 
Figure 70. LCST characterization of A) mPEG(350)-NG and B) mPEG(750)-NG. 
 
ProMMP-9 AMPA Activation: APMA (3.5 mg mmol) was dissolved in 1 mL of 0.1 M 
NaOH solution, then diluted four times with reaction buffer (TCC buffer: 50 mM TRIS 
HCl, pH 7.5, 1 mM CaCl2, 0.05% triton X-100) to give a 2.5 mM stock of APMA.  The 
pH was adjusted to pH 7.4 using 0.1 M HCl, then the APMA solution (250 µmol, 100 µL) 
was added to MMP-9 solution (10 µg; 109 pmol, 100 µL) and incubated with shaking for 
24 hours at 37 °C in 5% CO2. 
 
Activity Assay of MMP-9: MMP-9 activity of APMA incubated ProMMP-9 was assayed 
using the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2. Protease cleavage 
between the Gly-Leu bond releases the fluorescent 7-methoxycoumarin group from the 
quenching 2, 4-dinitrophenyl group, which can be monitored overtime with excitation at 
320 nm and emission at 405 nm. After 8 hours of APMA activation, MMP-9 enzymatic 
activity at 5 nM was assayed using 10 µM substrate (supplied in 6.07 mM stock in DMSO) 
in a 100 µL reaction mixture in buffer (TTC or TNC) with 10% v/v DMSO. These 100 µL 
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assays were performed in triplicate in a 96-well microplate at 37 °C using a Molecular 
Devices Spectramax M5 spectrophotometer. Activity of APMA incubated MMP-9 sample 
was monitored over 33 hours in both buffers. 
 
Substrate Cleavage by LC-MS: MMP-9 cleavable substrates mPEG(350)-
GPLG¯LLGC(NH2) (1 mg, 0.1 mmol) and mPEG(750)-GPLG¯LLGC(NH2) (1.3 mg, 0.1 
mmol) were incubated with activated MMP-9 (1 µg, 10.9 nM) in TTC buffer 7.4 (1 mL) at 
37 °C in 5% CO2 with shaking for 24 hours. The mixture was analyzed by LCMS. 
Chromatographic separation was conducted by a Thermo Scientific (Waltham, MA) 
Ultimate 3000 HPLC with a Thermo Acclaim PepMap RSLC C18 column (300 µm x 15 
cm, 2 µm particle size). MMP-9 incubated substrates were eluted using a gradient of 
acetonitrile containing 0.1% formic acid that increased from 5% to 50% for 45 min at a 
flow rate of 4 µl/min. Chromatographic separation was successful for mPEG(350)-
GPLG¯LLGC(NH2), with remaining starting material eluted at 37-39 min, product 
LLGC(NH2) eluted at 15-16 minutes, and mPEG(350)-GPLG eluted at 25-31 minutes 
(Figure 71). For mPEG(750)-GPLG¯LLGC(NH2), the remaining starting material eluted 
at 39-40 min, product LLGC(NH2) eluted at 15-17 minutes, and product mPEG(750)-
GPLG eluted at 25-35 minutes. Substrate products were measured immediately by mass 
spectrometry. Mass analysis was carried out on a Bruker HCTultra (Billerica, MA) ion trap 
mass spectrometer equipped with an electrospray ionization source. Typically, the 
electrospray needle voltage was kept at ∼4 kV, and the capillary temperature was set at 220 
°C.  
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Figure 71. LC-MS extracted ion chromatograms of MMP-9 cleavage of substrates A) 
mPEG(350)-GPLGLLGC(NH2) (37-39 min), with products mPEG(350)-GPLG (25-31 
min) and LLGC(NH2) (15-16 min) and B) mPEG(750)-GPLGLLGC(NH2) (39-40 min), 
with products mPEG(750)-GPLG (25-35 min) and LLGC(NH2) (15-17 min), and 
corresponding chemical structures of substrate and products. 
 
Nanogel Activation with MMP-9: Nanogels (2.5 mg/mL polymer) decorated with MMP-
9 cleavable substrates (3 mM) in TTC buffer pH 7.4 was incubated with activated MMP-9 
at final enzyme concentrations of 0.54, 5.4, and 54 nM (0.05, 0.5, and 5 µg/mL MMP-9, 
respectively) at 37 °C in 5% CO2 with shaking. At determined time points the enzyme 
activity was quenched with 1% (v/v) acetic acid to pH 3.5, then cleaved peptide was 
isolated from the mixture for MALDI characterization using a regenerated cellulose 
Amicon Ultra centrifugal filter with 3KDa MWCO.  Activated nanogel was purified by 
dialysis against DI water in a 100 KDa MWCO cellulose dialysis membrane for 24 hours.  
 
MALDI Characterization: Matrix solutions were prepared dissolving α-cyano-4-
hydroxycinnamic acid (CHCA) (10 mg/mL) in a solution containing ACN (50 µL), H2O 
(47.5 µL) and TFA (2.5 µL). The matrix solution was then mixed with the centrifuge 
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filtered nanogel solution that had been incubated with MMP-9. A Bruker Autoflex III time-
of-flight mass spectrometer was used for the MALDI-MS analysis of all samples. 
Acquisition of all mass spectra was done in reflectron mode with an accelerating voltage 
of 19 kV. Each spectrum is the average of 500 laser shots at 50% laser power. 
 
Fluorescamine Assay: The percentage of cleavage on the particle was determined by 
quantifying the N-terminal amines using fluorescamine Assay. Formulated product of 
cleavage nanogel (LLGC-NG) was used to generate a concentration dependent 
fluorescence calibration curve. Various concentrations of LLGC-NG (7.4 µg/mL- 0.74 
mg/mL) were prepared in PBS buffer pH 7.4. MMP-9 incubated and purified nanogels 
mPEG350-NG and mPEG750-NG were diluted in PBS buffer pH 7.4 (to 0.74 mg/mL) so 
that their maximum expected amine content would be within the LLGC-NG calibration 
curve. Non-activated mPEG350-NG and mPEG350-NG (0.74 mg/mL) were prepared as 
negative controls. In a 96 well (flat-bottomed) plate PBS buffer pH 7.4 (150 µL) and 
sample solutions (20 uL) were added to each well. Then, fluorescamine solution in DMSO 
(12 uL, 0.68 mg/mL) was added to each well. The fluorescence was obtained using a 
Molecular Devices Spectramax M5 plate reader (excitation: 390 nm; emission 465 nm). 
Average fluorescence values and deviation were obtained from replicate readings (n=3). 
Concentration of LLGC-NG versus fluorescence was used to generate an amine calibration 
curve, and the fluorescence of known test samples were used to determine amine content. 
 
Fluorescein Nanogel Labeling: To aqueous nanogel solutions (2.5 mg/mL, 0.5 mL) 
fluorescein-cysteamine (0.128 mg, 0.273 µmol) in acetone (10 µL) was added and stirred 
  174 
open for 6 hours until acetone evaporated. The conjugation was characterized by release of 
2-pyrinedithione by UV-Vis prior to dialysis against DI water in a 100 KDa MWCO 
cellulose dialysis membrane for 24 hours to remove any unconjugated fluorescein-
cysteine. Feed ratio of 10 mole percent PDS groups gave 8-9 mole percent conjugated 
fluorescein was achieved on nanogels LLGC-NG, mPEG350-NG, and MMP-9 activated 
mPEG350-NG. 
 
Cell Culture: Human cervical carcinoma (HeLa) cell line was grown in DMEM 
supplemented with 10% (FBS), 1% L-glutamine, and 1% antibiotic-antimycotic 
(comprised of 100 units/mL penicillin and 100 µg/mL streptomycin). All cells were grown 
at 5% CO2 and 37 °C. Digestion of cells for culture was done according to HeLa and 293A 
protocols from ATCC. 
 
Cytotoxicity Assay: Nanogel in vitro cytotoxicity was determined using the MTT assay 
for HeLa cell line. In a 96 well flat-bottomed plate 10,000 cells per well (16,000-32,000 
cells/cm2) in culture medium were seeded and incubated for 24 hours at 5% CO2 and 37 
°C. Nanogel samples in PBS buffer 7.4 were diluted with culture medium for final nanogel 
concentrations ranging from 0-1 mg/mL with 10 % PBS total. The plate’s culture medium 
was replaced with sample culture medium, or a solution of trypsin (0.5%) as the negative 
control, and incubated for 24 hours. MTT (10 µL, 5 mg/mL in culture media) was added 
to each well and incubation was continued for 3 hours. Culture plates were spun down 
(3,700 rpm, 10 minutes) and supernatant was removed. DMSO (100 µL) was added to each 
well and absorbance was obtained using a Molecular Devices Spectramax M5 plate reader 
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(lmax 540 nm and background subtraction 650 nm). Average absorbance values and 
deviation were obtained from replicate readings (n=4) and were compared to 100% 
viability of the positive control (10 % PBS, respective to sample dilutions) and 0.5 % 
trypsin as negative control.  
 
Confocal Microscopy Intracellular Uptake: HeLa cells were seeded at 30-50% 
confluency (~10,400 cells/cm2) in 4-chamber 35 mm glass bottom dishes and incubated 
overnight at 37 °C overnight in 5% CO2 before performing uptake. Culture media was 
removed and cells washed with PBS one time before adding new culture media containing 
fluorescein-labeled nanogels diluted to 0.1 mg/mL in DMEM (10´, diluted to 1´ with 
PBS). Samples were incubated for 2 hours. Nuclear staining (NucBlue, 80 µL per mL 
media) was added in the final 30-60 min of incubation. Media was removed from cells and 
washed 2-4 times with PBS, then live cell imaging buffer was added for confocal imaging. 
Assessment of fluorescein-conjugated nanogel intracellular uptake was recorded using 488 
nm laser and nuclear stain was detecting using a 405 nm wavelength laser. Assessment of 
DiI-loaded nanogel intracellular uptake was recorded using 540 nm laser and nuclear stain 
was detecting using a 405 nm wavelength laser. Confocal microscopy was performed on a 
Nikon Yokogawa spinning disk confocal microscope equipped with 40x or 100x oil 
objectives and an Andor EMCCD camera. 
  
Flow Cytometry: HeLa cells were seeded at 100,000 cells/mL in a glass bottom dish and 
maintained at 37 °C overnight in 5% CO2 before performing uptake. Culture media was 
removed and cells washed with PBS one time before adding new culture media containing 
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fluorescein-labeled nanogels diluted to 0.05 mg/mL in DMEM (10´, diluted to 1´ with 
PBS). Samples were incubated for 2 hours, then washed with PBS, trypsinized and 
collected by centrifugation. The cells were re-suspended in 200 µL PBS buffer and stored 
at 4 °C. A minimum of 100,000 cells were analyzed for each sample using a BD 
LSRFortessa. 
Table 25. HeLa cell Median FITC obtained by flow cytometry with 2 hour nanogel 
incubation. 
Sample Median FITC 
LLGC-NG(F) 85821 
mPEG350-NG(F) 26048 
mPEG350-NG(F) Active 42983 
mPEG750-NG(F) 15972 
mPEG750-NG(F) Active 22417 
 
Release Studies: The release of encapsulated model guest DiI was monitored by 
fluorescence spectroscopy using a Molecular Devices Spectramax M5 plate reader. DiI 
(0.35 mg) was dissolved in acetone (100 µL) then added to a 350 µL solution of 10 mg/mL 
aggregate of polymer p(OEGMA-co-PDSMA) and stirred was for 8 hours at room 
temperature, open to the atmosphere to allow for acetone to evaporate. Aggregates were 
crosslinked then post-functionalized with substrates as previously described. Nanogels 
were purified by dialysis using 100 KDa MWCO membrane and any non-encapsulated DiI 
was removed by filtration through a 0.45 µm filter. In a 96 well (flat-bottomed) plate TNC 
buffer pH 7.4 (90 µL) containing relevant stimuli (GSH, ProMMP-9, or MMP-9) and 
concentrations were added to each well. Then, nanogel solutions (10 µL, 17 µg/mL) of 
either Bare NG, mPEG350-NG, and mPEG750-NG were added to each well. The 
fluorescence was obtained for each well (excitation: 520 nm; emission 565 nm), and the 
average fluorescence values and deviation were obtained from replicate readings (n=3) 
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over 48 hours. 
 
DiI-loaded Nanogel Activation with MMP-9: DiI encapsulated mPEG350-NG (2.5 
mg/mL polymer) decorated with MMP-9 cleavable substrates (3 mM) in TNC buffer pH 
7.4 was incubated with activated MMP-9 (54 nM) at 37 °C in 5% CO2 with shaking. After 
24 hours, the enzyme activity was quenched with 1% (v/v) acetic acid to pH 3.5, then 
purified by dialysis against DI water in a 100 KDa MWCO cellulose dialysis membrane 
for 24 hours, and filtered. 
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CHAPTER 5 
 
BIOCOMPATIBLE POLY(L-GLUTAMIC ACID)-BASED POLYMERS FOR 
DRUG DELIVERY APPLICATIONS 
5.1 Introduction 
Use of biodegradable polymers as nanocarriers is of great importance as they can 
delivery therapeutics to the target site with minimal toxicity and side effects as a result of 
the vehicle.1 Biodegradable polymers, those that enzymatically or hydrolytically degrade 
within the body2, have become of increasing interest for a variety of medical applications 
including implants, prostheses, tissue engineering or regeneration, and delivery of 
therapeutics.3-4 For therapeutics, many systems are controlled by the rate of biochemical 
erosion or degradation and/or drug diffusion within the nanocarrier matrix leading to 
content release. Little investigation has been done on systems where the drug release 
mechanism is independent of the polymer degradation. Nanocarriers comprised of polymer 
precursors that have been synthesized by radical polymerization methods such as ATRP or 
RAFT are generally not biodegradable.3 Regardless of the apparent toxicity of such 
nanocarriers, a variety of diseases may benefit from therapeutic delivery using nanocarrier 
formulation for continual and long-term treatment that has known biocompatible 
degradation through catabolism and excretion. For therapeutic purposes such as 
chemotherapeutic delivery to tumors, for example, these materials should still maintain 
desirable cargo protection and structural stability until exposed to designed stimulus for 
release.5 Nanocarriers with stimuli and site-specific drug release and predictable 
biochemical degradation thus allow for greater control of targeted delivery. 
The biocompatibility and biodegradability of polymeric assemblies can be affected 
by a variety of polymer characteristics including the solubility, hydrophilicity or 
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lipophilicity, molecular weight, and chemical composition of the material. Naturally 
occurring polymers are typically degradable by enzyme digestion, and thus have variable 
degradation rates.3 Variability is based on the polymer type, location of administration, 
enzyme type, and enzyme concentration. Such biologically derived materials, however, are 
commonly bioactive and thus have the disadvantage of invoking a strong immune response. 
Synthetic polymers produced through ring opening polymerization (ROP) and 
condensation polymerization have potential to be biologically inactive and can be designed 
to include hydrolytically or enzymatically cleavable bonds.3 Various functional groups that 
could be incorporated into polymers for biodegradation include esters, orthoesters, 
anhydrides, carbonates, amides, imines, and ureas, among others.6 
Poly(L-glutamic acid), PG, is an artificial water soluble polypeptide polymer 
comprised of L-glutamic acid. Both the polymer and its degraded product, L-glutamic acid, 
are generally recognized as safe (GRAS) by the American Food and Drug Administration 
(FDA) evaluation and regulation.7 Cysteine proteases, namely cathepsin B, have been 
found largely responsible for lysosomal degradation of PG.7-8 Results from addition of 
lysosomal enzymes to PG, poly(L-aspartic acid) and poly(D-glutamic acid) have shown 
that PG is the most susceptible to degradation in the lysosome.9 Biodistribution analysis 
has shown that PG was mostly located in the kidney and urine, with very little accumulation 
in other tissues.10 The modification of PG with hydrophilic functionalities showed that the 
polymer was mainly excreted through the renal system, with little clearance by the RES.11 
It has been found to be non-immunogenic in humans with tolerated doses relevant to drug 
carrier quantities.12 However, the biodistribution results also found that within an hour of 
injection a large portion of the PG will have already left circulation.10  
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While the lack of toxicity for some of these materials are promising, their fast 
degradation and clearance reduce their applicability in drug delivery. However, because of 
the possibility for modification of these materials, this pitfall may be circumvented. The 
surface chemistry of nanoparticles has been shown to largely determine the immune 
systems response to the vehicle.13 PG has pendent carboxyl groups that are available for 
conjugation, which is promising for use in drug delivery applications. The degradation of 
PG has been shown to occur at lower charge density and at random coil regions of the 
polymer, as it has pH-dependent rod-like alpha-helix secondary structure.14 
Functionalization can affect the alpha-helix secondary structure of PG, and likewise 
lysosomal degradation has also been shown to increase with side chain modification.7 
Therefore, it would be interesting to develop a PG-based polymer that has compatible 
lysosomal degradation in the disassembled polymer state, but is resistant to this degradation 
in the assembled nanocarrier form.   
We therefore envisaged an amphiphilic PG-derivative comprised of hydrophilic 
PEG corona, and hydrophobic and cross-linkable disulfide-based core. We expect that 
these amphiphilic polymers will self-assemble into micellar aggregates in aqueous 
conditions and be capable of sequestering lipophilic guests. PEG has been shown to 
improve the circulation time in vivo for a variety of nanocarrier platforms including 
polymeric nanoassemblies through steric hindrance and reduction of non-specific 
interactions.15, 16 It is reasonable to expect that surface decoration of biodegradable 
polymers with PEG should decrease the rate of clearance and possibly also the rate of 
enzymatic degradation in circulation. The incorporation of redox-sensitive components in 
a molecular design has been extensively investigated34, including our own group work on 
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disulfide-crosslinked nanogels17, 18, which are promising for intracellular release of 
nanocarrier contents. With this project we aim to i) design and synthesize PG-based 
amphiphilic derivatives while having appropriate control over the polymer molecular 
weight, side chain composition, and solubility, ii) form self-assembled nanoscale 
aggregates capable of encapsulating hydrophobic guests, and chemical core-crosslinking 
into stable nanogels, similar to its poly(methyl methacrylate)-based counterparts, and  iii) 
evaluate the polymer and nanogel cytotoxicity and potential use as a delivery vehicle by 
cellular internalization. 
 
Scheme 11. Pictorial representation and corresponding chemical structures of PG-modified 
derivative, its amphiphilic self-assembly in aqueous media with hydrophobic guest, and 
crosslinking in response to reducing agent DTT. 
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5.2 Results and Discussion 
5.2.1 Synthesis and Characterization of Poly(L-glutamic acid) Derivatives 
Consistent with previous reports, synthesis was achieved by first the reaction of g-
benzyl-L-glutamate with triphosgene to form a-benzyl-L-glutamate-N-carboxyanhydride 
(NCA) monomer, which was polymerized through ring opening polymerization (ROP) to 
form poly(g-benzyl-L-glutamate) (PBLG) (Scheme 12).19 The polymerization was 
achieved using primary amine N-propylamine initiator. The use of non-nucleophilic bases 
and primary amines have been shown to form PBLG, with lesser polydispersity using 
nucleophilic amines.19-21 Various polymer molecular weights ranging from 9.5 to 43.2 KDa 
were prepared by varying the monomer and initiator feed ratio, so that any change in 
aggregation characteristics with molecular weight could be assessed (Table 26, Figure 
72). Further, these polymerizations were performed at room temperature so that 
71lymerizations would be terminated by amine terminus cyclization to form a substituted 
pyrrolidone ring.22 This can prohibit the use of PBLG to further polymerize other NCAs, 
however the amine group can be maintained by polymerization at low temperatures.23, 24 In 
this synthetic scheme, amine terminus is not desirable due to subsequent coupling 
chemistries. Matrix Assisted Laser Desorption/Ionization (MALDI) mass spectrometry 
characterization of PBLG supported that the amine terminus is a cyclized pyrrolidone ring 
(Figure 72). 
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Scheme 12. Synthesis of amphiphilic poly(L-glutamic acid) derivatives PG-g-PEG-g-PDS. 
 
The benzyl protecting groups on PBLG polymers were then be removed by NaOH 
to yield poly(L-glutamic acid) polymers. Benzyl deprotection was confirmed by 1H NMR 
spectroscopy by the disappearance of benzyl peaks (7.28 and 5.07 ppm). A portion of the 
PG carboxylic acid side chains were then functionalized with PEG using EDC coupling, 
resulting in grafting ratios of 28-30% PEG on PG-g-PEG polymers, determined by the 
relative integrations of methylene protons of PEG (3.36 ppm) compared to ethylene groups 
of total glutamic acid side chains (2.98-1.18 ppm). The remaining side chains were then 
functionalized with (2-pyridyldithio)ethanol (PDS) using DCC coupling, resulting in 
grafting rations of 68-70% PDS on PG-g-PEG- g-PDS polymers, determined by the relative 
integrations of the aromatic protons of PDS (8.46 ppm) compared to methylene protons of 
PEG (3.36 ppm). 
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Figure 72. PBLG characterization by A) DMF GPC chromatograms of various molecular 
weights, B) low resolution MALDI chromatogram of 24K PBLG, C) high resolution 
MALDI chromatogram for amine-terminus characterization, and D) chemical structures of 
pyrrolidone and amine terminus for PBLG. 
 
Table 26. Characteristics of PBLG and resultant PG-g-PEG-g-PDS derivatives. 
              PBLG                              PG-g-PEG-PDS 
 Mn (expected 
KDa) 
Mn 
(KDa)a 
Ð Mn (KDa)a Ð PEG (%)b PDS (%)b 
1 7 9.53 1.11 10.6 1.32 30 70 
2 15 23.6 1.06 12.5 1.44 30 68 
3 25 32.2 1.15 12.3 1.53 28 65 
4 35 43.2 1.23 12.8 1.46 30 70 
Note: Based on a) DMF GPC against a PMMA standard, b) 1H-NMR spectroscopy.  
 
Gel permeation chromatography (GPC) analysis of PG-g-PEG-g-PDS polymers 
gave similar Mn for polymers 1-4, ranging from 10.6-12.8 KDa, which were smaller than 
expected based on starting PBLG polymers. Because GPC analysis is calibrated against a 
poly(methyl methacrylate) (PMMA) standard, which is structurally very different to these 
polypeptide with secondary structure confirmations, we also examined molecular weight 
by 1H-NMR. 1H-NMR end group analysis of N-propyl amine composition for PG polymers 
1-4 gave molecular weights of 5.2, 13, 21, and 29 KDa, respectively, which are consistent 
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with expected masses following benzyl deprotection of PBLG precursors. End group 
analysis in PG-g-PEG-g-PDS polymers, however, gave 7.7, 9.0, 11, and 15 KDa for 
polymers 1-4, respectively. These values suggest some main chain hydrolysis occurred 
during aqueous grafting and purification steps. Some hydrolysis during post-modifications 
isn’t surprising, due to the hydrolytic susceptibility of PG. 8, 9, 14  
 Fourier transform infrared (FTIR) analysis was evaluated to for functional group 
composition and determination of poly(peptide) secondary structure (Figure 73). The 
FTIR spectrum of PBLG demonstrates peaks appearing at 1735 cm-1 (consistent with C=O 
stretching band of the benzyl ester group), 3293 cm-1 (consistent with amide N-H stretching 
in main chain), 1651 cm-1 (confirming the α-helix amide I band), and 1551 cm-
1 (confirming the α-helix amide II band), consistent with expectations that segments in 
PBLG are a α-helix conformational structure.25, 26 The absence of characteristic anhydride 
(C=O stretch) peaks at 1774 and 1832 cm-1 supports the conversion of NCA monomer to 
PLBG.26 The FTIR spectrum of PG detects the same peaks consistent with α-helix amide 
I and α-helix amide II band at 1643 and 1545 cm-1, respectively, and the absence of ester 
(C=O stretch) supporting successful benzyl deprotection. For PG-g-PEG-g-PDS, the 
presence of these peaks at 1653 cm-1, and 1546 cm-1, like those of PBLG and PG, 
demonstrate the grafted polymer also contains α-helix conformational structure, consistent 
with observations of PBLG-grafted polymers.27 It is possible the polymer contain random 
coil regions, as broadness of peak at 1653 and 1545 cm-1 may also contain signatures from 
amide I and amide II random coil, which can appear at 1657 and 1535 cm-1, respectively.26 
Further, the peaks at 1096 cm-1 (C-O-C stretch) and 2857 cm-1 (C-H stretch) are consistent 
with the PEG segments in PG-g-PEG-g-PDS. This peak at 2857 cm-1 could also be due to 
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PDS segments (C-H stretch) while aromatic signatures (C=C stretch) are within the same 
region of peaks observed for the amide I and amide II bands. 
 
Figure 73. FTIR spectrum of PBLG, PG, and PG-g-PEG-g-PDS polymers. 
5.2.2 Supramolecular Assembly Characterization of Polymers 
We then investigated the aggregation characteristics of these polymers to establish 
their capability to perform as nanocarrier materials. Due to their amphiphilicity, we expect 
that the polymers will assemble into micelle-type aggregates in aqueous media (Scheme 
11). Random copolymers PG-g-PEG-g-PDS (P1-4) were dispersed in an aqueous phase 
using repeated sonicate and chill cycles until they appeared dissolved. The formation of an 
amphiphilic aggregates of P1-4 with average hydrodynamic diameters of 10-18 nm were 
confirmed using dynamic light scattering (DLS) at concentrations of 5 and 10 mg/mL 
(Figure 74). While the polymers were slightly different in molecular weight, their 
aggregation sizes did not vary when prepared at the same concentration. Due to the known 
lower critical solution temperature (LCST) characteristics of PEG, the temperature 
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responsiveness of these polymer aggregates was characterized by DLS to determine if 
particle sizes could be manipulated. Size transitions were observed above 50 °C, with 130 
nm aggregates achieved at 60 °C. 
 
Figure 74. DLS characterization of PG-g-PEG-g-PDS aggregates A) P1-P4 at 5 and 10 
mg/mL, B) P1 size at various temperatures, C) corresponding plot of mean particle size vs. 
temperature, D) chemical structure of crosslink reaction, and D) absorption spectrum of 
nanogel crosslinking to various extents. 
 
The aggregates were then locked in confirmation through intra-aggregate disulfide 
crosslink formation using reducing agent DL-dithiothreitol (DTT) as previously reported 
for poly(methyl methacrylate)-based polymeric nanogels containing PDS moieities.28, 29 
The covalent crosslinking was achieved via the addition of a stoichiometric amount of 
DTT, which generates the corresponding quantity of free thiols on PDS moieties in the 
aggregate, which then reacts with remaining PDS moieties in the polymer chain. Controlled 
crosslinking to various extents was achieved by addition 5, 12.5, 25 and 50% DTT 
respective to mol PDS, calculated to be 14, 38, 45, and 100% crosslinked, respectively, by 
the amount of byproduct, 2-pyridinethione, observed by UV-Vis spectroscopy (Figure 74). 
After confirming this stoichiometric control in core crosslinking for this polymer, we then 
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evaluated the sizes of nanogels after crosslinking. Aggregates P2-P4 were crosslinked ~50 
and ~100% and then compared to their non-crosslinked precursor by DLS (Figure 75). 
Interestingly, we observed a slight increase in size for nanogels P2-P4 after crosslinking to 
20-30 nm, which was a greater increase for ~100% crosslinked than ~50% crosslinked. It 
is possible this size increase is a result of nanogel swelling from reduction in particle 
hydrophobicity that occurs from the loss of 2-(2-pyridyldithio groups during this 
crosslinking process. Transmission electron microscopy (TEM) analysis of crosslinked 
nanogels and showed the presence of spherical assemblies in the range of 10-30 nm 
(Figure 76). Crosslinked nanogels gave more distinct particles with size correlation with 
DLS than the polymer aggregate solution, which may be result of aggregation, or loss of 
particle integrity, during the drying process.  
 
Figure 75. UV-vis absorbance spectra of crosslinking for A) P2, B) P3, and C) P4, and the 
DLS of aggregates after crosslinking for D) P2, E) P3, and F) P4. 
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Figure 76. TEM of A) crosslinked nanogel and B) polymer solutions (2.5 mg/mL) drop 
casted then dried on carbon coated Cu grid. 
 
Next, we investigated the ability of this PG-g-PEG-g-PDS polymer to act as host 
for a hydrophobic model guest 1,1'-dioctadecyl-3,3,3',3'-tetramethyl indocarbocyanine 
perchlorate (DiI) in aqueous medium. DiI is not soluble in water unless a hydrophobic 
pocket of a suspension is provided. Polymer P2 was used to evaluate this amphiphilic 
random copolymer to encapsulate this host property, and following DiI addition, 
aggregates were crosslinked 0, 30, and 70%. Following dialysis purification and filtration 
to remove any non-encapsulated DiI, their absorbance spectrum and sizes were evaluated 
(Figure 77). This guest loading slightly increased the size of the aggregates, generating 
particles of 20-30 nm for 0, 30, and 70% crosslinked. As apparent by UV-vis spectroscopy, 
this polymer can perform as a nanocarrier host for water insoluble guest DiI, with 
absorption maximum at 562 nm.  
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Figure 77. DiI loaded nanogels of different crosslink density A) size by DLS and B) 
absorbance spectra, and C) chemical structure of DiI. 
5.2.2 Cytotoxicity and Cellular Internalization of Polymers 
Confocal microscopy was used to evaluate whether these nanogels are capable of 
internalizing in HeLa cells and 293T cells to evaluate their potential use as delivery 
vehicles. First cytotoxicity of both the 100% crosslinked nanogel and the polymer (both 
from polymer P4) was evaluated for both HeLa and 293T cell lines using the Alamar blue 
cytotoxicity assay. For the nanogel in both cell lines, viability >80% was observed up to 1 
mg/mL (Figure 78). However, the non-crosslinked polymer exhibited significant toxicity 
over 0.5 mg/mL for both HeLa and 293T cell lines. This could be attributed to the toxicity 
from PDS groups, due to known toxicity of 2-(2-pyridyldithio)ethanol, which are removed 
in the crosslink process. We therefore determined the nanogel to be compatible with cells 
tested, pending that the PDS groups are removed by crosslinking. To then evaluate the 
cellular internalization, nanogels were covalently modified with a thiol-modified 
fluorescein label. Nanogels were incubated with HeLa cells or 293T for 4 hours before 
confocal imaging, and uptake was observed using laser excitation at 488 nm for fluorescein 
(Figure 79). The cell nuclei were stained with the addition of DRAQ5 and was detecting 
using a 543 nm wavelength laser. From microscopy images the polymeric nanogel was 
shown to internalize in both 293T and HeLa cells. These results signify that these particles 
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are capable of cellular uptake, and therefore should be considered a candidate as a drug 
delivery vehicle. 
 
Figure 78. Alamar blue toxicity assay with 100% crosslinked nanogels and polymer PG-
g-PEG-g-PDS with A) 293T cell line and B) HeLa cell line. 
 
 
Figure 79. Confocal microscopy images using a 63´ ´ oil-immersion objective of right: 
fluorescein-labeled NG (green, 488 nm), middle: DRAQ5 nucleus stain (red 543 nm), and 
left: composite with brightfield image overlays of A) 293T cells and B) HeLa cells after 4-
hour incubation. 
5.3 Conclusions 
In summary, we have designed and synthesized an amphiphilic poly(L-glutamic 
acid)-based derivative capable of supramolecular self-assembly into nanoscale aggregates, 
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which can be chemically crosslinked with stoichiometric control. Furthermore, this 
nanocarrier can perform as a host, by encapsulation of hydrophobic guest in aqueous 
media. The potential for the use of such materials as delivery vehicles was evaluated by 
cell cytotoxicity analysis, finding high viability with both HeLa and 293T cell lines. The 
cellular internalization of these nanogels were also confirmed using confocal microscopy, 
by monitoring uptake of covalently-conjugated fluorescein tag. 
5.4 Experimental  
5.4.1 Materials and Methods 
All reagents were purchased from commercial source and used without further purification 
unless otherwise mentioned. The compound 2-(2-pyridyldithio)ethanol (PDS) was 
prepared as previously reported.28 Polymers were synthesized using ROP polymerization 
and purified by dialysis using a membrane with 3500 MWCO. 1H-NMR spectra were 
recorded on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of 
the deuterated solvent as the internal standard. Polymer molecular weights were estimated 
by gel permeation chromatography (GPC, Waters) using DMF as eluent at a flow rate of 1 
mL/min by a refractive index detector compared to poly(methyl methacrylate) (PMMA) 
standard. UV-visible absorption spectra were recorded on a Carry 100 Scan spectrometer. 
Dynamic Light Scattering (DLS) measurements were carried out on a Malvern 
NanoZetasizer. TEM images were recorded using a JEOL-2000FX instrument operating at 
an accelerating voltage of 100 KV. Fourier transform infrared (FTIR) spectra were 
recorded on Spectrum 100 FTIR spectrometer. Cytotoxicity assays were performed using 
Molecular Devices Spectramax M5 plate reader. Confocal experiments were obtained 
using Zeiss510 META confocal laser scanning microscope. 
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5.4.2 Experimental Procedures 
Synthesis of a-benzyl-L-glutamate-N-carboxyanhydride (NCA): Monomer a-benzyl-
L-glutamate-N-carboxyanhydride was prepared following a previously published 
procedure.30 L-glutamic acid γ-benzyl ester (2 g, 8.47 mmol) was dissolved in dry THF (50 
mL) in a 100 mL round bottomed flask and placed in a preheated oil bath at 60 °C under 
argon atmosphere. Triphosgene (1.25 g, 4.23 mmol) was dissolved in dry THF (2 mL) in 
a glass vial and added to the L-glutamic acid γ-benzyl ester solution. The reaction mixture 
was stirred for 6 hours, then stopped and allowed to cool to room temperature. Following 
evaporation under reduced pressure to 50 mL THF, the solution was precipitated in cold 
hexane to get a white color solid product in 94% yield. 1H NMR (400 MHz, CDCl3) δ 
(ppm): 7.35 (m, 5H, C6H5), 6.49 (s, 1H, NH), 5.14 (s, 2H, CH2), 4.37 (t, 1H, J=6.12, CH), 
2.60 (t, 2H, J=6.76, CH2), 2.27 (sex, 1H, J=7.32, CH2), 2.13 (sex, 1H, J=7.32, CH2). 
 
Figure 80. 1H NMR spectrum of a-benzyl-L-glutamate-N-carboxyanhydride. 
 
Synthesis of poly(g-benzyl-L-glutamate) (PBLG) 1: Poly(g-benzyl-L-glutamate) 
polymers were prepared according to a previously published procedure.31 NCA monomer 
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(800 mg, 3.04 mmol) was added to a Schlenk flask and dissolved in anhydrous DMF (3 
mL) under argon atmosphere. Then propyl amine (7.81 µL, 0.095 mmol) initiator was 
dissolved in anhydrous DMF (0.39 mL) and added to the Schlenk flask. The reaction 
mixture was stirred at room temperature for 48 hours. The reaction was stopped and the 
product was precipitated from diethyl ether to get the polymer as an off-white sticky 
product. GPC (DMF) Mn: 9.5 KDa; Ð: 1.11. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.28 
(broad peak, 5H, C6H5), 5.07 (broad peak, 2H, CH2), 3.96 (s, 1H, CH), 2.85-1.95 (broad 
peaks, 4H, 2xCH2), 1.70 (s, 2H, CH2), 0.96 (S, 2H, CH3).  
 
Figure 81. 1H NMR spectrum of poly(g-benzyl-L-glutamate) (PBLG) 1. 
 
Synthesis of poly(g-benzyl-L-glutamate) (PBLG) 2: NCA monomer (800 mg, 3.04 
mmol) was added to a Schlenk flask and dissolved in anhydrous DMF (3 mL) under argon 
atmosphere. Then propyl amine (3.68 µL, 0.044 mmol) initiator was dissolved in 
anhydrous DMF (0.18 mL) and added to the Schlenk flask. The reaction mixture was 
stirred at room temperature for 48 hours. The reaction was stopped and the product was 
precipitated from diethyl ether to get the polymer as an off-white sticky product. GPC 
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(DMF) Mn: 23.6 KDa; Ð: 1.06.  1H NMR (400 MHz, CDCl3) δ (ppm): 7.28 (broad peak, 
5H, C6H5), 5.07 (broad peak, 2H, CH2), 3.95 (s, 1H, CH), 3.05 (s, 1H, CH), 2.96 (s, 1H, 
CH), 2.83-1.77 (broad peaks, 4H, 2xCH2), 1.29 (s, 2H, CH2), 0.87 (s, 2H, CH3). 
 
Figure 82. 1H NMR spectrum of poly(g-benzyl-L-glutamate) (PBLG) 2. 
 
Synthesis of poly(g-benzyl-L-glutamate) (PBLG) 3: NCA monomer (800 mg, 3.04 
mmol) was added to a Schlenk flask and dissolved in anhydrous DMF (3 mL) under argon 
atmosphere. Then propyl amine (2.19 µL, 0.027 mmol) initiator was dissolved in 
anhydrous DMF (0.11 mL) and added to the Schlenk flask. The reaction mixture was 
stirred at room temperature for 48 hours. The reaction was stopped and the product was 
precipitated from diethyl ether to get the polymer as an off-white sticky product. GPC 
(DMF) Mn: 32.2 KDa; Ð: 1.15.  1H NMR (400 MHz, CDCl3) δ (ppm): 7.28 (broad peak, 
5H, C6H5), 5.07 (broad peak, 2H, CH2), 3.95 (s, 1H, CH), 2.86-1.21 (broad peaks, 4H, 
2xCH2), 1.24 (s, 2H, CH2).  
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Figure 83. 1H NMR spectrum of poly(g-benzyl-L-glutamate) (PBLG) 3. 
 
Synthesis of poly(g-benzyl-L-glutamate) (PBLG) 4: NCA monomer (800 mg, 3.04 
mmol) was added to a Schlenk flask and dissolved in anhydrous DMF (3 mL) under argon 
atmosphere. Then propyl amine (1.56 µL, 0.019 mmol) initiator was dissolved in 
anhydrous DMF (78 µL) and added to the Schlenk flask. The reaction mixture was stirred 
at room temperature for 48 hours. The reaction was stopped and the product was 
precipitated from diethyl ether to get the polymer as an off-white sticky product. GPC 
(DMF) Mn: 43.2 KDa; Ð: 1.23.  1H NMR (400 MHz, CDCl3) δ (ppm): 7.28 (broad peak, 
5H, C6H5), 5.07 (broad peak, 2H, CH2), 3.96 (s, 1H, CH), 2.99 (s, 1H, CH), 2.92 (s, 1H, 
CH), 2.81-1.50 (broad peaks, 4H, 2xCH2), 1.28 (s, 2H, CH2), 0.91 (S, 2H, CH3). 
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Figure 84. 1H NMR spectrum of poly(g-benzyl-L-glutamate) (PBLG) 4. 
 
Synthesis of poly(L-glutamic acid) (PG) 1: Poly(L-glutamic acid) polymers were 
prepared following a previously published procedure.32 PBLG 1 (551 mg, 2.51 mmol) was 
dissolved in 1,4-dioxane (5 mL) in 25 mL round bottom, then 1 M NaOH (151 mg, 3.78 
mmol) in deionized water was added dropwise, with stirring. The reaction mixture was 
stirred at room temperature for 12 hours, then purified by dialysis against deionized water 
for 48 hours. The product was lyophilized to get the polymer as an off-white powder. 1H 
NMR (400 MHz, D2O) δ (ppm): 4.34 (broad peak, 1H, CH), 3.16 (s, 2H, CH2), 2.45-1.81 
(broad peaks, 4H, 2xCH2), 1.51 (s, 2H, CH2), 0.88 (S, 2H, CH3). Benzyl deprotection was 
confirmed by the disappearance of benzyl peaks (7.28 and 5.07 ppm). 
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Figure 85. 1H NMR spectrum of poly(L-glutamic acid) (PG) 1. 
 
Synthesis of poly(L-glutamic acid) (PG) 2: PBLG 2 (510 mg, 2.32 mmol) was dissolved 
in 1,4-dioxane (5 mL) in 25 mL round bottom, then 1 M NaOH (140 mg, 3.45 mmol) in 
deionized water was added dropwise, with stirring. The reaction mixture was stirred at 
room temperature for 12 hours, then purified by dialysis against deionized water for 48 
hours. The product was lyophilized to get the polymer as an off-white powder. 1H NMR 
(400 MHz, D2O) δ (ppm): 4.34 (broad peak, 1H, CH), 3.16 (s, 2H, CH2), 2.27-2.16 (broad 
peaks, 2H, CH2), 2.16-1.83 (broad peaks, 2H, CH2), 1.50 (s, 2H, CH2), 0.88 (S, 2H, CH3). 
Benzyl deprotection was confirmed by the disappearance of benzyl peaks (7.28 and 5.07 
ppm). 
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Figure 86. 1H NMR spectrum of poly(L-glutamic acid) (PG) 2. 
 
Synthesis of poly(L-glutamic acid) (PG) 3: PBLG 3 (510 mg, 2.32 mmol) was dissolved 
in 1,4-dioxane (5 mL) in 25 mL round bottom, then 1 M NaOH (140 mg, 3.45 mmol) in 
deionized water was added dropwise, with stirring. The reaction mixture was stirred at 
room temperature for 12 hours, then purified by dialysis against deionized water for 48 
hours. The product was lyophilized to get the polymer as an off-white powder. 1H NMR 
(400 MHz, D2O) δ (ppm): 4.34 (broad peak, 1H, CH), 3.16 (s, 2H, CH2), 2.40-2.17 (broad 
peaks, 2H, CH2), 2.17-1.83 (broad peaks, 2H, CH2), 1.49 (s, 2H, CH2), 0.88 (S, 2H, CH3). 
Benzyl deprotection was confirmed by the disappearance of benzyl peaks (7.28 and 5.07 
ppm). 
 
H
H
N N
H
OHO
O
x
a
b e f
ca
fb
c
ed
d
-OH
  207 
 
Figure 87. 1H NMR spectrum of poly(L-glutamic acid) (PG) 3. 
 
Synthesis of poly(L-glutamic acid) (PG) 4: PBLG 4 (446 mg, 2.04 mmol) was dissolved 
in 1,4-dioxane (5 mL) in 25 mL round bottom, then 1 M NaOH (122 mg, 3.05 mmol) in 
deionized water was added dropwise, with stirring. The reaction mixture was stirred at 
room temperature for 12 hours, then purified by dialysis against deionized water for 48 
hours. The product was lyophilized to get the polymer as an off-white powder. 1H NMR 
(400 MHz, D2O) δ (ppm): 4.34 (broad peak, 1H, CH), 2.44-2.17 (broad peaks, 2H, CH2), 
2.17-1.81 (broad peaks, 2H, CH2). Benzyl deprotection was confirmed by the 
disappearance of benzyl peaks (7.28 and 5.07 ppm). 
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Figure 88. 1H NMR spectrum of poly(L-glutamic acid) (PG) 4. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) 1: PG 1 (97.1 
mg, 0.759 mmol) was dissolved in a 1:1 mixture of distilled water and DMF (3 mL), then 
EDC (43.6 mg, 0.227 mmol) and DMAP (27.8 mg, 0.227 mmol) were added and stirred 
for 20 minutes. Then poly(ethylene glycol) methyl ether amine, Mw 550, (125.2 mg, 0.227 
mmol) was added and stirred for 12 hours. The mixture was then purified by dialysis 
against acetone then DCM for 48 hours, then dried by evaporation under reduced pressure 
to yield of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) as a sticky solid. 1H 
NMR (400 MHz, CDCl3) δ (ppm): 3.64 (broad peak, 28H, 14´CH2), 3.37 (s, 3H, CH3), 
3.22 (s, 2H, CH2), 2.96-1.13 (broad peaks, 4H, 2´CH2), 1.07 (s, 2H, CH2), 0.87 (s, 3H, 
CH3). The amount of PEG grafted was determined as 30% side chains by the relative 
integrations of methylene protons of PEG (3.36 ppm) compared to ethylene groups of total 
glutamic acid side chains (2.98-1.18 ppm).   
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Figure 89. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-
PEG) 1. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) 2: PG 2 (149.1 
mg, 1.164 mmol) was dissolved in a 1:1 mixture of distilled water and DMF (3 mL), then 
EDC (67.0 mg, 0.349 mmol) and DMAP (42.6 mg, 0.349 mmol) were added and stirred 
for 20 minutes. Then poly(ethylene glycol) methyl ether amine, Mw 550, (192.2 mg, 0.349 
mmol) was added and stirred for 12 hours. The mixture was then purified by dialysis 
against acetone then DCM for 48 hours, then dried by evaporation under reduced pressure 
to yield of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) as a sticky solid. 1H 
NMR (400 MHz, CDCl3) δ (ppm): 3.62 (broad peak, 26H, 13´CH2), 3.36 (s, 3H, CH3), 
3.22 (s, 2H, CH2), 2.98-1.18 (broad peaks, 4H, 2´CH2), 1.07 (s, 2H, CH2). The amount of 
PEG grafted was determined as 30% side chains by the relative integrations of methylene 
protons of PEG (3.36 ppm) compared to ethylene groups of total glutamic acid side chains 
(2.98-1.18 ppm).   
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Figure 90. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-
PEG) 2. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) 3: PG 3 (124 
mg, 0.969 mmol) was dissolved in a 1:1 mixture of distilled water and DMF (3 mL), then 
EDC (55.8 mg, 0.291 mmol) and DMAP (35.6 mg, 0.291 mmol) were added and stirred 
for 20 minutes. Then poly(ethylene glycol) methyl ether amine, Mw 550, (159.8 mg, 0.291 
mmol) was added and stirred for 12 hours. The mixture was then purified by dialysis 
against acetone then DCM for 48 hours, then dried by evaporation under reduced pressure 
to yield of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) as a sticky solid. 1H 
NMR (400 MHz, CDCl3) δ (ppm): 3.62 (broad peak, 28H, 14´CH2), 3.36 (s, 3H, CH3), 
3.21 (s, 2H, CH2), 2.90-1.13 (broad peaks, 4H, 2´CH2), 1.06 (s, 2H, CH2). The amount of 
PEG grafted was determined as 28% side chains by the relative integrations of methylene 
protons of PEG (3.36 ppm) compared to ethylene groups of total glutamic acid side chains 
(2.90-1.13 ppm).   
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Figure 91. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-
PEG) 3. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) 4: PG 3 (195 
mg, 1.522 mmol) was dissolved in a 1:1 mixture of distilled water and DMF (3 mL), then 
EDC (87.6 mg, 0.456 mmol) and DMAP (55.8 mg, 0.456 mmol) were added and stirred 
for 20 minutes. Then poly(ethylene glycol) methyl ether amine, Mw 550, (251.1 mg, 0.456 
mmol) was added and stirred for 12 hours. The mixture was then purified by dialysis 
against acetone then DCM for 48 hours, then dried by evaporation under reduced pressure 
to yield of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-PEG) as a sticky solid. 1H 
NMR (400 MHz, CDCl3) δ (ppm): 3.63 (broad peak, 28H, 14´CH2), 3.37 (s, 3H, CH3), 
3.19 (s, 2H, CH2), 2.99-1.08 (broad peaks, 4H, 2´CH2), 1.04 (s, 2H, CH2). The amount of 
PEG grafted was determined as 30% side chains by the relative integrations of methylene 
protons of PEG (3.36 ppm) compared to ethylene groups of total glutamic acid side chains 
(2.99-1.08 ppm).   
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Figure 92. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol) (PG-g-
PEG) 4. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P1: PG-g-PEG 1 (43.3 mg, 0.388 mmol) was 
dissolved in a DCM (3 mL), then DCC (69.7 mg, 0.388 mmol) and DMAP (4.1 mg, 0.039 
mmol) were added and stirred for 20 minutes. Then 2-(2-pyridyldithio)ethanol (PDS) 
(126.5 mg, 0.677 mmol) was added and stirred for 24 hours. The mixture was then purified 
by dialysis against DCM for 48 hours, then dried by evaporation under reduced pressure to 
yield of poly(L-glutamic acid)-g-(polyethylene glycol)-g-pyridyldisulfide (PG-g-PEG-g-
PDS) as a sticky solid. GPC (DMF) Mn: 10.6 KDa; Ð: 1.32. 1H NMR (400 MHz, CDCl3) 
δ (ppm): 8.46, 7.71, 7.13, 4.28, 3.62, 3.36, 3.01, 2.76-1.18, 1.12, 0.86. The amount of PDS 
grafted was determined as 70% of side chains by the relative integrations of the aromatic 
protons of PDS (8.46 ppm) compared to methylene protons of PEG (3.36 ppm). 
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Figure 93. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) 1. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P2: PG-g-PEG 2 (42.3 mg, 0.33 mmol) was 
dissolved in a DCM (3 mL), then DCC (68.1 mg, 0.33 mmol) and DMAP (4.0 mg, 0.033 
mmol) were added and stirred for 20 minutes. Then 2-(2-pyridyldithio)ethanol (PDS) 
(123.6 mg, 0.661 mmol) was added and stirred for 24 hours. The mixture was then purified 
by dialysis against DCM for 48 hours, then dried by evaporation under reduced pressure to 
yield of poly(L-glutamic acid)-g-(polyethylene glycol)-g-pyridyldisulfide (PG-g-PEG-g-
PDS) as a sticky solid. GPC (DMF) Mn: 12.5 KDa; Ð: 1.44. 1H NMR (400 MHz, CDCl3) 
δ (ppm): 8.45, 7.69, 7.21, 4.28, 3.62, 3.36, 3.01, 2.75-1.22, 1.12, 0.86. The amount of PDS 
grafted was determined as 68% of side chains by the relative integrations of the aromatic 
protons of PDS (8.46 ppm) compared to methylene protons of PEG (3.36 ppm). 
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Figure 94. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) 2. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P3: PG-g-PEG 3 (46.1 mg, 0.36 mmol) was 
dissolved in a DCM (3 mL), then DCC (74.2 mg, 0.36 mmol) and DMAP (4.4 mg, 0.036 
mmol) were added and stirred for 20 minutes. Then 2-(2-pyridyldithio)ethanol (PDS) 
(134.7 mg, 0.72 mmol) was added and stirred for 24 hours. The mixture was then purified 
by dialysis against DCM for 48 hours, then dried by evaporation under reduced pressure to 
yield of poly(L-glutamic acid)-g-(polyethylene glycol)-g-pyridyldisulfide (PG-g-PEG-g-
PDS) as a sticky solid. GPC (DMF) Mn: 12.3 KDa; Ð: 1.53. 1H NMR (400 MHz, CDCl3) 
δ (ppm): 8.44, 7.69, 7.11, 4.28, 3.62, 3.35, 3.00, 2.75-1.19, 1.12, 0.86. The amount of PDS 
grafted was determined as 65% of side chains by the relative integrations of the aromatic 
protons of PDS (8.46 ppm) compared to methylene protons of PEG (3.36 ppm). 
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Figure 95. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P3. 
 
Synthesis of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P4: PG-g-PEG 3 (62.5 mg, 0.49 mmol) was 
dissolved in a DCM (3 mL), then DCC (100.6 mg, 0.49 mmol) and DMAP (6.0 mg, 0.049 
mmol) were added and stirred for 20 minutes. Then 2-(2-pyridyldithio)ethanol (PDS) 
(182.6 mg, 0.98 mmol) was added and stirred for 24 hours. The mixture was then purified 
by dialysis against DCM for 48 hours, then dried by evaporation under reduced pressure to 
yield of poly(L-glutamic acid)-g-(polyethylene glycol)-g-pyridyldisulfide (PG-g-PEG-g-
PDS) as a sticky solid. GPC (DMF) Mn: 12.8KDa; Ð: 1.46. 1H NMR (400 MHz, CDCl3) 
δ (ppm): 1H NMR (400 MHz, CDCl3) δ (ppm): 8.46, 7.70, 7.12, 4.29, 3.62, 3.36, 3.01, 
2.79-1.20, 1.14, 0.86. The amount of PDS grafted was determined as 70% of side chains 
by the relative integrations of the aromatic protons of PDS (8.46 ppm) compared to 
methylene protons of PEG (3.36 ppm). 
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Figure 96. 1H NMR spectrum of poly(L-glutamic acid)-g-(polyethylene glycol)-g-2-(2-
pyridyldithio)ethanol (PG-g-PEG-g-PDS) P4. 
 
MALDI Characterization: Matrix solutions were prepared dissolving α-cyano-4-
hydroxycinnamic acid (CHCA) (10 mg/mL) in a solution of THF. The matrix solution was 
then mixed with PBLG polymer for analysis. Acquisition of all mass spectra was obtained 
on a Bruker Omniflex time-of-flight mass spectrometer. 
 
Nanogel Formulation and Characterization: Deionized water was added to the polymer 
(2.5 mg/mL) and made into a particle suspension using cycles of sonication and chilling 
until the polymer appeared dissolved. Particles at 25 °C were crosslinked using a calculated 
amount of DTT for 1 hour as reducing agent as previously reported.28, 29 Controlled 
crosslinking was achieved by addition 5, 12.5, 25 and 50% DTT respective to mol PDS, 
calculated to be 14, 38, 45, and 100% crosslinked, respectively, by the amount of 
byproduct, 2-pyridinethione, using its molar extinction coefficient (8.08 x 103 M-1 cm-1 at 
343 nm)33 using UV-Vis spectroscopy. Dynamic light scattering (DLS) experiments to 
obtain aggregate and particle size were performed by using a digital correlator and 
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goniometer with a light source operating at 514 nm using a Malvern Nano Zetasizer-ZS. 
Dust was removed by filtering the solution through 0.45 µm polycarbonate filter. 
Aggregate temperature responsivity was evaluated from 25-60 °C at a correlation time of 
30 seconds. For each sample, 3 readings were recorded averaging 10 runs for the same 
sample. Final nanogel size measurements were obtained at 25 °C at a correlation time of 
30 seconds.  
 
DiI Encapsulation: Model guest 1,1'-dioctadecyl-3,3,3',3'-tetramethyl indocarbocyanine 
perchlorate (DiI) was dissolved in acetone (10 µL) then added to a solution of 1 mg/mL 
aggregate of polymers PG-g-PEG-g-PDS (P2) and stirred was for 8 hours at room 
temperature, open to the atmosphere to allow for acetone to evaporate. Aggregate solution 
was separated into three solutions and two were crosslinked using DTT and quantified by 
byproduct, 2-pyridinethione at 343 nm to be 30 and 70% crosslinked. Nanogels were 
purified by dialysis using 100 KDa MWCO membrane and any non-encapsulated DiI was 
removed by filtration through a 0.45 µm filter.  
 
Transmission Electron Microscope (TEM) Study: The polymer and nanogel solutions 
(2.5 mg/mL) characterized by DLS were analyzed by TEM measurements. The sample was 
drop casted (1 drop) on carbon coated Cu grid, then air dried for 12 hours.  
 
Synthesis of thiol-modified FITC: Fluorescein isothiocyanate (FITC) (61 mg, 0.158 
mmol), cystamine dihydrochloride (19 mg, 0.079 mmol) and triethylamine (110 µL, 0.788 
mmol) were dissolved in DMSO (1.2 mL) and stirred for 4 hours. Then tris(2-
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carboxyethyl)phosphine hydrochloride (54 mg, 0.188 mmol) was added and stirred for 1 
hour. The mixture was precipitated in diethyl ether and then washed with water. The 
resultant crude fluorescein-cysteamine was used for nanogel labeling without further 
purification, as previously reported.29 
 
Fluorescein Nanogel Labeling: To nanogel solutions (2.5 mg/mL, 0.5 mL) fluorescein-
cysteamine (0.625 mg, 1.34 µmol) in DMF (62.5 µL) was added and stirred for 8 hours 
until. The nanogel was purified by dialysis against DI water in a 100 KDa MWCO cellulose 
dialysis membrane for 24 hours to remove any unconjugated fluorescein-cysteamine.  
 
Cell Culture: Human cervical carcinoma (HeLa) and human embryonic kidney (293T) 
cell lines were grown in DMEM supplemented with 10% (FBS), 1% L-glutamine, and 1% 
antibiotic-antimycotic (comprised of 100 units/mL penicillin and 100 µg/mL 
streptomycin). All cells were grown at 5% CO2 and 37 °C. Digestion of cells for culture 
was done according to HeLa and 293T protocols from ATCC.  
 
Cytotoxicity Assay: Nanogel in vitro cytotoxicity was determined using the Alamar blue 
assay for HeLa and 293T cell lines. In a 96 well flat-bottomed plate 10,000 cells per well 
(16,000-32,000 cells/cm2) in culture medium were seeded and incubated for 12 hours at 
5% CO2 and 37 °C. Nanogel samples in PBS buffer 7.4 were diluted with culture medium 
for final nanogel concentrations ranging from 0-1 mg/mL with 50% PBS total, in triplicate. 
The plate’s culture medium was replaced with sample culture medium and incubated for 
24 hours. The cells were then incubated with a 10% Alamar blue in media for 4 hours. 
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Fluorescence was obtained using a Molecular Devices Spectramax M5 plate reader 
(excitation 560 nm, emission 590 nm) in a black 96-well flat bottom plate. Average 
fluorescence values and deviation were obtained from replicates (n=3) and were compared 
to 100% viability of the positive control (0 mg/mL nanogel). 
 
Confocal Microscopy Intracellular Uptake: HeLa (500K) and 293T cells (100k) were 
seeded in a single chamber 35 mm glass bottom dishes and incubated overnight at 37 °C 
overnight in 5% CO2 before performing uptake. Culture media was removed and new 
culture media containing fluorescein-labeled nanogels diluted to 0.25 mg/mL in DMEM. 
Samples were incubated for 4 hours. The cell nuclei were stained with the addition of 
DRAQ5 (5 µM) Media was removed from cells and washed 2-4 times with PBS, then live 
cell imaging buffer was added for confocal imaging. Assessment of fluorescein-conjugated 
nanogel intracellular uptake was recorded using 488 nm laser and nuclear stain was 
detecting using a 543 nm wavelength laser. Confocal microscopy was performed on a 
Zeiss510 META confocal laser scanning microscope and images were obtained using a 
63´ oil-immersion objective. 
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CHAPTER 6 
 
SUMMARY AND FUTURE DIRECTIONS 
6.1 Summary of the Dissertation 
 Nano-scaled materials have gained immense interest in therapeutic delivery, 
diagnostics, and sensing applications, among many others. In drug delivery, nanoparticles 
of various compositions have been pursued, broadly including metals, inorganic materials, 
polymers, lipids, dendrimers and biologics. Advances in polymerization synthetic 
techniques has led to the development of diverse block and random copolymers with 
sophisticated chemical and structural properties. The synthetic feasibility and modification 
chemistries of amphiphilic random copolymers, as well as their spontaneous self-assembly 
in aqueous systems, have progressed their candidacy for biological applications. In this 
dissertation, we investigated structural and stimuli-responsive features of such self-
assembling amphiphilic random copolymers towards the development of these 
nanomaterials for water insoluble therapeutics. 
In chapter 1, we examined the requirements of nanoparticles as carriers for water-
insoluble guests, and discussed the merits of amphiphilic random copolymers as hosts. In 
chapter 2, we studied the in vivo performance of core-disulfide crosslinked nanogels in 
tumor bearing mice using triple negative human mammary carcinomas models. Tumor 
accumulation of the NIR-labeled nanogels were evaluated using in vivo FMT imaging over 
72 hours following a single nanogel injection. Nanogel sizes and PEG content were 
optimized to achieve greater retention of total body probe, highest percent injected dose of 
the nanogel in the tumor, and to evaluate relative accumulations in other tissues. In chapter 
3, we further evaluated the safety and efficacy of these nanogels in triple negative human 
mammary carcinomas using docetaxel as chemotherapeutic guest. Tumor-bearing mice 
  224 
were treated with regimens of docetaxel-loaded nanogels, and any tumor inhibition or 
adverse effects were monitored and compared to regimens of free docetaxel. Some minor 
anti-tumor activity was observed in model BR1282, and anti-tumor activity was achieved 
for model BR1458, however did not exceed the efficacy of free docetaxel. However, while 
adverse effects on body weight were observed with free docetaxel, no adverse effects on 
body weight were observed in docetaxel-loaded nanogel samples. 
In chapter 4, we developed a methodology for enhancing the cell uptake of 
PEGylated nanogels in the presence of tumor-relevant enzyme MMP-9. We reported a 
nanogel capable of converting its surface properties from a passive PEGylated particle to 
an active amine decorated particle in the presence of MMP-9. Surface conversion was 
confirmed using MALDI mass spectrometry characterization of products, zeta potential 
measurements of surface charge, and fluorescamine assay to establish amine content. The 
enhanced uptake of protease-treated nanogel was supported by confocal microscopy by 
both a covalently conjugated fluorophore nanogel tag and non-covalently encapsulated 
hydrophobic model guest. 
We then introduced an alternative amphiphilic random copolymer design based on 
poly(L-glutamic acid) in chapter 5. The poly(L-glutamic acid) derivatives with grafted 
PEG and PDS moieties on carboxylate side chains were synthesized, and the resultant 
amphiphilic polymer were capable of supramolecular self-assembly into nanoscale 
aggregates. These polypeptide aggregates could be chemical crosslinked under reducing 
conditions, similar to its poly(methyl methacrylate) counterpart. The nanocarrier host 
properties were established by encapsulation of model hydrophobic guest, and low 
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cytotoxicity and cellular internalization were demonstrated on both HeLa and 293T cell 
lines.  
6.2 Future Directions 
Further understanding of the in vivo biodistribution of these nanogels could benefit 
from studying any dose-dependent effects of empty of nanogels and overall 
pharmacokinetic performance. In chapter 2, the smallest nanogels tested (~30-40 nm) 
achieved the highest tumor accumulation, so it may be worth examining nanogels from 10-
30 nm. Smaller particles may be able to achieve deeper tumor penetration, however may 
suffer from poor tumor retention. Further, smaller particles can have greater susceptibility 
to renal filtration through the kidneys. Conjugation of targeting ligands may also achieve 
enhancement in tumor retention and uptake. 
For these random copolymer systems, determining spatial density of PEG chains 
on their surface by particle counting and theoretical methods would improve the 
understanding of these nanogels. With these random copolymer-based nanogels we have 
shown fine control in the aggregation sizes with various solution manipulation techniques, 
including polymer molecular weight, concentration, temperature, and salt. However, thus 
far we do not have a firm grasp on the number of particles generated in solution under these 
various conditions. From a fundamental perspective, we may better understand this nanogel 
system using particle counting methods, and understand how solution manipulations 
impact the number of polymer chains per particle, and thus the polymer chain density or 
these particles in relation to size. With this understanding, we can further ascertain the 
surface coverage from post-modifications such as PEGylation. Likewise, this information 
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would lend well in active targeting strategies, such that we could quantifiably and reliably 
predict the number, and spatial arrangement, of targeting ligands on the particle surfaces.  
Further in vitro investigations of these materials could improve the understanding 
of in vivo performance and overall biological fate. First, evaluating the generation of 
protein coronas on these particles in serum, with relation to size, PEG weight percent 
decoration, and PEG length decoration would identify the parameters that would most 
greatly avoid opsonization and phagocytosis. Second, it is important to evaluate whether 
these parameters reduce the ability for immune cells in the reticuloendothelial system to 
clear these nanoparticles, including Kupffer cells in the liver, dendritic cells in the lymph 
nodes, and B cells in the spleen. We observed considerable localization for the nanogels in 
the liver, but we do not know whether that is an artifact of the fenestrated liver endothelium, 
or due to a high extent of Kupffer cell uptake and clearance. 
In chapter 3 the efficacy of docetaxel-loaded nanogels may have suffered from their 
low encapsulation efficiencies. Because these random copolymer nanogels are also being 
explored for delivery of proteins, it would be interesting to test the parameters determined 
in chapter 2 with a hydrophilic protein therapeutic cargo, rather than hydrophobic 
chemotherapeutic cargo. The hydrophilic-lipophilic-balance of these heavily PEGylated 
nanogels may be better candidates for protein cargo, which should be well protected within 
the particle interior and not leak. Alternative structural designs or formulation techniques 
will have to be realized to maintain core hydrophobicity and high surface PEG composition 
for hydrophobic delivery goals. 
In further investigation of tumor-relevant stimuli responsive systems, like those 
discussed in chapter 4, pursing alternative substrates with responsivity to other upregulated 
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MMPs would elucidate the versatility of this enhanced uptake strategy. For practical 
translation of these site-specific activation strategies, it would be beneficial to determine 
the time scales of in vivo extracellular retention and cellular internalization. We expect 
based on biodistribution studies that nanogels remain in the tumor region on the time scale 
of hours to days. However, we do not know what proportion of these nanogels are in the 
extracellular milieu compared to internalized in tumor cells at any given time. Cell 
internalization of these PEGylated passive nanogels is slow, so it would be fundamentally 
interesting to evaluate the equilibrium shift of intracellular vs. extracellular particles 
following activation. For enhanced tumor cell uptake, the nanogel “activation” process 
would need to be faster than the particle “internalization” process in situ. This process 
could be evaluated in vitro using cancer cells in an extracellular matrix mimic hydrogel. 
The enhanced internalization over time can be monitored and compared between non-
activated and activating conditions. One possible design of such an experiment is the co-
encapsulation of a FRET donor and acceptor pair inside the nanogel interior. Due to the 
proximity of the dyes, we’d expect non-internalized particles to primarily exhibit emission 
of the acceptor fluorescence from excitation of the donor. However, upon cell 
internalization and GSH guest release, recover of donor fluorescence should be observed 
as the distance increases between the dyes. In this way, the relative extracellular acceptor 
fluorescence and intracellular donor fluorescence could be monitored over time. 
Additionally, using hydrogels as extracellular matrix mimics would allow the investigation 
of these systems under flow.  This surface-conversional strategy is non-reversible, so a 
concern for these activation designs in the rate at which particles are internalized following 
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activation, compared to reentry into circulation as “active” particles as a competing 
process.  
Further, the compatibility of this MMP-9 responsive carrier design with protein 
cargo would give us more understanding of the guest protection and proteolytic 
susceptibility in polymeric nanogels for the application of protein delivery. Release studies 
of showed the unexpected result that MMP-9 caused some release of encapsulated guest, 
which was unique to active MMP-9 and not caused by inactive Pro-MMP-9. It is possible 
that MMP-9 is exhibiting some esterase behavior and cleaving some of the ester bonds on 
the poly(methacrylate) backbone of the polymeric nanogel. If this is the case, it would be 
easily avoided by using a poly(acrylamide)-based polymer. Nevertheless, evaluating the 
susceptibility of nanogels to MMP-9 and other upregulated proteases is vital for the 
development of cancer-relevant protein delivery. As proof of concept, trypsin digestion has 
been used to establish both the protection and release of proteins in nanoscopic systems. 
Similar evaluation using proteases the nanogels may be exposed to under various cancer-
relevant environments would validate their biological stability.  
 In chapter 5, we established preliminary proof-of-concept validation that grafted 
poly(peptide)-based amphiphilic random copolymers, with known secondary structure 
characteristics, would be capable of supramolecular self-assembly and nanocarrier 
properties. In future work, determining the degradation profiles in response to cathepsin B 
and other proteases would be important in determining relative serum stability and 
lysosomal degradation of the nanogel. This lysosomal degradation could also have 
implications in delivery strategies for lysosomal-relevant therapeutic cargo. Lastly, it 
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would be fundamentally interesting to determine the secondary structure characteristics of 
such self-assembling polypeptide derivatives. 
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